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ABSTRACT 
Paravolidaki, Chrysoula, M.Sc. University of Saskatchewan, Saskatoon, January 
2008. Labelling, Information Asymmetry and Functional Foods: A Case Study of 
Omega-3 Enriched Eggs. 
 
Supervisor: Dr. Richard S. Gray 
 
Currently, the labelling of functional food products is highly regulated in 
Canada. Although certain nutrient content claims and five generic health claims have 
been allowed, the inability to make additional nutrient content and health claims 
decreases functional food firms’ incentives to produce and commercialize new and 
healthy food products. This, in turn, has consequences for functional food demand, 
consumer welfare, and health care costs. The primary objective of this thesis is to 
examine the potential welfare implications of functional food labelling for Canadian 
society. 
A benefit cost analysis is conducted to examine a specific case study of omega-3 
enriched eggs. The benefit cost analysis evaluates the welfare effects of functional food 
labelling policy and helps realize the magnitude of potential benefits that could be 
gained if not for restrictive and complicated labelling regulations. Based on a range of 
assumptions and using three different scenarios to cover a range of estimates, the health 
benefits from the reduction in the risk of coronary heart disease due to the current 
consumption of omega-3 enriched eggs, and the production and labelling-related costs 
are estimated. By comparing the estimated benefits and costs, the results indicate that 
the current consumption of omega-3 enriched eggs provides a considerable net 
economic gain. Therefore, labelling information on health components can contribute to 
facilitating a healthy lifestyle with reduced medical costs, stimulating agricultural 
innovation, and increasing economic welfare. 
Realizing the positive overall impact that the current consumption of omega-3 
enriched eggs has on consumers’ health and economy in Canada, a possible policy that 
could regulate all eggs to be enriched with omega-3 fatty acids is proposed. This policy 
could potentially be used to correct not only information asymmetry but also the 
negative externalities that are created by health and disability insurances. The benefit 
cost analysis show that the health benefits would be greatly increased while costs would 
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slightly increase due to reduced labelling-related costs. Therefore, the results indicate 
that the net economic gain is even stronger if the mandatory development of omega-3 
enriched eggs were required. 
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CHAPTER 1: INTRODUCTION  
1.1. Background Information 
Functional foods have entered the global market in the past decade, rapidly 
gaining market share as value-added products (Kotilainen et al., 2006). Growing 
consumer awareness about health and nutrition has led to an increased demand for 
healthier products. Scientific evidence suggests that there are links between diet and 
disease control and prevention, prompting consumers to search for food products with 
additional health benefits that decrease the risk of diet-related chronic diseases. The 
functional food industry has begun to respond to this economic incentive by including 
healthier products among their offerings, often using product differentiation 
opportunities. The potential of a niche market of health conscious consumers with large 
disposable incomes is an important factor that is driving the food industry’s actions 
(Cash et al., 2006). Canada’s own functional food industry is following this global trend, 
experiencing considerable growth in the last decade.  
The provision of nutrition information is a pivotal factor for further development 
of the functional food market. Functional foods contain health attributes that are difficult 
for consumers to observe without proper dissemination of the information, often leading 
to market failures caused by information asymmetry. Legislative labelling measures— 
mandatory Nutrition Facts tables, nutrient content and health claims—have been 
introduced in Canada to address this problem. Labelling is often used to deliver 
information to consumers about product characteristics that cannot be determined even 
after consumption. These characteristics are referred to as “credence” attributes. 
Improving consumers’ means of education concerning functional foods is necessary in 
order to decrease the information asymmetry problem that exists. Thus, labelling could 
function as an important tool for building trust and confidence between consumers and 
producers (Raab and Grobe, 2003). 
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Labelling helps not only consumers to make healthy food choices but also 
producers because it is considered valuable advertising. Producers of functional foods 
can use nutrient content claims and health claims to increase their profits as long as the 
additional information generates more revenues than it costs (Golan et al., 2001). The 
larger profit margin of functional foods encourages greater numbers of firms to enter the 
functional food industry. Hence, nutrient content and health claims provide an incentive 
to firms to produce healthy goods by assuming that consumers will respond to this new 
information by changing their purchasing decisions to the firms’ benefits.  
Increased labelling information about the value-added attributes of functional 
foods has the potential to considerably improve the health of Canadians, and it is of 
critical social interest to achieve reduced health care costs through better food choices. 
Canada spent an estimated $148 billion, or $4,548 per person, on health care in 2006. 
After the effect of inflation is taken into account, this was almost three times what was 
spent in 1975 (CIHI, 2006a).1 In 2006, government (taxpayers) paid 70.3% ($104 
billion) of Canadians’ total health spending, while the private sector paid the remainder, 
29.7% ($44 billion) (CIHI, 2006a). The magnitude of the total spending on health care 
in Canada (both public and private sectors) reached 10.3% of GDP in 2006 (CIHI, 
2006b). Therefore, changing eating preferences through labelling can lead to a healthier 
Canadian labor force and increase overall efficiency in the Canadian economy. 
Although considerable agricultural research has been devoted to the development 
of foods with functional properties, the private sector has inadequate incentives to 
produce and provide consumers with healthier foods. This is due to an inflexible and 
complicated regulatory system and its effect on allowable claims for functional food 
products. The lack of additional nutrient content and health claims is seen as a major 
issue for the introduction of functional foods. The barriers to dissemination of 
information regarding products’ health attributes and the public good nature of this 
information reduces the incentives to private firms to invest in new healthier products 
(Avery et al., 1999; Feehan, 1998). Currently in Canada, government regulations 
approve only specific nutrients to be used on nutrient content claims and a limited 
number of health claims, thus reducing the range of functional foods entering the 
                                                 
1 Unless otherwise noted, all currency references are in CAN$. 
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market. These limitations reduce the potential growth of the functional food industry 
while simultaneously inhibiting social welfare. Consumers need to know the nutritional 
components of functional foods in order to make healthful eating choices and decrease 
the incidence of chronic diseases. Therefore, an adaptable and responsive regulatory 
regime that provides consumers with health information is necessary to increase societal 
welfare and improve economic efficiency. 
The moral hazard problem, which is created due to health and disability 
insurances concerns, is another factor that reduces functional food firms’ incentives to 
develop functional food products, and thus may also create market failures. Even 
informed consumers lack the full incentive to pay for healthier foods and consume 
optimal quantities of these foods as long as they are protected by either public or private 
health insurances. Accordingly, there is a reduced incentive to undertake disease 
prevention measures, and thus firms produce a lesser quantity of functional foods than 
socially optimal.  
1.2. Problem Statement 
The labelling of functional foods is highly regulated in Canada. Labelling for 
nutrient content is restricted to those nutrients that are deemed essential by Health 
Canada. Functional foods that contain elevated levels of other potentially beneficial 
compounds cannot be labeled. The use of health claims is also restricted to five pre-
approved generic health claims in Canada as opposed to seventeen health claims in the 
United States (Government of Canada, 2002). While there may be benefits attached to 
these restrictive regulations on labelling, it is clear that the inability to label functional 
foods has consequences for its demand, consumer welfare, and health care costs.  
Nutrition and health information remains a barrier to the widespread adoption of 
functional foods. The inability to label many functional foods has created significant 
barriers to their development and introduction in the Canadian diet. If consumers are not 
aware of the health benefits of consuming a functional food or unable to identify such 
foods on a grocery shelf these products will not be sold when they involve additional 
costs. In general, in the current climate regulations prevent food producers from making 
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additional nutrient content claims or health claims and from expanding the functional 
food market. 
Labelling can also be used as a vehicle to transfer nutrition information and 
affect consumption decisions. Therefore, labelling can correct the market inefficiency 
caused by asymmetric information and contribute to facilitating a healthy lifestyle with 
decreased medical costs. Federal intervention in food labelling is often proposed with 
the aim of achieving a social goal. The appropriate role for the government in labelling 
depends on the type of information involved and the level and distribution of the costs 
and benefits of providing that information (Golan et al., 2001). 
In order to evaluate the potential social and economic effects of labelling 
regulations in the functional food industry, a benefit cost analysis is presented to 
examine a specific case study of omega-3 enriched eggs. The current allowable specific 
nutrient content claims and limited health claims have resulted in a spectrum of 
functional foods available on the market. Omega-3 enriched eggs provide a good 
example of where labelling has allowed the introduction of functional food. However, 
agricultural innovation may be inhibited and health care costs will remain high if the 
regulatory system does not allow the labelling of other healthy nutrients. If labelling of 
omega-3 content were not allowed the product would possibly not exist in the market 
place. This study evaluates the importance of providing information through claims and 
examines the economic impact of the current regulatory labelling system. It also helps 
realize that additional health and economic gains are forgone due to restrictive labelling 
rules for new and potentially healthy functional foods.  
1.3. Objective 
The main objective of this thesis is to examine the potential welfare implications 
of functional food labelling for Canadian society by using the example of omega-3 
enriched eggs. The empirical analysis will estimate the welfare impacts of omega-3 
consumption by considering the reduction in the cost of coronary heart disease due to 
increased consumption minus production and labelling-related costs.  The theoretical 
framework will use a graphical analysis to describe how labelling and nutrition claims 
on functional foods can reduce information asymmetry. The moral hazard problem that 
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prevents consumers from consuming the socially optimal amount of functional food will 
also be briefly analyzed. 
1.4. Hypothesis 
This thesis will examine the following hypothesis: The labelling of omega-3 
enriched eggs has not led to benefits for Canadians.  
If this hypothesis is rejected, the thesis will demonstrate the potential importance 
of functional food labelling and the magnitude of potential benefits that could be gained 
if not for overly restrictive labelling regulation.  
1.5. Organization of Thesis  
The introduction to the thesis highlights the important role that diet plays in 
consumers’ health and how the labelling, nutrient content and health claims of 
functional foods can prevent information asymmetry and affect food choices, thus 
potentially reducing health care costs in Canada. The remainder of the thesis is 
structured into five chapters.  
Chapter Two provides background information regarding the functional food 
industry in Canada and then discusses the nutritional properties of omega-3 enriched 
eggs. In understanding these properties, information regarding the beneficial effects of 
omega-3 fatty acids is provided. The chapter concludes by estimating the direct and 
indirect costs of cardiovascular disease and coronary heart disease in 2006. 
 Chapter Three offers a brief description of the current regulatory system and its 
complications. The chapter also includes the theoretical model of the thesis and the 
graphical form of the model that is used to show the significance of federal intervention 
through labelling in the correction of information asymmetry. The magnitude of 
potential health care costs savings is also discussed.  
Chapter Four contains the case study—the omega-3 enriched eggs—that is being 
used to illustrate the significant beneficial effects of labelling information. The chapter 
begins with an estimate of current daily omega-3 fatty acids consumption and continues 
with an estimation of the reduction in coronary heart disease mortality through the 
increase in omega-3 fatty acid intake. This is followed by an estimation of production, 
labelling and marketing costs of omega-3 enriched eggs. In this chapter it is shown how 
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consumers benefit and improve their health by consuming eggs high in omega-3 fatty 
acids and the degree of health benefits in terms of health savings from this consumption 
compared to the costs.  
Chapter Five discusses the potential policy implications of labelling information. 
It includes the example of all eggs being mandated to be rich in omega-3 fatty acids. A 
benefit cost analysis is conducted to evaluate the overall impact if this policy were 
implemented. 
Lastly, Chapter Six offers a summary of the thesis and concludes with 
suggestions for further research. 
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CHAPTER 2: INDUSTRY BACKGROUND 
2.1. Introduction 
The purpose of this chapter is to provide an overview of the functional food 
industry in Canada. It also focuses on the healthy characteristics of a functional food—
omega-3 enriched eggs—and estimates cardiovascular disease costs in 2006, which will 
be used in the benefit cost analysis conducted in Chapter 4. The chapter begins with 
background information regarding functional foods and the factors that contribute to their 
market growth. Examples of functional foods showing their potential health benefits are 
provided. The role of nutrient content information on labels is also discussed, which 
explains how labels can decrease the information asymmetry problem caused by the 
credence attributes of functional foods. The chapter then provides information regarding 
the health benefits associated with omega-3 fatty acids and shows their importance to 
health. The chapter concludes with an estimation of cardiovascular disease (CVD) costs 
and coronary heart disease (CHD) costs, which can be considerably reduced by 
consuming a product with omega-3 fatty acids.  
2.2. Functional Foods: Background Information 
The fact that food is closely correlated with optimal health is not a novel concept. 
The tenet, “Let food be the medicine and medicine be the food,” espoused by 
Hippocrates, the father of medicine, shows the connection between nutrition and human 
health (Hippocrates, cited by Klotzbach et al., 1999). Almost 2,500 years later this 
philosophy is receiving renewed interest and underpins the introduction of functional 
foods in the marketplace (Hasler, 1998).  
The concept of functional foods was first developed in Japan in the mid-1980s. At 
that time, the government and health authorities in Japan considered the increased 
consumption of specific food types and an increased quality of life as important factors 
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for reducing the risk of chronic diseases, thereby helping control the rising health care 
costs, particularly in an aging population. (FSAI, 2006). The Japanese government 
launched a program to promote the development of foods with health and medicinal 
properties that would help Japanese citizens to maintain and improve their state of health. 
Since then, functional food science has been developed in a number of countries and 
accepted as being conceptually beyond nutrition (Arai et al., 2001). 
In recent years, consumers, governments and the agri-food industry have shown a 
growing interest in foods with health enhancing properties due to several critical factors 
(Benkouider, 2003; Drouin et al., 2002): 
(1)  an increased amount of information from health authorities and the media to 
consumers on nutrition and the link between diet and health; 
(2) continuously increasing health care costs; 
(3) consumers’ desires for an improved quality of life and a healthier lifestyle; 
(4) an aging population; 
(5) rapid advances in food science and technology; 
(6) increased incidence of self-medication; and 
(7) a changing regulatory environment. 
 
All the above factors have contributed to the development of the functional food 
industry in Canada. However, one of the most important factors, from an economic 
perspective, is rising health care costs. The health care system in Canada is under 
pressure because the expenditures associated with health services tend to grow every year 
due to diet-related chronic diseases in an aging population (i.e., cardiovascular disease, 
coronary heart disease, cancer, diabetes and obesity). The development of functional 
foods could reduce the risk of chronic diseases and enhance the ability to manage chronic 
diseases, thus, potentially decreasing health costs. 
Currently, some people, especially those over forty-five years of age, are very 
concerned about the correlation between diet and disease, and they have recognized that 
making healthy food choices can improve their health. This demand for foods with 
beneficial health attributes has provided an incentive for the functional food industry’s 
development in Canada. Thus, substantial improvements in quality of life and economic 
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savings are possible through the use of beneficial functional foods. However, consumers 
have to keep in mind that functional foods are only one component of improving their 
health, as other components, including exercise, reduced stress, and not smoking, can 
have a major impact on health. 
Conceptually, functional foods fall in the area between foods and medicine 
(Kotilainen et al. 2006) because they are foods with specific health-promoting properties. 
In an effort to distinguish between functional foods and drugs, the term nutraceutical was 
coined in 1989 by the Foundation for Innovation in Medicine (Brower, 1998). Despite 
some confusion, functional foods and nutraceuticals are different categories, compete in 
different markets and target different consumer preferences, needs and characteristics. At 
the retail level, functional foods compete for market share with the food industry whereas 
nutraceuticals compete with the pharmaceuticals, vitamins and supplements.  
Although the terms functional food and nutraceutical are commonly used 
interchangeably, there are no internationally accepted definitions for them. In 1998, the 
Health Protection Branch of Health Canada released a policy paper that proposed a 
definition for functional foods and nutraceuticals (Health Canada, 1998a). 
Health Canada has defined functional foods as follows: 
A functional food is similar in appearance to conventional foods, is consumed as 
part of a usual diet, and has demonstrated physiological benefits and/or reduces 
the risk of chronic disease beyond basic nutritional functions (Health Canada, 
1998a, p. 3). 
 
According to Health Canada, the definition of nutraceuticals differs substantially 
from that of functional foods: 
A nutraceutical is a product isolated or purified from foods that is generally sold 
in medicinal forms not usually associated with food. A nutraceutical is 
demonstrated to have a physiological benefit or provide protection against chronic 
disease (Health Canada, 1998a, p. 3). 
 
In January 2004, the term natural health product was introduced in Canada and 
seems to be a term that is unique to Canadian legislation (Canada Gazette, 2003a). 
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Natural health products are a combination of various types of products, including 
nutraceuticals, vitamins and minerals, herbal remedies, homeopathetic medicines, 
traditional Chinese medicines, probiotics, amino acids and essential fatty acids (Canada 
Gazette, 2003a). Recent surveys have shown that more than one-half of Canadian 
consumers regularly take natural health products indicating consumers’ self-care for and 
interest in their health (Canada Gazette, 2003a). The regulations for natural health 
products exclude food, meaning that, unlike nutraceuticals, functional foods are not 
included in this category.  
As indicated, the terms “functional foods” and “nutraceuticals” cannot be used 
interchangeably. Not only do they compete in different markets but they also are 
governed by different regulations regarding labelling and health claims. The claims used 
for nutraceuticals, which are similar to pharmaceuticals, are more direct and specific, 
while those used for functional foods are more general statements that aim to improve or 
maintain the population’s overall health, not to cure or treat a certain disease. More 
information about the labelling and claims that are currently allowable in Canada is 
covered in section 3.2.  
2.2.1. Functional Foods 
Although most foods consumed worldwide serve some function, in recent years 
the category of functional foods has come to include products that influence specific 
functions in the body and thereby beneficially affect people’s health and well-being. The 
field of functional foods contains two categories. The first includes a wide spectrum of 
foods that inherently contain functional components, thus the foods are unmodified, 
whereas the second category contains foods that are the result of technological innovation 
(Institute of Foods Technologists, 2007). 
Considerable scientific research has demonstrated that some substances (nutrients 
and non-nutrients) that occur naturally in food have noteworthy protective or disease 
preventive properties. Phytochemicals and zoochemicals have received a lot of attention 
due to their health-promoting attributes. Both are non-nutrient, physiologically-active 
functional food components, that are present in plant and animal materials, respectively, 
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in relatively small amounts (micronutrients) compared to macronutrients (fats, fiber, 
carbohydrates, proteins, and amino acids) (Unnevehr and Hasler, 2000; Hasler, 2000). 
Foods containing phytochemicals such as grains, legumes, fruits and vegetables, 
are already part of our daily diet. There is abundant evidence from epidemiological 
studies that the phytochemicals in fruits and vegetables can considerably reduce the risk 
of cancer, probably due to polyphenol antioxidants (Heber, 2004) and anti-inflammatory 
effects (Urquiaga and Leighton, 2000). For example, lycopene in tomatoes is a 
phytochemical that acts as an antioxidant and has been shown to lower the risk of 
prostate cancer (Giovannucci, 1999). Cruciferous vegetables such as broccoli and 
Brussels sprouts contain glucosinolates, a metabolite, which are synthesized from amino 
acids and may reduce the risk of cancer (Wang et al., 2002). The risk of cardiovascular 
disease can be reduced through consumption of certain foods, such as green tea, red 
wine, berries, grapes and soy foods (Zimmerman, 2000). 
In addition to phytochemicals, zoochemicals are found in animal sources and are 
also known for their healthful benefits. Omega-3 fatty acids—eicosapentaenoic acid 
(EPA) and docosahexanoic acid (DHA)—are found in abundance in cold-water fish such 
as salmon, trout, mackerel, and tuna (IFIC, 2003). These compounds contribute to 
protection from heart disease, improvement of mental functioning and maintenance of 
good vision. Conjugated Linoleic Acid (CLA) is naturally present in particular meats, 
such as beef, and dairy products, and can also help reduce the risk of heart disease, lower 
body fat, and increase muscle strength and bone mass (Kreider et al., 2002). Lastly, egg 
yolk contains a substantial amount of lutein and zeaxanthin, antioxidant carotenoids that 
have been linked to reducing the risk of cataracts and age-related diseases of the eye 
(macular degeneration) (Mares-Perman et al., 2002). 
Besides conventional foods that contain natural ingredients that boost health, 
several food products that result from technological innovation have been introduced in 
the market. A variety of functional foods have been commercially developed specifically 
recently to cover consumers’ nutritional needs and prevent serious chronic diseases. The 
term “industrial functional foods” will hereafter be used for these foods and defined as 
follows: 
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Industrial functional foods are the foods which can be produced by either adding, 
removing, enhancing, decreasing or modifying one or more components of a food 
and require an additional marginal cost to introduce a health benefit.  
 
In the current Canadian market there are a variety of fortified or enhanced foods 
that are specifically created to reduce disease risk. Some well-known examples include 
calcium-enriched orange juice, cereals with soya, grains with added fiber and eggs 
enhanced with omega-3 fatty acids. 
A list of functional foods, natural and industrial, is presented in Table 2.1. The 
table shows some of the available functional foods and their functional components. It 
also shows the potential health benefits that can be obtained by regularly consuming 
those foods. 
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   Table 2.1. Examples of functional components. 
Components Source Potential Benefit 
Lutein, Zeaxanthin  kale, collards, spinach, corn, eggs, citrus  
may contribute to 
maintenance of healthy 
vision  
Lycopene  
tomatoes and processed 
tomato products, 
watermelon, red/pink 
grapefruit  
may contribute to 
maintenance of prostate 
health  
Beta glucan  oat bran, oatmeal, oat flour, barley, rye  
may reduce risk of 
coronary heart disease 
(CHD)  
Monounsaturated fatty 
acids (MUFAs) 
tree nuts, olive oil, Nexera 
canola oil may reduce risk of CHD 
PUFAs-Omega-3 fatty 
acids-DHA/EPA  
salmon, tuna, marine, and 
other fish oils 
may reduce risk of CHD; 
may contribute to 
maintenance of mental 
and visual function  
Conjugated linoleic acid 
(CLA)  beef, lamb, some cheese  
may contribute to 
maintenance of desirable 
body composition and 
healthy immune function 
Sulforaphane  
cauliflower, broccoli, 
broccoli sprouts, cabbage, 
kale, horseradish  
may enhance 
detoxification of 
undesirable compounds; 
bolsters cellular 
antioxidant defenses  
Stanol/Sterol esters 
fortified table spreads, 
stanol ester dietary 
supplements 
may reduce risk of CHD 
Soy Protein  soybeans and soy-based foods 
foods may reduce risk of 
CHD  
B9 (Folate) 
beans, legumes, citrus 
foods, green leafy 
vegetables, fortified 
breads and cereals 
may reduce a woman’s 
risk of having a child 
with a brain or spinal 
cord defect 
Vitamin D sunlight, fish, fortified milk and cereals 
helps regulate calcium 
and phosphorus; helps 
contribute to bone health; 
may contribute to healthy 
immune function; helps 
support cell growth 
Source: IFIC, 2006. 
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Some health-conscious consumers have realized that the development of 
functional foods could prevent the risk of lifestyle chronic conditions, and most 
consumers agree that eating healthily is a better way to manage illness through 
prevention rather than using medication (Hasler, 2002). This has led to the increased 
acceptance and consumption of functional foods with health-promoting capabilities, 
something demonstrated by impressive growth in sales worldwide (Menrad, 2003). 
2.3. Functional Food Industry in Canada 
New product development has increased at a rapid rate and the sales of functional 
foods have risen worldwide. However, the lack of a formal definition for functional foods 
makes it difficult to estimate the size of the market (MacDonald, 2004). According to 
Nutrition Business Journal, in 2006 the estimated size of the global functional food 
market was US$85 billion, or 37.6% of the global nutrition industry (US$226 billion) 
(Nutrition Business Journal, 2007)2. The major markets for functional foods and 
nutraceuticals are located in the US, Europe, Japan and Asia (Newton, 2001). In 2001, 
the Canadian market represented approximately 3% of the global nutrition market 
(US$6.8 billion) (Jarvis et al., 2001). Functional foods accounted for 42% of the US$6.8 
billion, which means that almost US$2.9 billion were spent on functional foods in 
Canada in 20013. Canada’s functional food and nutraceutical industry has the potential to 
significantly increase its market share and develop due to its innovative capabilities. 
Research and development is critical to this rapidly developing field. Key players in the 
research of functional food products include governments, the academic community, 
institutions, and industry, all of which work together to advance collective interests 
(AAFC, 2005).  
The results from a functional foods and nutraceuticals survey conducted by 
Statistics Canada indicated that there were 389 firms, ranging from small start-up 
companies to multinational organizations, engaged in activities related to either 
functional foods, nutraceuticals, or both during 2004-05 (Statistics Canada, 2007a). One-
                                                 
2 The segments of the nutrition industry are dietary supplements (vitamins, minerals, herbs & botanicals, sports 
nutrition, specialty supplements), natural and organic food, natural and organic personal care and household products 
and functional foods (Nutrition Business Journal, 2007). 
3 In 2004, a Global market review of functional foods estimated that 41% of the US$6.6 billion dollar market is spent 
on functional foods (Global market review of functional foods-forecasts to 2010, 2004). 
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quarter of these companies were involved with both functional foods and nutraceuticals, 
while 30% of them were only involved in functional food activities. This survey showed 
that the industry was gaining momentum as, compared to the results of a 2002 survey, the 
number of functional food and nutraceutical firms increased by 32.3% (Statistics Canada, 
2005). The industry also generates about $2.9 billion in revenues and employs over 
12,000 individuals with functional food- and nutraceutical-related duties (Statistics 
Canada, 2007a). Firms with functional food- or nutraceutical-related activities spent 
$74.5 million in 2004 on research and development (R&D), which accounted for almost 
half the total funds spent on R&D by these firms. The fact that they would invest 
significant amounts in R&D for functional foods and nutraceuticals indicates that they 
considered these products and processes as important to their long-term competitiveness 
(Statistics Canada, 2007a).  
Canada’s functional food and nutraceutical sector is experiencing considerable 
growth due to a high demand for the development of nutritious products. The food and 
nutraceutical companies focus heavily on R&D to produce commodities with value-
added ingredients. The industry range from globally recognized companies such as 
Ocean Nutrition Canada (omega-3 fatty acids), Bioriginal Food and Science (essential 
fatty acid oils), Forbes Medi-Tech (plant sterols), and Institut Rosell (probiotics) to major 
multinational corporations such as Kellogg’s, Heinz, Quaker, Unilever, Dupont, 
Novartis, Cargill, and Hormel, which are also active in this sector (AAFC, 2005). It is 
also worth mentioning that Canada is a leader in the development and manufacturing of 
essential fatty acid (EFA) products from plant and marine sources, including evening 
primrose oil, flaxseed, borage, hemp, and marine animal oils (AAFC, 2005).  
Functional foods and nutraceuticals offer a special opportunity for the Canadian 
agri-food industry to develop in both domestic and international markets (AAFC, 2005). 
The agriculture industry is an important contributor to the Canadian economy, and 
companies invest in research and development to produce commodities with nutritionally 
valuable constituents. Thus, the functional food industry, in collaboration with the 
research community, has the potential to stimulate growth in the value-added agri-food 
sector.  
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However, while the market for functional foods is increasing worldwide, the 
long-term success of functional foods is not yet known for it depends on their 
effectiveness in reducing the risk of a disease, their safety, and consumer confidence in 
the health benefits they provide. Consumers will trust the beneficial effects of functional 
foods only when proper information is provided. What consumers need is truthful and 
credible information in order to make informed food choices. The next part of this 
chapter discusses the information asymmetry problem faced by the functional food 
industry. 
2.4. Functional Foods and Information Asymmetry 
Recently, Canada’s agri-food sector has experienced major challenges as demand 
has increased for products with health promoting capabilities. In such markets where 
conditions are changing rapidly, the flow of information to consumers becomes a primary 
determinant of economic welfare. However, this market information is often imperfect, 
incomplete, inaccessible, asymmetrically distributed, non-standardized, or costly to 
collect (Caswell and Mojduszka, 1996). Hence, potential market failures from 
information asymmetry arise because consumers face uncertainty regarding the true 
nature of product attributes, and as a result they make choices that are not well aligned 
with their preferences (Teisl and Roe, 1998). 
According to Nelson (1970) and Darby and Karni (1973), there are three types of 
goods available in the consumer market. Search goods are those whose characteristics 
(price, colour, size) can be determined and evaluated prior to purchase. An example of 
this would be the purchase of a pair of shoes or a dress, as the consumer can search for 
the price, select the preferable color, and try it on before buying it. Experience goods are 
those whose characteristics (taste, durability, quality) are difficult to observe in advance 
and can only be ascertained after purchase and consumption. Some examples of this type 
are a can of tuna, a bottle of milk, a jar of jam, tomatoes, or meat. While consumers can 
only identify the true quality of a product after consuming it, the reputation of the seller, 
a brand image, or a quality guarantee become important quality signals for the purchaser 
(Hobbs, 1998). Lastly, credence goods are those goods whose quality, safety, and 
effectiveness cannot be adequately assessed even after the products are purchased and 
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consumed. Thus, individuals face some degree of uncertainty that cannot be factored into 
purchasing decisions unless there is perfect information (Bureau et al., 1997). Examples 
of these include some services, such as those of a mechanic, the expertise of a doctor, or 
the nutritional or health component of a food product (Hobbs, 1998).   
Functional foods fall into the category of credence goods as they contain 
nutritional characteristics that cannot be identified by the consumers even after 
experiencing the good. This has a number of implications for consumer assurance of 
product efficacy and safety, the possibility of consumer fraud, and the potential for 
misleading representations of product quality and effectiveness (Akerlof, 1970; Nelson, 
1970; Darby and Karni, 1973; Leland, 1979). For example, consumers cannot detect the 
fiber contained in oats or the omega-3 fatty acids included in milk without the provision 
of proper and credible information. The role of information is crucial because consumers 
cannot directly perceive the benefit, such as through taste (Urala and Lähteenmäki, 
2004). 
Buyers have less knowledge than sellers (e.g., concerning the production process, 
product origin, nutritional content, or safety issues), which means that information is 
asymmetrically distributed (Verbeke, 2005). One possible effect is that sellers have 
incentives to exaggerate, mislead, or lie in their claims. As a result of the small supply of 
information, consumers are unable to make choices that reflect their preferences. In other 
cases, relevant market information may be imperfect (i.e., it may not exist or it may be 
contradictory). This situation often arises when the long-term health effects of a food or 
food attributes are unknown, or when scientific opinions differ about the health 
consequences of consumption (Golan et al., 2001). This occurred in the early days of the 
BSE and dioxin crises, where scientists and government held opposing views on the 
potential health risks (Verbeke, 2005). 
Dissemination of information aims at reducing problems resulting from 
information asymmetry (Rabinowicz, 1999; Lusk et al., 2004; Hobbs, 2004). Logically, if 
asymmetric information is at the core of market failures, it can reasonably be assumed 
that better information and more transparency will be at the core of any solution 
(McCluskey and Swinnen, 2004). Information regarding the nutrition attributes and 
health effects of functional foods is the key factor behind the success of the functional 
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food market. Such information should be communicated clearly, understandably, and 
truthfully to consumers for there is a need to understand both a product’s features and its 
associated health benefits. When consumers become aware of the link between attributes 
and beneficial consequences, they show stronger purchase intentions. Thus, the high 
societal costs of diseases related to food consumption can be significantly decreased due 
to proper and full provision of information.  
In situations where asymmetric information is unavoidable and causes market 
inefficiencies and failures, a government can either provide information or impose 
regulations to compel manufacturers to do so (Cash et al., 2004). Individuals cannot 
make rational food choices without complete information. They are also daily faced with 
an abundance of health information that is difficult to understand and evaluate (Cash et 
al., 2004). Thus, they need information about the implications of new research and 
products from sources on which they can trust and rely (Unnevehr et al., 1999). A wide 
variety of government nutrition programs provide consumers with information and 
education in order to improve their health by changing their diets (Aldrich, 1999). 
Government is also responsible for the regulation of advertising and food labelling, 
which can influence food consumption decisions.  
Labelling is an effective policy tool that can enhance economic efficiency by 
delivering information to consumers on nutritious attributes and health-enhancing 
properties of functional foods. Consumers can now use the information found on product 
labels to select nutritious goods and ameliorate their well-being. A healthier lifestyle in 
well-nourished citizens can decrease market inefficiencies related to burgeoning health 
care costs.   
At the same time, producers can use labelling as an advertising tool. Producers 
have an economic incentive to produce healthy and nutritious products because many 
consumers are increasingly interested in selecting a nutritious and balanced diet to 
maintain or improve their health. That the demand for functional foods is continuously 
increasing will stimulate producers to provide information in order to increase sales. 
Consequently, labelling can be beneficial for both consumers and producers.  
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Generally, labels are designed to serve four main objectives: 
(1) to promote fair competition among producers and product marketability 
(Hadden, 1986); 
(2) to increase consumer access to information (Hadden, 1986); 
(3) to reduce risks to individual consumer safety and health (Hadden, 1986); and 
(4) to influence individual consumption choices so as to align them with social 
objectives (Golan et al., 2001). 
 
These objectives can only be achieved if the information is clear, credible, and 
comprehensible to assist Canadians in making appropriate food choices, thus achieving a 
social goal. Format and context of the information are important elements in maximizing 
the potential of labeled information to influence its audience (Golan et al., 2001). 
Consumers are more likely to pay attention to a label only if its information is explicit, 
concise, and understandable. Consumer surveys have shown that packages with overly 
detailed labels and numerous warnings tend to affect consumers negatively and may 
cause them to ignore the information completely (Golan et al., 2001). Even if consumers 
are interested in the information on the label, they may have difficulty extracting the 
important information. As a result, overloading a label in an attempt to solve market 
inefficiencies may result in consumer confusion, indifference, or loss of confidence due 
to poor understanding (Verbeke, 2005).   
Labelling is even more effective when it is accompanied by consistent and 
achievable standards, testing services, certification services, and enforcement. These 
third-party services can be provided by several different entities, such as national 
governments, international organizations, consumer groups, producer groups, and private 
entities (Golan et al., 2001). The provision of these services aims at reducing transaction 
costs (i.e., search, negotiation, and monitoring costs) and increasing the benefits of 
labelling by strengthening labelling claims. Thus, they enhance the credibility of product 
labels and claims, hopefully making consumers more willing to consume the functional 
foods.  
Although the provision of truthful and accurate information is currently regulated, 
there are a variety of demographic factors that play a fundamental role in the use of 
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labels. Demographic factors such as gender, education level, nutritional knowledge, 
income, age, and risk perceptions induce the provision of labelling information and can 
affect interest in food and health issues among members of society (Mueller, 1991). 
Women more than men, for example, tend to be aware of nutrition issues and pay 
attention to healthy ingredients of a product. This can be explained by the high levels of 
responsibility that women often have for several aspects of food preparation and 
consumption, as well as their increased interest in a healthy diet (Worsley and Scott, 
2000). Furthermore, nutritionally informed consumers and consumers with high 
disposable incomes show a greater interest in the consumption of better quality and 
healthier foods. Elderly and middle-aged consumers are also more concerned about 
eating healthily than younger people because they tend to experience more life-
threatening conditions that are not fully under their control (Lester, 1994). Lastly, it has 
been noticed that people who have a family member with a diet-related health condition 
tend to be very concerned about their own diet and select foods with nutritious attributes. 
The information on the labels aims at satisfying various consumers’ needs and 
concerns about the food. People seek information on both the nutritional content and the 
health benefits of a product in order to achieve healthier lifestyle and prevent illnesses 
related to diet. For this reason, Canadian regulatory authorities have approved “nutrition 
labels,” “nutrient content claims,” and “health claims” that have the potential to 
contribute to the achievement of public health objectives and correct the market failures 
caused by asymmetrically distributed information (Hawkes, 2004). For instance, omega-3 
fatty acids can be labeled due to their multi health-promoting attributes (see section 2.5), 
and so several foods rich in these beneficial fatty acids have been developed and 
introduced in the Canadian market.  
2.5. Omega-3 Fatty Acids 
There is strong scientific evidence showing that omega-3 fatty acids can 
beneficially affect various functions in the human body and thus improve the 
population’s collective health. This section begins with a discussion of the important role 
of omega-3 fatty acids on health. In particular, the health impacts of each of the three 
major components of omega-3 fatty acids are discussed separately. Also, given the low 
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level of omega-3 fatty acids observed in western populations like Canada (Simopoulos, 
1991), recommendations were established in order to reduce the risk of developing 
threatening diet-related conditions (Kris-Etherton et al., 2002). Currently, omega-3 fatty 
acids are considered beneficial nutrients and are approved for insertion on both labels and 
nutrient content claims. Thus, several products enhanced with these beneficial fatty acids 
are now available in the market. Omega-3 enriched eggs, which represent a major 
functional food, have garnered considerable attention due to their increased levels of 
omega-3 fatty acids. The consumption of these eggs can substantially contribute to 
increased levels of omega-3 fatty acids, thereby contributing to increased wellness.  
2.5.1. The Importance of Omega-3 Fatty Acids to Health 
There are three major categories of dietary fatty acids: saturated fatty acids; 
monounsaturated fatty acids; and polyunsaturated fatty acids, each of which are 
distinguished by their chemical structure. Saturated fatty acids (SFA) contain no double 
bond, are solid at room temperature, and are usually derived from animal sources (e.g., 
lard or butter). However, most plant fats are high in monounsaturated (MUFA) fatty 
acids, which contain one double bond, and polyunsaturated fatty acids (PUFA), which 
contain two or more double bonds; both are liquid at room temperature (Erasmus, 1986, 
p. 29). Currently, the role of omega-3 polyunsaturated fatty acids in growth and 
development as well as in health and disease prevention—particularly coronary heart 
disease (CHD)—is one of the fastest growing research areas in nutritional science. As a 
result, knowledge of these fatty acids has grown significantly (Simopoulos, 1999a). This 
section focuses on omega-3 polyunsaturated fatty acids and their impact on ameliorating 
the health of the population.  
In order to better understand the importance of omega-3 fatty acids in health, two 
distinct families of PUFA, omega-3 (n-3), and omega-6 (n-6) fatty acids are discussed. 
The principal fatty acids of the omega-3 and omega-6 families, which are alpha-linolenic 
(ALA, 18:3n-3) and linoleic (LA, 18:2n-6) fatty acids, respectively, are considered 
essential fatty acids because they cannot be synthesized by the body. Hence, they must be 
supplied through diet (Simopoulos, 1991) or supplementation (Covington, 2004). They 
are important components of cell membranes (Simopoulos, 1991) and play a fundamental 
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role in several physiological functions. Both can be metabolized to their longer chain and 
highly unsaturated fatty acids (LCPUFA) through elongation and desaturation. ALA can, 
to a limited extent, be converted in the body to eicosa-pentaenoic (EPA, 20:5n-3) and 
later to docosahexaenoic (DHA, 22:6n-3) fatty acids, while LA can be converted to 
arachidonic acid (AA, 20:4n-6) (Simopoulos, 1991). Although ALA and LA are not 
interconvertible and are metabolically and functionally distinct (Simopoulos, 2002), they 
compete for the same enzyme systems for desaturation into their LCPUFA (Jacobsen, 
2004). This means that the excessive consumption of foods rich in omega-6 may 
compromise the conversion of ALA to LCPUFA, which in turn adversely affects health 
(Davis, 2002). Therefore, the right balance between the intake of omega-6 and omega-3 
fatty acids is of vital importance (Jacobsen, 2004). 
A proper choice of a variety of food products can ensure the appropriate intake of 
omega-3 and omega-6 PUFA and prevent potential incidences of disease. ALA is present 
in vegetable oils (e.g., soybean, hempseed, and canola oil), with flaxseed having the 
highest concentration—57% of total fatty acids (Flax Council of Canada, 2003a). It is 
also found in green leafy vegetables (e.g., spinach, purslane, and kale,) and walnuts 
(Covington, 2004). Fish, especially fatty fish such as salmon, tuna, mackerel, halibut, and 
herring, and fish oils are rich sources of EPA and DHA (Covington, 2004). Additionally, 
algae and seaweed contain abundant quantities of these two LCPUFA. Although much of 
the current scientific research has concentrated on the health effects of fish, it is not yet 
confirmed whether there are functional differences between plant and marine PUFA. 
Lastly, LA is found primarily in vegetable and plant oils, such as corn, safflower, 
soybean, and sunflower, whereas AA is found in animal products, such as meat, poultry, 
and eggs (Fitzpatrick, 2005). 
Nowadays, omega-3 fatty acids have captured considerable attention due to their 
health-promoting characteristics, which assist in prevention and management of chronic 
diseases such as coronary artery disease, hypertension, inflammatory and autoimmune 
disorders, and cancer (Simopoulos, 1991). The link between omega-3 fatty acids and low 
occurrence of CHD became apparent in the 1970s when three investigators observed a 
low rate of CHD events in Greenland’s Eskimos despite a diet rich in fat (Bang et al., 
1980). The researchers proposed that the Eskimos’ diet consisted largely of marine 
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animals (e.g., fish, seal, and whale), known to have a high content of LCPUFA. The same 
conclusion was drawn from Hirai et al. (1980) and Kagawa et al. (1982), who found a 
low incidence of CHD among Japanese people residing in fishing villages. After these 
observations were made, additional scientific investigations, although not unambiguous, 
confirmed the beneficial impact of omega-3 fatty acids on health and particularly on the 
heart. 
ALA is of particular interest for its role in heart health. It has been observed that 
populations with higher intake levels of ALA have a low risk of cardiovascular diseases 
such as coronary heart disease (CHD) and stroke (Flax Council of Canada, 2003b). Also, 
clinical studies have examined the effect of ALA and reported a substantial decrease in 
blood total cholesterol and low-density lipoprotein (LDL) cholesterol, which are risk 
factors for CHD (Chan et al., 1991). Furthermore, it has been observed that the 
Mediterranean diet, which consists of a variety of healthy food products with high levels 
of ALA helps maintain a balance between omega-3 and omega-6 fatty acids. Many 
studies have demonstrated that people who follow a diet rich in omega-3 foods, including 
whole grains, fresh fruits and vegetables, and olive oil, as well as moderate wine 
consumption, are less likely to lead to any heart disease event (de-Lorgeril et al., 1999; 
Singh et al., 2002). This is because ALA has been shown to increase blood clotting time 
(McDonald et al., 1989; Weaver et al., 1990), and so can reduce the likelihood of 
thrombosis and hence a CHD risk. 
Mounting evidence also supports the beneficial effects of EPA and DHA. EPA 
serves as direct precursor to eicosanoids, a group of biologically active compounds that 
provide strong antiarrhythmic and antithrombotic actions on the heart and have 
demonstrated anti-inflammatory properties (Flax Council of Canada, 2003b; Lutter and 
Tucker, 2002). These properties may help prevent or reduce the symptoms of rheumatoid 
arthritis (Horrobin, 1987; Recht et al., 1990; Shapiro et al., 1996) and asthma (Broughton 
et al., 1997). They are also required to help repair damaged tissue (Flax Council of 
Canada, 2003b). However, different eicosanoids derived from AA are biologically active 
in very small amounts, and if they are formed in large amounts (Simopoulos, 1991) they 
tend to promote inflammation and increase blood pressure, platelet aggregation, and cell 
proliferation (Lee et al., 1993; Chow, 1993). For this reason, adequate amounts of 
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omega-3 fatty acids, which produce beneficial eicosanoids, are necessary for a healthy 
diet.  
DHA, the second major LCPUFA, is necessary for proper growth and 
development (Flax Council of Canada, 2003b). Specifically, it is naturally highly 
concentrated in the brain and the retina (Duque, 1997), and appears to play a prominent 
role in promoting cognitive function and eye health. Therefore, the brain and retina are 
dependent on a continuous DHA supply for optimal function (Salem et al., 2001). DHA 
also assists in nervous system development (Uauy et al., 1996). The demand for DHA is 
highest during the latter part of pregnancy and infancy (Ghebremeskel et al., 2000) 
because it is regarded as essential for the proper visual and neurological development of 
infants (Nettleton, 1993; Crawford et al., 1997; Das and Fams, 2003). Furthermore, DHA 
reduces or inhibits risk factors involved in various diseases, such as cardiovascular 
diseases (Kromann and Green, 1980; Kang and Leaf, 1996; Nordøy et al., 2001). Finally, 
it is well established that LCPUFA reduce blood triglyceride levels (Weber and 
Raederstorff, 2000) and hypertension (Leaf and Weber, 1987), which are considered 
important cardiovascular risk factors. To sum up, DHA together with EPA can provide 
preventive effects on chronic diseases and contribute to maintenance of physical and 
mental well-being.   
Attention must be paid, however, to the amount of the daily omega-3 intake, 
particularly EPA and DHA. Consuming massive amounts of marine omega-3 fatty acids 
may harm consumers’ health. The American Food and Drug Administration (FDA) has 
recommended that consumers limit their intake of EPA and DHA to 3 grams per day, 
with no more than 2 grams coming from dietary supplements (Tarantino, 2006). This 
ruling includes specific consideration of the reported effects of omega-3 fatty acids on 
glycemic control in patients with diabetes, on bleeding tendencies, and on low-density 
lipoprotein (LDL) cholesterol levels (Tarantino, 2006). 
2.5.2. Attempts to Increase Omega-3 Fatty Acids in Canada 
It has been observed that the current level of omega-3 fatty acids in the typical 
diet of industrialized countries is extremely low relative to the level of omega-6 fatty 
acids, which exist in excessive amounts (Simopoulos, 1991; Mantzioris, 1995). Increased 
 25
consumption of meats and LA-rich vegetable oils and declining vegetable and fish 
consumption can lead to an imbalance in the ratio of omega-6 to omega-3. The current 
ratio of omega-6 to omega-3 intake in Western Europe and the United States ranges from 
15:1 to 20:1 (Simopoulos, 2001) compared with an estimated ratio of 1:1 during human 
evolution (Simopoulos, 1991; Eaton and Konner, 1985; Leaf and Weber, 1987). This 
imbalance, along with an omega-3 fatty acids deficiency, is associated with increased risk 
of serious health diseases.  
Concerned about this imbalance of omega-6 and omega-3 in the diet and its 
potential negative effects on health, a number of countries (Canada, Sweden, United 
Kingdom, Australia, Japan) as well as the World Health Organization and North Atlantic 
Treaty Organization have issued formal population-based dietary recommendations for 
omega-3 fatty acids (Kris-Etherton et al., 2002) to encourage a more balanced ratio of 
omega-6 and omega-3 fatty acids that would optimize the benefits of both fatty acids 
(Jacobsen, 2004). The Institute of Medicine (IOM) of the National Academies, in 
partnership with Health Canada, established the Dietary Reference Intakes (DRIs)4 for 
Energy and Macronutrients (Health Canada, 2005; Institute of Medicine, 2002). The 
Acceptable Macronutrient Distribution Range (AMDR) for ALA is estimated to be 0.6-
1.2% of energy, or 1.3 to 2.7 g/d on the basis of a 2000-calorie diet (Kris-Etherton, 
2002). Additionally, up to 10% of the adequate intake for ALA can be provided by EPA 
and DHA (Health Canada, 2005). No specific recommendations were set for EPA and 
DHA as IOM indicated that LCPUFA can contribute to the recommended ALA intake 
(Institute of Medicine, 2002). The lower boundary of the range is based on an Adequate 
Intake (AI) set for ALA, which represents median intake levels that prevent an essential 
fatty acid deficiency, while the upper boundary corresponds to the highest ALA intakes 
from foods consumed by individuals in the United States and Canada (Kris-Etherton et 
al., 2002). The estimated recommended intake of LA is 5-10% of energy (Health Canada, 
2005). In order to meet the recommended intakes of omega-3, AHA dietary guidelines 
suggest consuming two fish meals per week, with an emphasis on fatty fish (i.e., salmon, 
herring, and mackerel), and using liquid vegetable oils containing ALA (Kris-Etherton et 
                                                 
4 The Dietary Reference Intakes replaced the U. S. Recommended Dietary Allowances (RDAs) and the Canadian 
Recommended Nutrient Intakes (RNIs). 
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al., 2002), while simultaneously restricting the consumption of food products with high 
LA content. These recommendations intend to provide guidance in the selection of a diet 
that will include recommended amounts of omega-3 and omega-6, and reduce the risk of 
developing diet-related chronic diseases. According to Health Canada, the ratio of 
omega-6 to omega-3 fatty acids is recommended to a range between 4:1 and 10:1 (Health 
and Welfare Canada, 1990) in order to reduce the competitive influence of high LA 
intakes on ALA metabolism to its LCPUFA (Holub, 2002), and thus achieve an 
appropriate balance of these fatty acids.  
Although recommendations to increase the omega-3 intake in diets were made, it 
seems difficult to change the dietary pattern of western populations, which is 
characterized by foods high in refined carbohydrates, saturated and trans fatty acids, and 
vegetable oils high in omega-6 fatty acids but which contain little omega-3 fatty acids 
(Simopoulos, 2003). It was observed that people generally have extremely low levels of 
LCPUFA in relation to ALA due to declining consumption of seafood. Many people do 
not enjoy the taste of fish and believe that they can still get the appropriate intake of 
LCPUFA by consuming vegetable oils with high ALA content. However, even though 
ALA can be converted to EPA and DHA, the conversion is modest and controversial 
(Kris-Etherton et al., 2002). For example, Pawlosky et al. (2001) estimated a 0.2% 
conversion, whereas Emken et al. (1994) found 15%. 
In order to assist consumers in boosting their omega-3 intake, new food choices 
are currently available in the consumer market all over the world. Their potential health 
benefits, along with the ability to label omega-3 fatty acids, have encouraged the food 
industry to introduce more omega-3 fatty acids in the food supply through the 
development of food products enriched in these fatty acids. Genetic modification has 
been used to develop a new generation of plants (e.g., canola, corn and soybeans) that 
produce seeds with an increased omega-3 fatty acid profile (Gebauer et al., 2006) or to 
enhance the levels of EPA and DHA in flax (Fitzpatrick, 2005). The aquaculture industry 
is also growing as the demand for fish oil for fish feed production and human 
consumption is increasing (Jacobsen, 2004). Furthermore, spreads (e.g., margarines and 
mayonnaise) and salad dressings are becoming common products with increased levels of 
omega-3 fatty acids. Other new and innovative omega-3 enriched food products include 
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juices, bread, cereals, snack bars, cookies, pastas, and soups. For example, in February 
2007, Tropicana, a division of PepsiCo, Inc., launched the first orange juice with MEG-3 
(fish-based micro-encapsulated omega-3 powders) in both Canada and the United States 
(Hein, 2007). Additionally, research is intensively focused on the increase of omega-3 
fatty acid content of animal products, such as meat (Howe et al., 2002; Scollan et al., 
2003; Lopez-Ferrer et al., 2001), milk (Kitessa et al., 2004), and eggs (Lewis et al., 
2000a; Howe et al., 2002), by altering the composition of animal feed (Simopoulos, 
1999b). The omega-3 fatty acid content of animal feed is enhanced with the addition of 
fishmeal, flax, and omega-3 fatty acids (Simopoulos, 1999b). New to the Canadian and 
Japanese markets is omega-3 enriched pork, which was developed by a company based in 
Winnipeg, Manitoba (Flax Council of Canada, 1998). In 2005, it received approval to 
label its product. Consequently, a variety of food products can serve as good vehicles for 
omega-3 fatty acid enrichment, which have the potential to improve the population’s 
health and reduce the risk of nutrition-related chronic conditions.  
Increased consumer awareness, in combination with recognizable healthy 
compounds of omega-3 fatty acids, made feasible the nutrition labelling of omega-3 
enriched products. Health Canada made regulations for omega-3 labelling and gave the 
chance to producers to make nutrient content claims that can state that the product is 
“source of omega-3 polyunsaturated fatty acids,” “contains omega-3 polyunsaturated 
fatty acids,” or “provides omega-3 polyunsaturated fatty acids” (CFIA, 2003a). Health 
Canada and the Canadian Food Inspection Agency (CFIA) have also approved certain 
biological role claims that refer to the generally recognized nutritional function of energy 
or nutrients as an aid in maintaining the functions of the body for the maintenance of 
good health or for normal growth and development (CFIA, 2003b). An acceptable 
biological role claim is that “DHA, an omega-3 fatty acid, supports the normal 
development of the brain, eyes and nerves” (CFIA, 2003b), and can only be used if the 
food is a source of the nutrient. Biological role claims are not made for a food or for an 
ingredient in a food, but for the energy value or nutrients in a food (CFIA, 2003b). In 
contrast, the FDA has approved a qualified health claim on both conventional foods and 
dietary supplements containing omega-3 fatty acids that states that “supportive but not 
conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may 
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reduce the risk of coronary heart disease” (FDA, 2004). The FDA remains conservative 
because more scientific evidence is needed to confirm the effect of omega-3 fatty acids 
on the risk of CHD in the general population.   
2.5.3. The Case of Omega-3 Enriched Eggs  
In recent years, omega-3 enriched eggs have gained increased public attention as 
they provide an alternative food source for the delivery of the health-promoting omega-3 
fatty acids. The development of the omega-3 enriched egg began as a Canadian 
endeavour in the 1990s. The industry needed to improve the nutrition health profile of 
eggs because high cholesterol concerns were resulting in a rapid decline in the 
consumption of regular eggs (Flax Council of Canada, 2006). In an effort to find a 
solution to this problem, which affected the egg industry, Dr. Jeong Sim, a professor of 
Agricultural, Food, and Nutritional Science at the University of Alberta, created the 
Canadian Designer Egg, which is enriched with omega-3 fatty acids (Sim, 2007). Dr. Sim 
pioneered the introduction and marketing of Designer Eggs to the commercial market in 
Canada. According to the Canadian Egg Marketing Agency, omega-3 enriched eggs 
currently account for 15% of the Canadian egg market (Flax Council of Canada, 2006). 
Eggs can be easily enriched with omega-3 PUFA through dietary modification of 
the laying hens (Lewis et al., 2000a). Extensive research has found that adding a 
percentage of flax, canola oil, sea algae, or other omega-3 rich products to the ration of 
chicken feed would produce eggs that have an increased level of omega-3 (Pickering, 
2003). In Canada, incorporating mainly flax seed into the laying hen diet has enhanced 
the omega-3 PUFA content. Using flax as 10% or 20% of a poultry ration can increase 
the ALA content of egg yolk fat from 0.4% in the ordinary egg to 4.6% and 8.9%, 
respectively (Flax Council of Canada, 2007). Thus, the ALA of the flax, combined with 
the hen’s own conversion of ALA to EPA and DHA, can make eggs a healthy food 
product, and hence desirable for health conscious consumers.  
Omega-3 enriched eggs provide about twelve times more omega-3 fatty acids 
than regular eggs, based on an average omega-3 content of 0.5 grams in omega-3 
enriched eggs versus 0.04 grams in regular eggs, as illustrated in Table 2.2 (Flax Council 
of Canada, 2003b). This is an average content of omega-3 PUFA, as different brands of 
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omega-3 enriched eggs include different levels of omega-3 PUFA. Nonetheless, the 
number of calories, the amount of protein, and the total fat remain almost the same to that 
of regular eggs, while cholesterol is slightly less in some omega-3 enriched eggs than 
regular eggs. The same remains, also, of taste and versatility. Taking into account that 
omega-3 enriched eggs can serve as an ideal source of omega-3 PUFA, many people find 
it more practical to increase egg consumption rather than fish consumption.  
 
Table 2.2. Comparison of the nutrient content of omega-3-enriched eggs and 
regular eggs1. 
Nutrient Omega-3 Enriched Eggs Regular Eggs2 
Energy 74 calories3 75 calories 
Protein 6.2 g3 6.2 g 
Total Fat 4.8 g3 5.0 g 
Saturated Fat 1.5 g4 1.6 g 
Monounsaturated Fat 2.1 g4 1.9 g 
Polyunsaturated Fat 1.3 g4 0.68 g 
Total Omega-6 Fatty Acids 0.78 g4 0.64 g 
Total Omega-3 Fatty Acids 0.50 g5,6 0.04 g 
Cholesterol   182 mg4   212 mg 
1 Abbreviations: g=grams, mg=milligrams  
2 Nutrient content obtained from U.S. Department of Agriculture Nutrient Database, Release 15, available 
at www.nal.usda.gov/fnic/foodcomp. 
3 Average of two brands of omega-3 enriched eggs. 
4 Average of three brands of omega-3 enriched eggs. 
5 Average of five brands of omega-3 enriched eggs. 
6 On average, an omega-3 enriched egg contains about 0.34 grams of ALA and 0.13 grams of EPA + DHA. 
One omega-3 enriched egg contains a total of about 0.5 grams (500 milligrams) of omega-3 fatty acids. 
(The figure for total omega-3 fatty acids includes several minor omega-3 fatty acids, in addition to the main 
omega-3 fatty acids, ALA, EPA, and DHA). 
Source: Flax Council of Canada, 2003b. 
 
However, one of the barriers to enhancing the appeal of consuming omega-3 
enriched eggs is consumers’ perception that increasing egg consumption is related to high 
blood cholesterol levels, resulting in serious health problems. The American Heart 
Association (AHA) does not specify a desirable egg intake, but it recommends 
consuming no more than three to four egg yolks per week (assuming a weekly cholesterol 
intake of more than 300 mg daily) (Flax Council of Canada, 2003b).  
In order to assess the impact of omega-3 enriched eggs on both serum lipids and 
other risk factors, research studies have been conducted and suggest that some consumers 
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can eat one egg daily with no adverse health effects. Specifically, one study reported that 
most consumers who follow a low-fat, low-cholesterol diet plan can eat twelve omega-3 
enriched eggs per week without an increase in total or LDL cholesterol level (Lewis et 
al., 2000b). Two more studies showed that adding four omega-3 enriched eggs per day in 
a regular diet does not affect the total and LDL cholesterol concentrations (Ferrier et al., 
1995; Oh et al., 1991). Another study found that eating four omega-3 enriched eggs per 
week resulted in a significant decrease in blood platelet aggregation, which is a risk 
factor for CHD (Van Elswyk et al., 1998). Therefore, omega-3 enriched eggs can help 
reduce the risk of CHD, which is a major health concern in Canada, by decreasing major 
CHD risk factors. 
Several clinical and epidemiological studies have also illustrated that dietary 
cholesterol is not the major determinant of plasma cholesterol level in healthy 
individuals. As such, there is no need to set restrictions on egg consumption (McNamara, 
1997). Some studies suggest that eating three to fourteen regular eggs per week has no 
effect on blood lipid levels (Voster et al., 1992), especially if the saturated fat level 
remains low (Edington et al., 1989; Garwin et al., 1992). Another study reported that 
moderate egg intake should not be rigorously restricted in healthy individuals (Scnohr et 
al., 1994). Lastly, a recent large-scale study suggests that consumption of up to one egg 
per day is unlikely to have substantial overall impact on the risk of cardiovascular (CVD) 
or stroke among healthy adults (Hu et al., 1999a). It should be noted, however, that in 
some people plasma total and LDL cholesterol is easily affected by dietary cholesterol, 
and so in such cases modest egg consumption is recommended.   
In conclusion, the enrichment of eggs with omega-3 fatty acids has provided a 
workable solution to those consumers who are interested in increasing their omega-3 
PUFA intake. The consumption of omega-3 enriched eggs on a regular basis can make a 
substantial contribution to the recommended daily intake of omega-3 PUFA to achieve a 
more balanced omega-6 to omega-3 ratio, thus decreasing the risk of developing a diet-
related chronic disease, particularly CHD. Furthermore, the ability to label omega-3 fatty 
acids has stimulated many egg producers to develop these eggs and meet the needs and 
preferences of the niche market. Omega-3 enriched eggs are already commercialized in 
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many countries all over the world and have received wide acceptance due to their 
healthful omega-3 properties (Surai and Sparks, 2001).  
2.6. Economic Impact of CVD 
2.6.1. Direct and Indirect CVD Costs 
For many decades, cardiovascular disease (CVD) remains the major chronic 
condition that causes great concern in Canada and around the world.5 CVD, mainly heart 
disease and stroke, is the prominent cause of illness, disability, and premature death 
among Canadians. In 2004, CVD claimed the lives of 72,338 Canadians and accounted 
for 31.9% of all deaths in the country (Statistics Canada, 2004). Although the death rate 
of CVD has decreased over the last thirty years, CVD continues to be the leading cause 
of mortality in Canada. CVD has the largest economic impact of all diagnostic categories 
as it poses enormous cost, both direct and indirect, on individuals and on society.  
The direct cost of CVD in Canada needs to be reduced because it creates an 
enormous burden on the health care system. “Direct cost is defined as the value of goods 
and services for which payment was made and resources used in treatment, care and 
rehabilitation related to illness or injury” (Heart and Stroke Foundation of Canada, 2003). 
The direct cost of CVD is composed of hospital care expenditures, drug expenditures, 
physician care expenditures, expenditures for care in other institutions, and additional 
health expenditures such as health research.  
The indirect cost of CVD is even greater because CVD has a high probability of 
being fatal. “Indirect cost refers to the value of economic output lost because of illness, 
injury-related work disability, or premature death” (Heart and Stroke Foundation of 
Canada, 2003). The major components of indirect CVD costs are mortality costs (i.e., 
premature death), morbidity costs due to long-term disability and morbidity costs due to 
short term disability. It is noteworthy that a large proportion of the cardiovascular events 
occur among people less than fifty years of age. Avoiding death and disability in people 
at or near the peak of their earnings potential generates large indirect cost savings to 
society (Oster and Thompson, 1996). 
                                                 
5 Cardiovascular diseases refer to diseases and injuries of the heart, the blood vessels of the heart, and the system of 
blood vessels (veins and arteries) throughout the body and within the brain (Heart and Stroke Foundation of Canada, 
2002). 
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The last official report containing data regarding the costs of CVD in Canada 
refers to 1998. In 1998, the total economic burden of CVD was $18,472.9 million in 
Canada and ranked first in total cost, followed by musculoskeletal, cancer, injuries, 
respiratory, and other diseases. The direct cost of CVD reached $6,818.1 million (36.9% 
of total CVD cost) and exceeded, to a large extent, the direct cost of the other diagnostic 
categories. Nonetheless, the indirect cost of CVD reached $11,654.8 million (63.1% of 
total CVD cost) and outweighed the direct cost of CVD, demonstrating the importance of 
indirect cost of CVD for individuals, society, and the health care system. More 
specifically, in terms of direct cost of CVD in 1998, hospital expenditures represented by 
far the largest direct cost, which accounted for $4,161.8 million, or 61% of the total 
direct cost of CVD. Drug expenditures accounted for $1,772.8 million, which represented 
26% of the total direct CVD cost. Also, physician costs and the cost of CVD research 
represented 12.1% and 0.9% of the total direct cost of CVD, respectively (Health 
Canada, 1998b; Heart and Stroke Foundation of Canada, 2003).6 
Mortality accounted for $8,250 million, or 70.8%—the largest proportion—of 
total indirect CVD cost. The costs of morbidity due to long-term disability as a result of 
CVD cost the Canadian economy $3,151.5 million, or 27% of total indirect cost of CVD, 
while the cost of morbidity due to short-term disability represented 2.2% of the total 
indirect cost of CVD (Health Canada, 1998b; Heart and Stroke Foundation of Canada, 
2003). It is worth mentioning that there is an extra cost to the individual, that of pain and 
suffering, which is not taken into consideration in the indirect costs. 
The two main categories of CVD are coronary heart disease (CHD) and stroke or 
cerebrovascular disease. CHD, also called ischemic heart disease (IHD) or coronary 
artery disease (CAD), results from a reduced blood supply to the heart, and accounts for 
more than half of all deaths due to CVD (Mirolla, 2004); stroke is responsible for fewer 
deaths than CHD. As a result, CHD represents a large portion of CVD costs. According 
to 1998 health costs data, hospital expenditures of CHD were $1,274.8 million, while 
drug costs were $512.7 million. Other categories of direct costs, such as physician and 
additional direct costs (e.g., health research), are not reported. In terms of indirect costs, 
                                                 
6 Expenditures for care in other institutions, as well as additional direct health expenditures except health research, are 
only available for all diagnostic categories (Health Canada, 1998b). 
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mortality costs and morbidity costs due to long-term disability from CHD reached 
$4,845.8 and $567.9 million, respectively. No data are available for morbidity costs due 
to short-term disability from CHD. 
Although CVD is the most costly contributor to both direct and indirect health 
costs in Canada, it is also largely preventable (Heart and Stroke Foundation of Canada, 
2003). Following a healthy diet that includes fruits, vegetables, whole grains, poultry, 
and fish, and limits unhealthy fats, can improve health status and prevent the risk of a 
CVD event, fatal or nonfatal. Therefore, the need for medical care may decrease and 
Canada’s escalating CVD costs may be reduced. 
Nowadays, consumers can choose food products high in omega-3 fatty acids due 
to nutrition labelling which is supported by the public, health professionals, and the food 
industry. Nutrition intervention can be effective in controlling CVD and, thus, in 
decreasing costs related to treatment and prevention of CVD. If CVD costs can be 
reduced even slightly due to improved nutrition labelling and additional nutrient and 
health claims, considerable health care savings can be achieved. The provision of health 
information through labelling can contribute to the choice of a more balanced diet, which 
can avert a range of diet-related chronic conditions and attached costs.   
2.6.2. Estimation of CVD Costs 
It is anticipated that CVD will continue to have a negative impact on welfare in 
Canada if no preventive measures are taken. In this section, an estimation of CVD costs 
in general, and CHD costs in particular, for 2006 was performed based on 1998 figures. 
Table 2.3 depicts the estimation of CVD costs ($2006), while Table 2.4 provides 
estimates for CHD costs ($2006). (All the estimated numbers in the tables are bolded).  
The total direct and indirect costs of CVD, as estimated for 2006, are shown in 
Table 2.3. For the estimation, the direct and indirect costs of CVD, as reported in 1998, 
were used. As previously noted, in terms of direct costs, expenditures for care in other 
institutions and additional direct health expenditures apart from health research were not 
classified by diagnostic category in the 1998 Health Canada report. So, in order to take 
into consideration these other direct costs, an assumption is made—it is assumed that 
these costs are the same proportion of total direct health care costs (hospital, drug, and 
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physician costs) for each diagnostic category separately as they are for all diagnostic 
categories together. Thus, a calculated ratio was used to measure the other direct costs of 
CVD for 1998. After calculating the total direct costs of CVD in 1998, the change in CPI 
and the change in population were used to estimate the total direct costs of CVD in 2006 
dollars. The total indirect costs of CVD ($2006) were also estimated by applying the CPI 
and population change to the total indirect cost of CVD in 1998.   
Therefore, according to these estimates, CVD cost the Canadian health care 
system an estimated $13,902.9 million ($2006) annually in total direct costs, which 
represents 48% of the total cost of CVD. Productivity losses due to premature death, as 
well as short-term and long-term disability, cost the economy an additional $14,877.1 
million, which accounts for 52% of the total CVD cost. Hence, the total cost attributed to 
CVD is estimated to be $28,780.2 million per annum.7   
                                                 
7 A detailed calculation of the cost categories of direct and indirect costs of CVD for 2006 is provided in Appendix A. 
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Table 2.3. Estimation of total direct and indirect costs of CVD in Canada ($2006). 
  CVD All diseases 
DIRECT COSTS 
Hospital Costs (HC) (millions CAN$) 4,161.8 27,638.4 
Drug Costs (DC) (millions CAN$) 1,772.8 12,385.2 
Physicians Costs (PC) (millions CAN$) 822.3 11,686.9 
Total HC,DC,PC (millions CAN$) 6,756.9 51,710.5 
Other Direct Costs (ODC) (millions CAN$)1  4,073.5 31,174.7 
Ratio ODC/Total HC,DC,PC2  0.603 0.603 
Health Research Costs (HRC) (millions CAN$) 61.2 1,069.7 
Total Direct Costs ($1998) (millions CAN$)3  10,891.6 83,954.9 
Change in CPI (1998-2006)4 0.19 0.19 
Change in population (1998-2006)5 0.08 0.08 
Total Direct Costs ($2006) (millions CAN$)6  13,902.9 107,166.7 
   
INDIRECT COSTS 
Mortality Costs (MC) (millions CAN$) 8,250 33,481.5 
Morbidity Costs due to Long-Term Disability (LTDMC) 
(millions CAN$) 3,151.5 32,178.7 
Morbidity Costs due to Short-Term Disability (STDMC)  
(millions CAN$) 253.3 9,819.4 
Total Indirect Costs ($1998) (millions CAN$)7 11,654.8 75,479.6 
Change in CPI (1998-2006)  0.19 0.19 
Change in population (1998-2006) 0.08 0.08 
Total Indirect Costs ($2006) (millions CAN$)8 14,877.1 96,348.1 
   
TOTAL COST9 
Total Cost ($1998) (millions CAN$) 22,546.4 159,434.5 
Total Cost ($2006) (millions CAN$) 28,780.1 203,514.8 
1 Other Direct Costs (ODC) include the expenditures for care in other institutions and additional direct health 
expenditures. However, they are the net of Health Research Costs. The ODC for CVD were calculated as a ratio by 
multiplying 6,756.9 (Total HC, DC, PC) with the ratio ODC/Total HC, DC, PC, which is 0.603. 
2 The ratio was calculated by dividing 31,174.7 by 51,710.5. This ratio is applied for CVD in order to calculate the 
other direct costs, assuming that the other direct health costs occupy the same proportion of total direct health care 
costs for each diagnostic category. 
3 The Total Direct Costs ($1998) were calculated by summing HC, DC, PC, ODC, and HRC. 
4 Source: Statistics Canada, 2007b. Consumer Price Index (CPI) for 1998 was 91.3, and 109.1 for 2006. The change in 
CPI was calculated by subtracting 91.3 from 109.1 and dividing by 91.3. 
5 Source: Cansim via E-Stat, Table 051-0005. Quarterly population estimates. The average population estimate for 
1998 was 30,125,715, and 32,581,490 for 2006. The change in population was calculated by subtracting 30,125,715 
from 32,581,490 and dividing by 32,581,490. 
6 Total Direct Costs ($2006) = [Total Direct Cost ($1998)+(Total Direct Cost ($1998)*change in CPI)+(Total Direct 
Cost ($1998)*change in population)] = [10,891.6+(10,891.6*0.19)+(10,891.6*0.06)]. 
7 Total Indirect Costs ($1998) were calculated by summing MC, LTDMC, and STDMC. 
8 Total Indirect Costs ($2006) = [Total Indirect Cost ($1998)+(Total Indirect Cost ($1998)* change in CPI)+(Total 
Indirect Cost ($1998)* change in population)] =  [11,654.8+(11,654.8*0.19)+(11,654.8*0.06)]. 
9 Total Cost is the sum of Total Direct and Total Indirect Costs. 
Source: Author’s estimates (see text for detail). 
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Several people experience a CHD event, either fatal or non-fatal, suggesting that 
CHD is a major category of CVD, and thus has the largest portion of CVD costs. 
Although the 1998 report provides some data on CHD costs, it does not report the costs 
of all the components of direct and indirect costs. So, before estimating CHD in 2006 
dollars, there is a need to measure those CHD costs that are not available. These costs 
include some direct costs, such as physicians, other direct and health research costs, and 
morbidity costs due to short-term disappearance from the indirect cost category. 
 Table 2.4 presents the results of the estimation of the 1998 CHD costs that were 
not reported, as well as the estimation of the total direct and indirect costs of CHD for 
2006. In order to measure the CHD costs that are not available in the 1998 Health Canada 
report, it is assumed that each of these costs represents the same proportion of total 
hospital and drug costs for each category of CVD separately as it does for all CVD 
categories combined. The ratios were calculated based on CVD costs and used to 
measure the unreported costs of CHD. The total direct and indirect costs were thus 
calculated for 1998 using an estimate of all the components of direct and indirect costs of 
CHD. Then, using the direct and indirect costs of CHD in combination with the change in 
CPI and the change in population, the total direct and indirect costs of CHD for 2006 
were estimated.  
As the estimates demonstrate, the total direct cost of CHD reached an estimated 
$4,187.6 million ($2006), and account for 37% of the total cost of CHD. Additionally, 
indirect costs outweigh the direct costs of CHD—an estimated $7,064 million ($2006), or 
63% of the total costs of CHD. This means that there is a large possibility of a CHD 
incident being fatal, highlighting the need to improve diets and follow healthy lifestyles. 
Consequently, CHD creates a total estimated cost to the Canadian economy of $11,251.6 
million8 ($2006) and accounts for 39% of the total cost of CVD.  
                                                 
8 A detailed calculation of the cost categories of direct and indirect costs of CHD for 2006 is provided in Appendix A. 
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Table 2.4. Estimation of total direct and indirect costs of CHD in Canada ($2006). 
  CVD CHD 
DIRECT COSTS 
Hospital Costs (HC) (millions CAN$) 4,161.8 1,274.8 
Drug Costs (DC) (millions CAN$) 1,772.8 512.7 
Total HC,DC (millions CAN$) 5,934.6 1,787.5 
Physician Costs (PC) (millions CAN$)1 822.3 247.7 
Ratio PC/Total HC,DC2 0.1 0.1 
Other Direct Costs (ODC) (millions CAN$)3 4,073.5 1,226.9 
Ratio ODC/Total HC,DC4 0.7 0.7 
Health Research Costs  (HRC) (millions CAN$)5 61.2 18.4 
Ratio HRC/Total HC,DC6 0.01 0.01 
Total Direct Costs ($1998) (millions CAN$)7 10,891.6 3,280.5 
Change in CPI (1998-2006)8 0.19 0.19 
Change in population (1998-2006)9 0.08 0.08 
Total Direct Costs ($2006) (millions CAN$)10 13,902.9 4,187.6 
   
INDIRECT COSTS 
Mortality Costs (MC) (millions CAN$) 8,250 4,845.8 
Morbidity Costs due to Long-Term Disability (LTDMC)  
(millions CAN$) 3,151.5 567.9 
Total MC,LTDMC (millions CAN$) 11,401.5 5,413.7 
Morbidity Costs due to Short-Term Disability (STDMC)  
(millions CAN$)11 253.3 120.3 
Ratio STDMC/Total MC,LTDMC12 0.02 0.02 
Total Indirect Costs ($1998) (millions CAN$)13 11,654.8 5,534 
Change in CPI (1998-2006) 0.19 0.19 
Change in population (1998-2006) 0.08 0.08 
Total Indirect Costs ($2006) (millions CAN$)14 14,877.1 7,064 
   
TOTAL COST15 
Total Cost ($1998) (millions CAN$) 22,546.4 8,814.5 
Total Cost ($2006) (millions CAN$) 28,780.1 11,251.6 
1 Physician Costs of CHD were calculated by multiplying 0.1 (Ratio PC/Total HC, DC) with 1,787.5 (Total HC,DC) of 
CHD. 
2 The ratio was calculated by dividing 822.3 (Physicians Costs) by 5,934.6 (Total HC, DC) of CVD. 
3 Other Direct Costs of CHD were calculated by multiplying 0.7 (Ratio ODC/Total HC, DC) with 1,787.5 (Total 
HC,DC) of CHD 
4 The ratio was calculated by dividing 4,073.5 (Other Direct Costs) by 5,934.6 (Total HC, DC) of CVD. 
5 Health Research Costs of CHD were calculated by multiplying 0.01 (Ratio HRC/Total HC, DC) with 1,787.5 (Total 
HC,DC) of CHD. 
6 The ratio was calculated by dividing 61.2 (Health Research Costs) by 5,934.6 (Total HC, DC) of CVD 
7 Total Direct Costs ($1998) were calculated by summing HC, DC, PC, ODC, and HRC. 
8 Source: Statistics Canada, 2007b. Consumer Price Index (CPI) for 1998 was 91.3, and 109.1for 2006 . The change in 
CPI was calculated by subtracting 91.3 from 109.1 and dividing by 91.3. 
9 Source: Cansim via E-Stat, Table 051-0005. Quarterly population estimates. The average population estimate for 
1998 was 30,125,715, and 32,581,490 for 2006. The change in population was calculated by subtracting 30,125,715 
from 32,581,490 and dividing by 32,581,490. 
10 Total Direct Costs ($2006) = [Total Direct Cost ($1998)+(Total Direct Cost ($1998)* change in CPI)+(Total Direct 
Cost ($1998)* change in population)] = [3,280.5+(3,280.5*0.19)+(3,280.5*0.06)]. 
11 Morbidity Costs of CHD due to Short-term Disability were calculated by multiplying 0.02 (Ratio STDMC/Total 
MC, LTDMC) with 5,431.7 (Total MC, LTDMC) of CHD. 
12 The ratio was calculated by dividing 253.3 (Morbidity costs due to Short-term disability) by 11,401.5 (Total MC, 
LTDMC) of CVD. 
13 Total Indirect Costs ($1998) were calculated by summing MC, LTDMC, and STDMC. 
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14 Total Indirect Costs ($2006) = [Total Indirect Cost ($1998)+ (Total Indirect Cost ($1998)* change in CPI)+ (Total 
Indirect Cost ($1998)*change in population)] = [5,534+(5,534*0.19)+(5,534*0.06)]. 
15 Total Cost is the sum of Total Direct and Total Indirect Costs. 
Source: Author’s estimates (see text for detail). 
2.7. Summary 
This chapter looked at the health attributes of functional foods and their potential 
beneficial effects on consumers’ health, and hence on reducing health care costs. The 
increased demand for foods with health-enhancing properties has led to significant 
growth of the functional food industry in Canada. How labelling, nutrient claims, and 
health claims can assist consumers in making healthy food choices was also discussed. 
This contributes to the correction of the information asymmetry problem and therefore to 
potential savings in health care costs. In addition, this chapter explicitly described 
omega-3 enriched eggs, which are a recent functional food with health promoting 
attributes. Such healthy food is very important as the typical Canadian diet is 
characterized by low levels of omega-3 fatty acids, potentially resulting in serious health 
conditions, particularly CHD. An unhealthy population can negatively affect economic 
welfare by raising health care costs. An estimation of CVD and CHD costs in Canada 
was also performed, illustrating that billions of dollars are spent every year on diet-
related diseases like CVD, whose risk can be substantially minimized by making 
healthier food choices. However, the lack of information may deter consumers from 
improving their diet. Therefore, additional nutrient content and health claims are 
necessary to help improve the health of consumers and decrease health care costs.
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CHAPTER 3: DEVELOPMENT OF THE THEORETICAL MODEL 
3.1. Introduction 
This chapter discusses the current regulatory labelling system in Canada. The lack 
of comprehensive Canadian legislation, which may hinder development of nutritious 
products and create barriers to trade, is described and the need for improvement is 
suggested. A graphical illustration is provided of the effect of health information 
provided via food labelling on social and market welfare. Initially, a case is examined 
where labelling is not available in the market and thus consumers are unaware of the 
healthy properties of functional foods. It continues with a case where health and nutrition  
labels can be used for functional foods (natural and industrial) and claims can also be 
used to assist individuals to manage their diet. The increased consumption of functional 
foods and the increase in health care savings are graphically depicted, reflecting the 
potential contribution of health information and, hence, food labelling. A graphical 
comparison of a voluntary and compulsory labelling system is then provided, showing the 
difference in health benefits. The chapter concludes with a discussion of the negative 
externality that prevents a socially optimal level of consumption of functional foods, and 
proposes some possible solutions. 
3.2. Canadian Regulatory Framework for Functional Foods 
In Canada, all food and drugs are regulated under the Food and Drugs Act and 
Regulations. Labelling products with nutrition information helps Canadian consumers 
make healthier and more informed dietary choices, which may prevent chronic nutrition-
related diseases, thus generating a savings in medical costs. Until recently in Canada, 
nutrition labelling was voluntary. However, Health Canada made amendments to the 
Foods and Drugs Act regulations, and so on 1 January 2003 these new regulations were 
officially published in the Canada Gazette Part II (Canada Gazette, 2003b). The 
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regulation of nutrition labelling of foods became mandatory for large manufacturers on 
12 December 2005, while small manufacturers have until December 12, 2007 to 
implement the new nutrition label format (Canada Gazette, 2003b; Nutrition Labelling 
Regulations, 2007). The new nutritional labelling regulations also allow firms to make 
nutrient content claims as well as health claims on food labels  
3.2.1. Mandatory Nutrition Labelling and Nutrient Content Claims 
The new regulations require almost all prepackaged foods to carry a mandatory 
Nutrition Facts table that lists calories and thirteen core nutrients, including the amount of 
fat, saturated and trans fats, cholesterol, sodium, carbohydrate, fiber, sugars, protein, 
vitamins A and C, calcium and iron in a specified amount of food. The Nutrition Facts 
table looks the same on most products and the listing of nutrients appears in a 
standardized format in order to help consumers compare similar products. The 
information is provided as an amount in grams and as a percentage (%) of Daily Value 
(Canada Gazette, 2003b). Daily Value can be used to determine whether a food item has 
a little or a lot of a particular nutrient in a specified amount of food. It should also be 
mentioned that any other nutrient that is added to a food or that is the subject of a claim 
must also be declared in the Nutrition Facts table. 
Labels can also include nutrient content claims that emphasize the specific 
nutrient contained in a product. According to the CFIA, “A nutrient content claim is any 
statement or expression which describes, directly or indirectly, the level of a nutrient(s) in 
a food or group of foods” (CFIA, 2003c). Nutrient content claims are voluntary within the 
new labelling regulation, but if used they have to observe specific criteria outlined in the 
regulations guidelines. Some examples include “low sodium,” “sugar-free,” “reduced in 
fat,” “source of omega-3 polyusaturates,” “high source of fiber,” and “trans fat free.” 
Nutrient content claims serve a different function than information on the label’s 
Nutrition Facts table. Although the Nutrition Facts table provides useful and detailed 
information, it may be relatively ineffective at capturing a consumer’s interest in the first 
place (Ippolito and Mathios, 1993). However, nutrient content claims may be more 
helpful and encourage consumers to consume healthier products and improve their diets. 
The federal government’s aim is to provide additional information through the Nutrition 
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Facts table to consumers who are aware of healthy eating patterns, as well as to stimulate 
indifferent portions of the population to consume more nutritious foods via nutrient 
content claims. Presumably, nutrition information should be accompanied by consumer 
education to be even more effective. 
3.2.2. Health Claims 
The new labelling regulations also allowed diet-related health claims for the first 
time in Canada. Diet-related health claims are considered statements that describe the 
characteristics of a diet associated with the reduction of the risk of developing a diet-
related disease or condition (e.g., osteoporosis, cancer, or heart disease) (Canada Gazette, 
2003b). An example of such a claim is, “A healthy diet with adequate calcium and 
vitamin D, and regular activity helps to achieve strong bones and may reduce the risk of 
osteoporosis. (Naming the food) is a good source of calcium” (Canada Gazette, 2003b). 
Consumers now have the opportunity to select from a variety of foods with healthy 
attributes and improve their well-being by minimizing the risk of chronic disease. 
The regulation and permission of health claims in Canada also benefits food 
companies, as health claims can be used as a marketing technique (Hawkes, 2004). 
Producers are willing to increase research and development to find new ways of 
producing products that have health benefits. Furthermore, some products are being 
reformulated (e.g., foods that now are free of saturated and trans fat) by changing their 
nutritional composition in order to meet the criteria to qualify for health claims (Lutz, 
2005).   
In November 1998, Health Canada published a policy recommendation on health 
claims for foods. The policy recommended that structure/function and risk reduction 
claims be permitted for foods, while therapeutic claims (i.e., that a product can cure, treat, 
mitigate, or prevent illness) should continue to be regulated as drugs (Health Canada, 
1998a; Health Canada, 2000; Health Canada, 2001). In the policy paper, Health Canada 
described structure/function claims as the effect of a food or a diet on a structure or 
physiological function in the human body (e.g., calcium helps to build strong bones) 
(Health Canada, 2000). A risk reduction health claim describes the relationship between 
the consumption of a food or a diet and reduction in the risk of developing a chronic 
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disease or abnormal physiological state by significantly altering a major risk factor or 
factors recognized to be involved in its development (e.g., calcium helps reduce the risk 
and progression of osteoporosis) (Health Canada, 2000). 
These claims are distinguished into two types, generic and product-specific health 
claims. Manufacturers apply generic health claims to any food or food product that meets 
the criteria for the claim (Health Canada, 2000). This is in contrast to product-specific 
health claims, which are made for a proprietary product. This means that they cannot be 
generalized to other similar products unless acceptable supporting evidence is provided 
(Health Canada, 2000). In other words, the food product must have been designed to 
provide a specific and documented effect (Asp and Laser Reutersward, 1998). Permitting 
product-specific health claims can also promote industry innovation through the 
development of products with healthy characteristics. However, it has been argued that 
such claims should not be allowed as they undermine the general principle that total diet, 
not individual foods, is the key to good health (Hawkes, 2004). A procedure for product 
specific health claims has not yet been fully developed in Canada (Lutz, 2005). 
Figure 3.1. Types of claims and types of food products. 
Source: Health Canada (2000). 
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New Canadian regulations permit five generic diet-related health claims—four of 
them for disease risk-reduction and one for tooth decay. The regulations set out the 
prescribed wording for permitted claims to ensure that they are consistent, accurate, and 
non-deceptive (Canada Gazette, 2003b). The current permitted generic diet-related health 
claims are the following (Fitzpatrick, 2004; Health Canada, 2006): 
1. Sodium : hypertension. 
2. Calcium : osteoporosis. 
3. Saturated and trans fats and cholesterol : coronary heart disease. 
4. Fruits and vegetables : cancer. 
5. Sugar alcohols : tooth decay. 
 
In addition to the above generic health claims, there are four more health claims 
that Canadian regulatory authorities are still examining. Although United States has 
already approved these claims, decisions are pending in Canada for the following four 
claims (Fitzpatrick, 2004): 
1. Folate : neural tube defects 
2. Fibre-containing grain products, fruits, and vegetables : cancers 
3. Fruits, vegetables and grain products that contain fibre, particularly soluble 
fibre : risk of coronary heart disease 
4. Soluble fibre : risk of coronary heart disease. 
 
Diet-related health claims can affect food purchase decisions and improve health 
and well-being. Both nutrient content and health claims are considered very useful for 
attracting consumers’ attention and encouraging them to consume functional foods. The 
Nutrition Facts table provides more in-depth information regarding the nutritional 
composition of a product to help consumers assess whether it satisfies their health needs 
and preferences. 
Several surveys have been conducted to evaluate consumers’ perceptions and 
attitudes related to health claims on functional foods. They have illustrated that most 
consumers consider health claims useful and helpful as they help them achieve and 
maintain a healthy lifestyle. In Canada, a telephone survey about products with functional 
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benefits reported that most respondents believed packaging should promote the health 
benefit that it provides, rather than solely indicate the presence of the component itself 
(National Institute of Nutrition, 2000). This indicates that consumers prefer health claims 
to content claims—47% rated them as very useful compared to less than 10% who saw 
little or no value for health claims (National Institute of Nutrition, 2000). Other studies 
performed in Scandinavia (Bech-Larsen and Grunert, 2003), the U.K. (Food Standards 
Agency and COI Communications, 2004) and the U.S. (Fullmer et al., 1991) have 
indicated similar attitudes and opinions related to health claims amongst consumers, 
demonstrating the significance that health claims have in consumers’ purchasing 
decisions.  
Regulatory authorities in Canada aim to protect the public from false and 
misleading claims and to make sure that nutrient and health claims are based on scientific 
evidence. Consumers need to have a clear understanding of, and a strong confidence level 
in, the scientific criteria used to document health effects and claims (EUFIC, 2006). Some 
consumer groups exhibit high levels of skepticism and concern about health claims, and 
feel that regulations are necessary in order to ensure that health claims are based on 
scientific evidence and can achieve nutritional goals (Carretson and Bulton, 2000). With a 
clear regulatory framework, consumers are becoming more willing to consume functional 
foods, meaning that the risk of developing nutrition-related diseases may decrease. 
3.3. Complications in Marketing Functional Foods 
Canada’s regulatory system has been improved over the last decade. In 1996, 
Canada was among the least favorable regulatory environment for allowing health claims. 
Since that time, progress has been made with respect to the definition of health claims 
and the availability of five generic claims (MacDonald, 2004). However, the regulatory 
system is currently being challenged by rapid scientific and technological advancement, 
global markets, evolving business practices, higher public expectations of government 
and business, and cross-boundary health and environmental risks (Government of 
Canada, 2005a; Government of Canada. 2005b; External Advisory Committee on Smart 
Regulation. 2004). The lack of an adequate, effective, flexible and comprehensive legal 
framework discourages investment in the research and development of functional foods 
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with potential health benefits, as well as undermines consumer confidence in functional 
foods. When firms cannot label any beneficial ingredient, they have no incentive to do 
research and supply the food market with new healthful products. For example, although 
a variety of healthful nutrients such as beta-glucan, lutein, and selenium may improve and 
maintain the general population’s health status, they are not currently approved to appear 
on food labels as health claims, suggesting the restrictive nature of the regulatory system. 
The Canadian regulatory regime for functional foods and nutraceuticals needs to 
be reviewed and updated to cover evolving consumer needs, retain confidence, and 
promote competition among companies. It is necessary for the system to recognize the 
beneficial effects of functional foods on Canadians’ health and provide the food industry 
with the appropriate incentives to expand the availability of new nutritious products 
necessary for a reduction in diet-related diseases. Canada’s legislation has to keep pace 
with science development in order to both protect the health and safety of citizens and 
promote innovation. 
The need for regulatory reform is crucial not only domestically but also 
internationally. Canadian firms, wishing to export their products, face transaction costs 
due to the difference in the regulatory systems under which foreign companies operate 
(Hobbs, 2002). In cases where Canadian standards for ingredients and final products 
differ from those of the international market, particularly the U.S., production might 
become less efficient, thereby reducing Canada’s attractiveness as a plant location 
(External Advisory Committee on Smart Regulation, 2004). The regulatory differences 
between Canada and its major trading partners may hurt Canadian economic 
competitiveness in terms of trade and investment opportunities (External Advisory 
Committee on Smart Regulation, 2004). Some examples showing the regulatory 
differences between Canada and the U.S. are presented in Table 3.1. 
 
 
 46
  Table 3.1.  Examples of Canada/U.S. regulatory differences. 
Issue Canadian Approach U.S. Approach 
Antiperspirant deodorant Aluminum content requires a Drug Identification Number No DIN required 
Trans fat on nutrition 
labels 
In order to be considered a 
“trans fat free” product trans 
fat must be below 0.2g of 
trans fatty acids (1) per 
reference amount and 
serving of stated size, or (2) 
per serving of stated size if 
the food is a prepackaged 
meal 
In order to be 
considered “trans fat 
free”, product must have 
less than 0.5g per 
reference amount and 
serving size 
Fortification of breakfast 
cereals and other food 
products 
Canadian regulations specify 
which foods may be fortified 
and the levels for their 
fortification with vitamins 
and minerals 
The U.S. has no limits 
on the levels of vitamins 
and minerals used to 
fortify food products 
Fortified water 
Addition of vitamins and 
minerals to bottled water 
prohibited 
Bottled water may be 
fortified with vitamins 
and minerals 
Frozen pizza 
BHA, BHT, and caramel 
colour are approved 
additives but cannot be used 
in pepperoni and sausage 
chunks 
BHA, BHT, and 
caramel colour are 
permitted for use in 
pepperoni and sausage 
chunks 
Cheddar-flavoured 
popcorn 
Cheese seasoning must be 
less than 49% real cheese 
Up to 53% real cheese 
seasoning used 
Auto anti-theft 
immobilizers 
Proposed requirement for 
immobilizers accepting 
Canadian and European 
standards 
An option for US for 
high theft line vehicles 
Source: External Advisory Committee on Smart Regulation, 2004. 
 
An External Advisory Committee on Smart Regulation was established in May 
2003 to renew the Canadian regulatory environment (External Advisory Committee on 
Smart Regulation, 2004). The aim of Smart Regulation is to improve Canada’s regulatory 
system, including the regulations in the agriculture and agri-food sector that promote 
consumer health and innovation. The Committee tries to create a more effective, flexible, 
transparent, and well-coordinated regulation which will adapt quickly to new scientific 
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advances and nutrition discoveries. The objectives of Smart Regulation are the following 
(Government of Canada, 2005b):     
• enhanced coordination across the federal government and better co-operation with 
other governments in Canada and internationally to help set and meet national 
objectives that promote social, environmental, and economic well-being, and 
improve Canadians’ quality of life; 
• increased policy coherence and integration of social, economic, and 
environmental principles and objectives into all stages of policy, regulation, and 
decision making; 
• improved transparency, efficiency, timeliness, and predictability of regulatory and 
decision-making processes, and reduced administrative burden for businesses and 
citizens; 
• strengthened planning and priority setting and more proactive and timely problem 
and risk identification to facilitate responsive regulation and better protect the 
public interest; 
• improved identification, management, and mitigation of aggregate and unintended 
impacts on areas and sectors through greater use of longer-term, integrated, and 
whole-of-government approaches to regulation; and 
• strengthened regulatory management from design to implementation, and 
evaluation of regulation for the continuous improvement and ongoing renewal of 
regulation across government. 
 
Regulatory coordination among governments is a key issue that can contribute to 
the improvement and effectiveness of the regulatory system, but remains a major problem 
in Canada. Federal and provincial/territorial governments in Canada share regulatory 
responsibilities in several areas, including agriculture, environment, food safety, 
pharmaceuticals, and transport (External Advisory Committee on Smart Regulation, 
2004). In the area of pharmaceuticals, for instance, the federal government is responsible 
for approving drugs for market, while provincial governments regulate the selection of 
drugs used in each provincial medical system (External Advisory Committee on Smart 
Regulation, 2004). Additionally, not only are federal governments responsible for food 
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regulations but provincial governments have jurisdictions over some aspects of food 
regulation (e.g., provincially inspected food processing facilities for products that will not 
cross inter-provincial borders). However, issues of overlapping jurisdiction and 
duplication have been raised in reviews of Canadian regulatory practice since at least the 
1980s, resulting in considerable costs to the Canadian economy (External Advisory 
Committee on Smart Regulation, 2004).   
A challenge to federal and provincial/territorial cooperation is the lack of 
coordination between federal departments. Very few regulatory issues fall under the 
exclusive mandate of a single federal department. In the food processing sector, for 
example, there can be as many as three different federal departments and agencies with 
regulatory responsibility in this area — Health Canada, Environment Canada, and the 
Canadian Food Inspection Agency (CFIA). This is in addition to Agriculture and Agri-
Food Canada (AAFC), which holds the broader policy responsibility for this sector 
(External Advisory Committee on Smart Regulation, 2004). Each of these agencies is 
responsible for the safety and health of Canadians and regulates the food products before 
entering the market. This means that cooperation between them is necessary in order to 
improve the regulatory regime.  
Food companies have expressed dissatisfaction as they deal with different federal 
and provincial authorities that sometimes have different regulatory requirements. This 
can complicate the approval of functional foods, forcing companies away from the 
research and development of new nutritious products. The lack of cooperation can 
seriously affect the efficiency of the regulatory system. Non-cooperation increases 
production costs for the food industry and creates a complex regulatory environment, all 
of which acts as a disincentive to investment in Canada. The multiplicity of federal 
regulators also creates barriers to citizens’ and businesses’ participation in the regulatory 
process (External Advisory Committee on Smart Regulation, 2004).  
3.4. Graphical Illustration of Social Welfare Before and After Food Labelling 
The functional food industry encounters two crucial market failures that may need 
federal intervention in order to be resolved. The first one, which will be explicitly 
discussed and analyzed in this thesis, is the information asymmetry problem that arises 
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due to credence attributes of functional foods. This problem deters consumers from 
making informed decisions about the purchase and consumption of nutritious goods and 
goods with potential health benefits. As a result, the economy incurs health care costs 
caused by diet-related chronic diseases. While the introduction of mandatory labelling 
and nutrient content and health claims are important tools for communicating valuable 
nutrition information, even greater access to information could improve the health of 
Canadians, thereby benefiting the economy.  
A negative externality effect is another form of potential market failure in the 
functional food market. Consuming an unhealthy diet can lead to negative externalities 
because consumers do not pay the full health care costs that are associated with unhealthy 
eating, hence decreasing economic welfare. When individuals are protected by health 
insurance, a moral hazard problem is created and consumers—even these with nutritional 
knowledge—have a reduced incentive to restrain their consumption of goods with 
adverse health effects. This situation results in market inefficiencies and reduces welfare. 
Although this thesis concentrates on asymmetrically distributed information, some 
possible solutions for the moral hazard problem are proposed and briefly discussed at the 
end of this chapter.  
In subsection 3.4.1 the effect of information asymmetry through the absence of 
labelling is graphically depicted, highlighting the social welfare loss in terms of health 
care costs. Then, in subsection 3.4.2, two graphs (one for natural functional food and one 
for industrial) are provided, taking into consideration food labelling and claims. The 
graphs show the importance of the information supplied through food labels in the 
reduction of medical costs. 
3.4.1. The Case of No Labelling 
Recently, many consumers have shown a growing concern about their diet and 
health. They seek products with nutritious characteristics and beneficial health properties 
in order to improve their health and decrease the risk of developing a chronic disease. 
Although they are interested in leading a balanced diet by consuming functional foods, 
they are restricted by a lack of adequate information provided by nutrient content and 
health claims. This information is necessary for consumers to help them make food 
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choices that best reflect their dietary needs. When a consumer is uninformed about the 
health benefits of a functional food, neither the private or social health benefits are 
reflected in the consumer demand. As a result, the problem of asymmetric information 
arises and the quantity consumed of a functional food can diverge considerably from the 
social optimum.  
The lack of health information and resulting negative social welfare is depicted in 
Figure 3.2. Specifically, this graph combines the private demand curve and the social 
marginal benefit curve, and shows the limited consumption of a natural functional food 
when food labels are not available. The social marginal benefit curve is denoted as SMB , 
and shows the social benefits gained from the consumption of a functional food. DP
UN  
represents the private demand curve of uninformed consumers due to a lack of labelling. 
The private marginal cost is denoted as MCP  and it is flat due to the competitive market 
structure. The social marginal benefit curve, denoting the health benefits from the 
consumption of a functional food, is higher than the private demand curve because 
functional food consumption can affect health care costs, which are paid mostly by the 
Canadian government.9 
When people are not informed about the beneficial health effects of functional 
foods or the adverse effects of some components that other foods contain (e.g., trans fatty 
acids), they will not change their food consumption choices if they are otherwise satisfied 
with their eating patterns. Some may consume a small amount of almost each functional 
food that contains a naturally healthy component (e.g., olives, oats, tomatoes, canola oil) 
even though they are not informed about its healthy properties. However, functional 
foods that result from technological developments will not exist in a market where there 
is no nutrition information because their higher production cost will prevent them from 
being able to compete with natural functional foods (see section 3.4.2, Figure 3.5). The 
intersection of a private demand curve and a marginal cost curve gives the price UNPP and 
the quantity consumed UNPQ of a natural functional food. Consumers will not consume 
more than this quantity when they are not provided with pertinent health information 
through labelling. 
                                                 
9 Private medical insurances also contribute to increased health care costs because they create moral hazard. Individuals 
consume unhealthy products knowing that health insurance will cover most costs of a chronic disease. 
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As far as welfare analysis is concerned, the consumer surplus from the 
consumption of UNPQ  natural functional food is equal to the area 
UN
PEDP  while there is no 
producer surplus due to the competitive market. The consumer and producer surplus do 
not capture the external health benefits which arise from the reduction in health care costs 
and are equal to the area ABDE. As Figure 3.2 illustrates, this unavailability of health 
information creates dead weight loss, equal to the area BCD, which is measured by direct 
and indirect health care expenditures.  
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Figure 3.2. Social welfare loss due to lack of labelling information. 
 
In some cases, uninformed individuals will unknowingly consume some 
functional foods. This means that they consume a healthy food because they like its taste 
or quality. Nutrition information is not available through labelling to influence their 
consumption choices. Although consumers lack nutrition information, this consumption 
provides them with an unknown health benefit because it contributes to their improved 
health. For example, some people consume oats because they like the taste. This 
satisfaction gives them a direct private benefit while simultaneously gaining a health 
benefit from the oat fiber, which has beneficial health effects. Yet consumers do not 
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realize this health enhancement if they are not aware of the health impacts of oat fiber. In 
Figure 3.3, the private marginal benefit curve ( MBP
UN ) has been inserted to illustrate the 
additional private health benefit obtained due to the improved health. The area FGDE 
represents the unrealized private health benefit that ignorant consumers gain. The external 
social health benefits are depicted by the area ABGF, while the dead weight loss due to a 
lack of labelling information remains the same and equal to the area BCD.  
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Figure 3.3. Social welfare loss due to lack of labelling information with the 
marginal benefit. 
 
3.4.2.  The Case of Labelling and Social Benefits 
In an effort to correct the market failure caused by information asymmetry, the 
Canadian government recently enforced mandatory nutrition labelling in almost all pre-
packaged food products and allowed the use of nutrient content claims and five health 
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claims.10 Consumers can now identify and consume some functional foods that contain 
nutritious attributes and avoid foods that have negative health effects. The dissemination 
of favorable information through food labels can substantially increase the demand for 
functional foods, while nutrient content and health claims can assist in shifting the 
demand curve even closer to the social optimum.  
Consumers now have the chance to choose from a variety of functional foods as 
both categories, natural and industrial, are available in the market. The two types of 
functional foods, as well as their contribution in the reduction of health care costs, are 
explained below. 
As was discussed in the first part of this chapter, the consumption of functional 
foods that contain healthy ingredients inherently takes place even in the absence of health 
information. However, the availability of food labelling can increase this consumption 
and make people healthier. As Figure 3.4 illustrates, labelling information results in an 
upward shift in the private demand curve, which now represents the private marginal 
benefit curve MBP
IN( ) for it includes the marginal health benefits that informed consumers 
gain from the consumption of a functional food. The provision of labelling information 
also shifts upwards the marginal cost curve, which now includes the labelling costs. The 
intercept of the private marginal benefit curve of informed consumers and the marginal 
cost curve increases the equilibrium price from UNPP  to 
IN
PP , and the equilibrium quantity 
from UNPQ  to 
IN
PQ . The consumer surplus increases and equals to the area 
IN
PFJP . The 
private health benefits are equal to the area FJKE, while the area GJKD represents the 
health benefits that informed consumers gain from the additional consumption of a 
functional food due to labelling. The external social health benefits in terms of health care 
savings are increased, too, and are equal to the area AIJF. This means that distribution of 
information ameliorates consumers’ health and, hence, increases health savings (area 
BIJG). Despite labelling information, society still bears dead weight loss equal to ILJ due 
to the negative externalities caused by public or private health insurances. 
                                                 
10 Canadian regulators also allow natural health products (vitamins and minerals, herbal products, homeopathic 
medicines and probiotics) in the market. Consumers now have the chance to protect and improve their health via natural 
health products (Canada Gazette, 2003a).  
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In case the market structure of natural functional foods is non competitive, there 
would be an oligopolistic price markup, meaning that the price would be greater than the 
marginal cost. We consider the oligopolistic case in the later discussion regarding 
industrial functional foods. 
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Figure 3.4. Natural functional food: Private and social welfare benefits due to 
labelling information. 
 
The situation is different in the case of industrial functional foods. As was 
mentioned in section 3.4.1, in the absence of health information, industrial functional 
foods are not available in the market because their costs are higher and consumers cannot 
distinguish between them and conventional foods. As Figure 3.5 depicts, the marginal 
cost curve of an industrial functional food is higher than that of a natural functional food, 
resulting in zero consumption when there is no food labelling. However, with the 
introduction of labelling, food companies start producing foods with health-enhancing 
properties by adding, enriching, or removing food additives. Thus, a wide range of 
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functional foods enter the market, giving consumers the choice to switch to a healthy 
balanced diet, thereby reducing health care costs. 
The introduction of labelling information leads to an upward shift in the marginal 
cost curve, which represents the marginal cost including the labelling costs. Given the 
fixed costs and the limited number of functional food firms, there would be a markup 
over price, called as oligopolistic price markup. This markup is the difference between 
the oligopolistic price ( )indP  and the marginal cost ( )tslabellingMC cos+ . 
The welfare effect of the introduction of technologically developed functional 
foods is showed in Figure 3.5. The consumer surplus is given by the area indEDP  while 
the producer surplus equals to the area DGFPind . The external social health benefits from 
a reduction in health care costs are equal to the area ABDE. The dead weight loss due to 
the negative externalities created by health insurances equals to BCG. 
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Figure 3.5. Industrial functional food: Private and social welfare benefits from 
health information. 
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As was shown graphically, both labels and claims found on food products help 
consumers make informative purchasing choices and increase the consumption of foods 
with healthy characteristics. Although consumers are not homogeneous—some 
consumers will pay more attention to food labels, such as those with a family history of a 
chronic disease—food labelling plays a crucial role in informing individuals and reducing 
health care costs. Yet, food labelling only partially corrects the market inefficiency 
because the private marginal benefit and the social marginal benefit curves cannot 
coincide due to the negative externality that exists in the market, to be discussed in 
section 3.6. 
3.5. Voluntary versus Mandatory Food Labelling 
Before mandatory food nutrition labelling was implemented in Canada, 
companies used voluntary labelling to differentiate their products. Food companies 
marketing products with healthy components were willing to label this component in 
order to capture a greater market share, while those supplying products with normal or 
negative attributes had no incentive to label. As a result of incomplete labelling, 
consumers often could not make purchasing decisions that would best reflect their 
preferences.  
Mandatory labelling may be more effective policy for addressing information 
asymmetry. If companies are forced to label their products, they are more likely to 
modify their products to reflect consumer preferences. This kind of regulation encourages 
competition and increases research activities and innovation. With greater access to food 
information, consumers can choose to increase the consumption of healthy food products 
in order to lower the risk of nutrition-related diseases. Although a regulation to label 
almost all prepackaged food products would increase costs (e.g., cost of product 
reformulation, product testing, labelling, and marketing), the health care savings could be 
large enough to outweigh the costs, leading to a healthier population and general 
economic gain.  
Gray et al. (2006) studied the efficacy of three different policies designed to limit 
the consumption of trans fatty acids (TFAs). A voluntary labelling system, a mandatory 
labelling system, and a ban on food products with TFA greater than 2% were compared. 
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The results showed that the cost to industry from mandatory labelling is greater than 
voluntary labelling, but that coronary heart disease (CHD) health benefits are by far 
larger in magnitude, making mandatory TFA labelling very advantageous for the 
Canadian economy. An additional economic gain would be also achieved from a TFA 
ban (Gray et al., 2006). 
In Figure 3.6, the private and social health benefits from voluntary and mandatory 
labelling are depicted. The marginal cost for voluntary and mandatory labelling is 
assumed to be the same. The private marginal benefit curve in the case of a voluntary 
labelling system lies below the private marginal benefit curve in the case of a mandatory 
labelling due to limited information provided to consumers, resulting in reduced health 
care savings. The market structure of industrial functional foods may be oligopolistic, 
meaning that the price under mandatory labelling ( )mandP  and the price under voluntary 
labelling ( )VolP  are greater than the marginal cost. The quantity consumed ( INPVolQ ) of an 
industrial (or natural) functional food when it is voluntarily labeled is less than the 
quantity consumed ( INPMandQ ) when consumers gain full information through mandatory 
labelling. The shaded area HBGI represents the social (private and external social) health 
savings that are forgone when consumers are not fully informed due to a voluntary 
labelling system. Hence, mandatory food labelling can contribute to an improvement in 
individuals’ health and enhance economic efficiency. However, it is worth noting that if 
the mandatory labelling cost was significantly higher than voluntary labelling cost, the 
welfare impacts of mandatory labeling would no longer be unambiguously positive. 
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Figure 3.6. Voluntary versus mandatory food labelling: Private and social welfare 
benefits. 
 
3.6. Negative Externality Effect and Possible Solutions 
Although nutrition information can play an important role in improving diet and 
thus reducing both private and social health care costs to a significant extent, as was 
shown in Figures 3.4 and 3.5, the economic incentives created by either public or private 
health insurance limits the socially optimal level of functional food consumption. Insured 
consumers have a lower incentive to consume products with nutritious properties as long 
as they are protected by medical and disability insurance, which covers a large amount of 
the costs associated with various chronic conditions. The large health-care externality due 
to health insurance creates a moral hazard by reducing the incentive to consume a socially 
appropriate amount of a functional food. This market inefficiency deters even the 
informed consumers from fully modifying their diets, thereby having a negative effect on 
social welfare. In Figures 3.4 and 3.5, the social welfare loss due to the negative 
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externality effect is equal to the areas ILJ and BCG, respectively. So, it is clear that some 
proportion of health care costs can be reduced only if this market failure is corrected. 
In theory, there are several propositions that could be used as solutions to this 
problem, but, as is discussed below, all are difficult to implement (Gray and Malla, 
2004). The first would be to correct the market failure through an assignment of property 
rights. Governments could assign the cost of medical treatment to individuals. In this 
case, individuals would therefore be more careful of what foods they consume and would 
have a greater incentive to adopt a healthier lifestyle. However, this policy would 
unlikely achieve the intended results as private insurance would become popular, as in the 
United States, leaving a scope for moral hazard within these insurance pools. 
 A second possible solution would be the modification and improvement of 
private and public health insurance contracts to better reflect consumer choices. However, 
given the large influence of genetics and other risk factors in determining disease risk, 
altering insurance payoffs may be insufficient to eliminate the externality (Malla et al., 
2007). Also, it would be difficult and extremely expensive to inspect an individual’s 
intake of components with adverse health effects. Thus, the consumption externality 
would continue to affect negatively economic welfare. In such cases, government 
intervention might be necessary to correct the market failure caused by the externality.  
The third policy option would be to regulate the production and importation of 
certain food products with harmful substances. The regulatory limits on the amount of the 
externality produced and imported could improve market outcomes. The U.S. Food and 
Drug Administration has already enforced this type of regulation for certain food 
additives that are prohibited from use because of cancer or other disease threat (Gray and 
Malla, 2004). In Canada, similar restrictions have been placed on imports of certain U.S. 
animals and their products to protect human health (Canada Gazette, 2007).   
The fourth solution would be to either impose a tax on the production or 
consumption of foods with a negative externality or implement a subsidy on the 
consumption of healthier foods. The size of a Pigovian tax (subsidy) would be equal to 
the damage (benefit) of the negative (positive) externality. This means that a government 
can enforce a tax on products with unhealthy attributes equal to the health care costs, or 
provide subsidies to encourage the consumption of nutritious and healthy goods. The 
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regulation of Pigovian taxation offers an effective means of achieving market efficiency 
by addressing incentive problems and increasing economic surplus. However, it is 
considered very complex and difficult to control because each food with a harmful 
(beneficial) health additive would have its own level of tax (subsidy), something costly to 
implement.  
Although so-called “fat taxes” have been proposed, mostly as a means of 
addressing food-related concerns, it has been suggested that “thin subsidies” would be a 
way of tackling unhealthy eating habits (Cash et al., 2005). Fat taxes aim to discourage 
the purchase of foods that are least nutritious or most harmful by increasing the effective 
price to consumers. However, subsidizing the costs of healthy food would reward and 
encourage people to eat healthier foods rather than punish them when they eat poorly 
(Cash et al., 2005). Making unhealthy food products more expensive may potentially 
decrease their consumption, even though it is uncertain whether that would lead 
consumers to switch to healthier products. According to Cash, if the government 
subsidized fruits and vegetables to lower their price by just one percent, 9,680 fewer 
cases of coronary heart disease and ischemic stroke would occur per year in U.S. (Cash et 
al., 2005). Therefore, instituting subsidies for the consumption of healthier food products 
may have a greater outcome on reducing health care costs than taxing harmful foods. 
3.7. Conclusion 
This chapter discussed the current regulatory framework in Canada and indicated 
how mandatory labelling and claims can affect purchasing decisions and improve health. 
However, the limited number of allowable nutrient and health claims prevents increased 
consumption of some nutritious food products because consumers are unaware of this 
information. This decreases the food industry’s incentive to perform research and supply 
the market with healthy products. A well-organized and modern regulatory system is 
necessary in order to encourage research, investment, and international trade, and reduce 
the size of deadweight losses identified in this chapter. 
The chapter graphically illustrated the beneficial effects of food labelling on 
private and social welfare. Specifically, the graphical model illustrated how the policy of 
providing health information assisted consumers in modifying their diet, and thus 
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decreased health care costs.  The critical role that both food labels and claims have in 
influencing the population’s health through changing consumer demand for functional 
foods is apparent in the graphs. Individuals now have the option to make informed food 
choices and improve their health by reducing the risks of a chronic disease. The more 
informed that consumers become the greater the savings in the cost of illness, as long as 
information is clear, truthful, and based on scientific evidence. 
In Chapter Four, the measurement of welfare benefits and costs from food 
labelling is estimated to evaluate the current contribution of information to the economy. 
In particular, the net effect of labelling omega-3 enriched eggs is calculated by estimating 
health care cost savings, as well as production and labelling-related costs.
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CHAPTER 4: A BENEFIT COST ANALYSIS OF OMEGA-3 ENRICHED 
EGGS IN CANADA 
4.1. Introduction 
The aim of this chapter is to test the hypothesis stated at the outset by conducting 
a benefit cost analysis of omega-3 enriched eggs. Such analysis is required to gain a 
better understanding of the associated benefits and costs which will then be used to 
investigate the net social benefits, if they exist, of labelling omega-3 enriched eggs. The 
use of labelling and nutrient content claims in omega-3 enriched eggs can contribute to 
health improvement, particularly by reducing the risk of CHD, thereby reducing health 
care costs. However, the enhancement of eggs with omega-3 PUFA, as well as their 
labelling and marketing, create extra costs for egg producers. Comparing the estimated 
health benefits and costs of producing and marketing omega-3 enriched eggs, the 
economic impact of providing information through labelling can be measured.  
This chapter begins with an estimated increase in the level of omega-3 PUFA 
(ALA, EPA+DHA) if consumers were to substitute a regular egg with an omega-3 
enriched egg. The chapter then provides a review of plant-derived omega-3 and marine-
derived omega-3 studies which have been carefully examined and used to estimate the 
relationship between ALA and the risk in CHD mortality and between EPA+DHA and 
the risk in CHD mortality. Based on this relationship the related health care savings are 
estimated. An estimation of production and other costs (labelling, testing and marketing) 
of omega-3 enriched eggs follows. The chapter concludes with a measurement of the net 
benefit and benefit cost (B/C) ratio, which will determine the efficacy of Canada’s 
labelling policy. 
4.2. Description of the Methodology 
To quantify the potential economic impact of the health promoting effects of 
omega-3 enriched eggs analyzed in section 2.5, it is useful to develop estimates under a 
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range of plausible assumptions. The analysis is supported by scientific evidence from the 
health science literature and is based on a range of assumptions about the level of the 
effect of omega-3 fatty acids on coronary heart disease (CHD), the categories of medical 
costs (direct and indirect) that are used, and the link between CHD and health costs. The 
purpose of the analysis is to quantify the range of potential health care cost savings from 
labelling omega-3 enriched eggs and to reveal the sensitivity of the estimates to changes 
in key assumptions of the analysis.  
In order to provide a plausible range of estimates for the reduction in CHD cost, 
three different scenarios are reported. The High Scenario includes the most optimistic 
estimation of health care costs savings, the Base Scenario is a reasonable estimate based 
on the medical and nutritional information, and the Low Scenario presents a conservative 
estimate. 
For the measurement of the potential health care savings due to the consumption 
of omega-3 enriched eggs, three steps, similar to those taken by Malla et al. (2007), are 
followed: 
(1) Estimation of the possible increased omega-3 fatty acids intake (ALA and 
EPA+DHA) due to consumption of an omega-3 enriched egg. 
(2) Calculation of the reduction of CHD mortality due to increased omega-3 fatty 
acids (ALA and EPA+DHA) intake by using information reported in health 
studies. 
(3) Calculate cost savings related to reduced CHD.  
After estimating the potential health benefits of omega-3 PUFA obtained from the 
current consumption of omega-3 enriched eggs, an estimation is provided of the costs 
incurred by the current production, labelling, and marketing of omega-3 enriched eggs. 
Specifically, the extra feed and the fixed, labelling, testing, and marketing costs that egg 
producers bear are calculated based on various assumptions. Then, taking into 
consideration both benefits and costs, the overall impact on society is calculated in order 
to evaluate the efficiency of labelling omega-3 enriched eggs.  
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4.3. An Estimated Increase in Omega-3 Fatty Acids Intake via the Consumption 
of an Omega-3 Enriched Egg 
Attempting to decrease the risk of diet-related illnesses and improve Canadians’ 
health, omega-3 enriched eggs were developed to respond to health-conscious 
consumers’ needs. These novel eggs are considered a crucial functional food category 
due to the high content of omega-3 polyunsaturated fatty acids. Compared to regular 
eggs, the additional amount of omega-3 fatty acids found in omega-3 enriched eggs has 
the potential to make a major contribution to health improvement and wellness, and thus 
a likely reduction in CHD risk costs. The first step of the benefit analysis is focused on 
the specification of the extra ALA and EPA+DHA intake received from the consumption 
of omega-3 enriched eggs instead of conventional eggs.  
 As indicated in Table 2.2 (subsection 2.5.3), omega-3 enriched eggs contain 
much higher levels of total omega-3 fatty acids (0.50 g) than do regular eggs (0.04 g). On 
average 0.34 g (68% of total omega-3 fatty acids) of ALA, 0.13 g (26% of total) of 
EPA+DHA, and 0.03 g (6% of total) of several minor omega-3 fatty acids are included in 
an omega-3 enriched egg. Using the same proportions, it is calculated that 0.0272 g of 
ALA, 0.0104 g of EPA+DHA, and 0.0024 g of minor omega-3 fatty acids are present in 
regular eggs. 
By knowing the level of omega-3 fatty acids in both omega-3 enriched eggs and 
regular eggs, we can calculate that consumers gain an additional in 0.313 g of ALA and 
0.12 g of EPA+DHA if they substitute conventional eggs with omega-3 enriched eggs. 
Based on this increase in omega-3 fatty acids, the potential health care savings can be 
estimated once the relationship between ALA and EPA+DHA intake and the risk in CHD 
mortality is specified.  
4.4. An Analysis of Plant-derived Omega-3 Fatty Acids (ALA) 
4.4.1. A Brief Review of ALA Studies 
A search of the literature has revealed a substantial number of experimental 
(randomized controlled trials) and observational studies (prospective cohort studies, case-
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control studies, and cross-sectional studies)11 discussing and measuring the effect of ALA 
intake on fatal and non-fatal CHD, as well as on CVD events in general. Most of the 
studies suggest that an increased intake of ALA is recommended for both primary and 
secondary prevention of CHD due to its cardioprotective and antiarrhythmic effects. 
These studies show a significant reduction in the incidence of CHD as well as in 
mortality (Hu et al., 1999b; Dolecek, 1992; Dolecek and Granditis, 1991; Pietinen et al., 
1997; de-Lorgeril et al., 1999; Singh et al., 1997; Singh et al., 2002). However, other 
research studies have reported no such inverse associations (Ascherio et al., 1996; Oomen 
et al., 2001).  
Although some studies measured the effect of ALA intake on the incidence of 
CHD, the estimates in this thesis are based on those studies that reported a reduction in 
the risk of CHD mortality. This was done because the majority of ALA studies examined 
the effect of ALA intake on the risk of fatal CHD rather than CHD events (fatal and non-
fatal). After reviewing the nutritional literature, a total of nine studies were identified. Six 
observational studies (five prospective cohort studies and one cross-sectional study) 
examined the effects of ALA intake in people without previously diagnosed 
cardiovascular disease (primary prevention). The remaining three, which are 
experimental studies (specifically, randomized controlled trials), measured the impact of 
ALA intake on individuals with a history of a heart disease event (secondary prevention). 
Five of the nine studies were excluded from the estimation for reasons explained below.  
One of the primary prevention studies, a cross-sectional examination by Djoussé 
et al. (2001) that included 4,406 participants was omitted because, while it examines the 
effect of ALA intake on the risk of coronary artery disease (CAD)12 mortality, it reports 
only the prevalence odds ratio, which differs from the relative risk that all the other 
studies report. Nonetheless, the results of this study suggest that a higher intake of ALA 
is associated with a lower prevalence odds ratio of coronary artery disease (CAD) in both 
men and women.  
Another primary prevention study, the Multiple Risk Factor Intervention Trial 
(MRFIT), which consisted of 12,866 male participants aged 35-57 years, was also 
                                                 
11 For definitions, see the Glossary of Terms in Appendix B. 
12 Coronary Artery Disease (CAD) is the term given to heart problems caused by narrowed heart arteries. This can 
ultimately lead to a heart attack (American Heart Association, 2007). 
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omitted because participants were determined to be at high risk of CHD and may have 
biased the results. Nevertheless, Dolecek (1992) and Dolecek and Granditis (1991) 
showed an inverse association between ALA intake and fatal CHD, fatal CVD, and all 
cause mortality. Specifically, a significant 32% reduction in CHD mortality was reported 
when the highest (2.81 g/d) and lowest (0.87 g/d) quintiles of ALA intake were 
compared. 
Three additional secondary prevention studies (randomized controlled trials) were 
not taken into consideration for the estimation because omega-3 enriched eggs are aimed 
at the general population, not those with a history of CHD. This is because healthy people 
can maintain both their health status and reduce the risk of an incidence of CHD by 
keeping a balanced level of omega-3 fatty acids through consumption of omega-3 
enriched eggs. However, people who have experienced a CHD event follow special 
treatments, which probably include drugs and supplements. Thus, these studies may be 
biased, which, according to Wang et al. (2004), could invalidate the results. Nevertheless, 
it is worth mentioning the outcomes of these results, which indicated a beneficial effect of 
ALA intake on heart disease mortality.    
In the Lyon Diet Heart Study, a randomized single-blind secondary prevention 
trial, a Mediterranean-type diet was compared with a prudent Western-type diet in 
myocardial infarction (MI) (heart attack) survivors. The experimental group (192 
patients), which consumed a Mediterranean diet enriched with 1.8 g/d ALA, had a 
significant 65% reduction of cardiac deaths compared with the control group (219 
patients), which consumed 0.67 g/d ALA as part of their usual diet (de-Lorgeril et al., 
1994; de-Lorgeril et al., 1999). 
In a double-blind, placebo-controlled trial in India, all patients had experienced an 
acute myocardial infarction (AMI) (heart attack). One hundred and twenty patients in the 
experimental group received 20 g/d mustard oil containing 2.9 g/d ALA, an amount that 
was 3.6 times higher than the one that the 118 patients of the control group received. 
Subjects consuming mustard oil had a significant 40% lower risk of cardiac death than 
those receiving a placebo treatment (Singh et al., 1997). 
The last secondary study was another Indian trial conducted by Singh et al. 
(2002). Four hundred and ninety-nine patients in the experimental group consumed an 
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Indo-Mediterranean diet rich in whole grains, fruits, vegetables, walnuts, and almonds, 
while 501 patients in the placebo (control) group consumed a local diet similar to the step 
I National Cholesterol Education Program (NCEP) prudent diet. Patients in the 
intervention group, who consumed 1.8 g/d ALA, experienced a significant 67% reduction 
in total cardiac deaths than those in the control group who consumed 0.8 g/d ALA. 
A total of four primary prevention studies (prospective cohort studies) were used 
to estimate the link between ALA intake and the risk of CHD mortality. Two concluded a 
negative relation between ALA intake and fatal CHD, while the other two observed no 
beneficial effect of ALA intake on the risk of CHD death. A review of the results of the 
primary prevention studies follows. 
Hu et al. (1999b) assessed the intake of ALA by use of a 116-item food-frequency 
questionnaire given to 76,283 female nurses, aged 30-55 years, without previously 
diagnosed cancer or cardiovascular disease. In this study, approximately 70% of ALA 
was derived from vegetable or plant sources (e.g., salad dressings and vegetable oils). 
The result showed that the highest quintile of ALA intake (1.36 g/d) was significantly 
associated with a 45% reduction in fatal CHD compared to the lowest quintile of ALA 
intake (0.71 g/d). 
Pietinen et al. (1997) examined the relation between intake of ALA and the risk of 
CHD in 21,930 male smokers, aged 50-69 years, in Finland who were free of diagnosed 
CVD. All participants in the Finnish Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention Study completed a detailed diet questionnaire. The study observed an inverse 
association between the intake of ALA and risk of coronary death in simultaneous 
models. In particular, a significant 25% reduction in the risk of coronary death was 
reported when the highest quintile (2.5 g/d) of ALA intake was juxtaposed against the 
lowest quintile (0.9 g/d). 
The following two primary prevention studies found no association between ALA 
intake and CHD mortality. In the Health Professionals Follow-Up Study, 43,757 U.S. 
health professionals aged, 40-75 years and free of diagnosed CVD or diabetes, completed 
a 131-item food-frequency questionnaire. The study reported a lower risk of total 
myocardial infarction (including non-fatal MI and fatal CHD), but not of fatal CHD 
(Ascherio et al., 1996). 
 68
In the Zutphen Elderly Study conducted by Oomen et al. (2001) in Netherlands, 
the study population consisted of men aged 64-84 years and free of CAD (Coronary 
Artery Disease) at baseline. Dietary ALA intake was assessed by using a cross-check 
dietary history method adapted to the Duch habitual food consumption pattern 
(Bloemberg et al., 1989). The study’s outcome showed a non-beneficial effect of dietary 
ALA intake on the risk of CAD incidence and mortality. The possible increased risk of 
CAD may have been associated with the consumption of foods that contained trans fatty 
acids (e.g., margarines and meat), which were the main sources of ALA. 
According to Wang et al. (2004), all four prospective studies had a good 
methodological quality, and some provide strong evidence for the fundamental role of 
ALA in benefiting health and preventing fatal heart disease. However, the inconsistent 
results found in two of the primary prevention studies create doubt regarding the health 
promoting effects of ALA. This heterogeneity might be explained by the fact that ALA 
can come from different dietary sources (e.g., meat or vegetable oils), which creates 
difficulty in recognizing whether ALA or other dietary factors impact the risk of heart 
disease (Brouwer et al., 2004). Also, the effects of risk factors for heart disease, such as 
tobacco or alcohol use, can substantially impact the final result. 
The next subsection will examine the way in which the relationship between the 
intake of 1 g/d ALA and CHD mortality has been estimated by using all the above-
mentioned studies. 
4.4.2. Estimated Relationship of ALA and CHD Mortality 
The four primary prevention studies (prospective cohort studies) provided all the 
information necessary to estimate the effect of ALA intake on CHD mortality. Table 4.1 
summarizes the key elements of these studies, which contributed to the final combined 
estimation. The process used to find the estimated change in the risk of fatal CHD from a 
0.1 g increase in ALA is explained below. 
All the studies save for Oomen et al. (2001) reported the intake of ALA in g/d. 
The lowest intake of ALA is characterized as the base, which was compared with the 
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higher intakes of ALA called “trials.” The studies also measured the relative risks13 of 
fatal CHD for each different dose of ALA. For example, Hu et al. (1999b) found that a 
higher intake of ALA was associated with a lower relative risk (RR) of fatal CHD. 
Specifically, from the lowest to the highest intakes of ALA in g/d, 0.71, 0.86, 0.98, 1.12, 
and 1.36, the relative risks were 1, 0.99, 0.90, 0.67, and 0.55, respectively. The increase 
of both ALA intake and relative risk were calculated and are shown in Table 4.1. For 
instance, considering the study conducted by Hu et al., increasing ALA intake by 0.65 g/d 
(named ΔALA(trial 4-base) on the table) can decrease the relative risk by 45% (named 
ΔRR (base-trial 4) in the table). In other words, an extra 0.65 g/d ALA could reduce the 
risk of CHD mortality by 45%. In order to make the results of the studies comparable, it 
was necessary to calculate the change in risk of CHD mortality due to a 0.1 g increase in 
intake of ALA. Because this change has been measured for each trial of the studies, the 
average change in risk of fatal CHD due to a 0.1 g increase in the dose of ALA was 
calculated for every study. The main assumption at this point is linearity in the 
relationship between ALA intake and the risk of CHD mortality.  
In order to find accurate and consistent results, the weighted average was 
considered so that studies with larger numbers of participants and longer durations carried 
more weight. This is because the number of participants may affect the credibility of the 
study. The larger the number of participants, the more credible the study may be. The 
duration of studies was also of particular interest as the effect of ALA intake on the risk 
of heart disease can only be realized in the long-run, especially in the primary prevention 
of CHD death. The total weighted average for every 0.1 g/d increase in ALA intake was 
found to be 0.02. In other words, for every 0.1 g/d increase in ALA, the risk of fatal CHD 
is reduced by 2%. 
                                                 
13 The relative risks, which have been adjusted for risk factors of CHD as well as dietary factors, were used for the 
estimation. The relative risk is used in research studies to compare the likelihood of an event between two groups (the 
experimental and the control).  
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               Table 4.1. Estimation of CHD change due to 0.1 g per day ALA based on four prospective cohort studies. 
  
Hu et al., 
1999b 
Pietinen et al., 
1997 
Ascherio et al., 
1996 
Oomen et al., 
20011 SUM 
ALA base (g/d)2 0.71 0.9 0.8 0.98  
ALA trial 1 (g/d) 0.86 1.2 0.9 1.25  
ALA trial 2 (g/d) 0.98 1.5 1.1 1.64  
ALA trial 3 (g/d) 1.12 1.9 1.2   
ALA trial 4 (g/d) 1.36 2.5 1.5    
ΔALA (base-base)  (g/d)3 0 0 0 0  
ΔALA (trial 1-base) (g/d) 0.15 0.3 0.1 0.27  
ΔALA (trial 2-base) (g/d) 0.27 0.6 0.3 0.66  
ΔALA (trial 3-base) (g/d) 0.41 1 0.4   
ΔALA (trial 4-base) (g/d) 0.65 1.6 0.7    
RR base (Pbase/Pbase)4 1 1 1 1  
RR trial 1 (Ptrial 1/Pbase) 0.99 0.95 1.14 0.99  
RR trial 2 (Ptrial 2/Pbase) 0.90 0.94 1.04 1.59  
RR trial 3 (Ptrial 3/Pbase) 0.67 0.87 1.38   
RR trial 4 (Ptrial 4/Pbase) 0.55 0.75 1.06    
ΔRR (base-base) (Δ(Pbase/Pbase))5 0 0 0 0  
ΔRR (base-trial 1) (Δ(Ptrial 1/Pbase)) 0.01 0.05 -0.14 0.01  
ΔRR (base-trial 2) (Δ(Ptrial 2/Pbase)) 0.1 0.06 -0.04 -0.59  
ΔRR (base-trial 3) (Δ(Ptrial 3/Pbase)) 0.33 0.13 -0.38   
ΔRR (base-trial 4) (Δ(Ptrial 4/Pbase)) 0.45 0.25 -0.06    
ΔRR (base-base)/0.1ΔALA6 ־ ־ ־ ־ 
ΔRR (base-trial 1)/0.1ΔALA 0.01 0.02 -0.14 0.00  
ΔRR (base-trial 2)/0.1ΔALA 0.04 0.01 -0.01 -0.09  
ΔRR (base-trial 3)/0.1ΔALA 0.08 0.01 -0.10   
ΔRR (base-trial 4)/0.1ΔALA 0.07 0.02 -0.01    
Average ΔRR/0.1ΔALA7 0.05 0.01 -0.06 -0.04  
Number of follow-up years 10 6.1 6 10  
Number of Participants 76,283 29,930 43,757 667  
Years * Participants 762,830 182,573 262,542 6,670 1,214,615 
Total weighted average8     0.02 
 71
1 The median intakes for the tertiles were 0.40%, 0.50%, and 0.67% of total energy. The ALA intake in g/d has been calculated by using 1 g=9 kcal conversion 
based on 2,200 kcal daily energy intake. 
2 ALA base g/d is the lowest intake of ALA provided to subjects as a comparison with the higher intakes, which are named “trials.” 
3 The change in ALA intake (ΔALA) is calculated by subtracting the lowest intake of ALA (ALA base) from the higher intakes (ALA trials). 
4 The relative risk (RR) of CHD mortality, as has been reported by the studies. The RR is the ratio of the probability of CHD mortality occurring in the trials versus 
the base. 
5 The change in relative risk (ΔRR) is calculated by subtracting the RR of the higher intakes (RR Trials) from the RR of the lowest intake (RR base). 
6 The change in RR due to 0.1 g change in intake of ALA has been calculated by multiplying the change in RR (ΔRR) by 0.1 and dividing by the change in ALA 
intake (ΔALA). 
7 The average ΔRR/0.1ΔALA was calculated by taking the average of [ΔRR (base-trial 1)/0.1ΔALA, ΔRR (base-trial 2)/0.1ΔALA, ΔRR (base-trial 3)/0.1ΔALA, 
ΔRR (base-trial 4)/0.1ΔALA]. 
8 The total weighted average is the sum of the weighted averages found in each study. The weighted average for each study = (average 
ΔRR/0.1ΔALA*(Years*Participants))/Sum of (Years*Participants). The weighted average for each study is:  
Hu et al., (1999b): weighted average = 0.03 
Pietinen et al., (1997): weighed average = 0.002 
Ascherio et al, (1996): weighted average = -0.01 
Oomen et al, (2001): weighted average = -0.0002. 
Source: Author’s calculations (see text for detail). 
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4.5. An Analysis of Marine-derived Omega-3 Fatty Acids (EPA+DHA) 
4.5.1.  Review of EPA+DHA Studies 
After the observations of the preceding section were made, a number of further 
studies were examined for the association between EPA+DHA and the risk of CHD. A 
literature review of observational and experimental studies identified twenty-three 
studies (eighteen primary prevention studies and five secondary studies) examining the 
relationship between fish consumption or EPA+DHA intake and the risk of CHD 
mortality. From these studies, eleven primary prevention studies were excluded because 
they did not provide the information necessary to quantify this relationship. In 
particular, two studies (Pietinen et al., 1997; Salonen et al., 1995) were excluded 
because they underlined that the possible harmful effects of fish consumption in Finland 
could be explained by the high intake of mercury from contaminated fish. Four other 
studies (Vollset et al., 1985; Norell et al., 1986; Shekelle et al., 1985; Curb and Reed, 
1985) were eliminated because they were published as short reports (e.g., letters to 
editors) that provided incomplete information on RR estimation or fish intake (He et al., 
2004). Two more studies were omitted because one (Mann et al., 1997) was restricted to 
health-conscious individuals while the other (Rodriguez et al., 1996) comprised heavy 
smokers (>30 cigarettes/d). Another study (Dolecek and Granditis, 1991; Dolecek, 
1992) was omitted because the participants were determined to be at high risk of CHD. 
The last two studies, Yuan et al. (2001) and Osler et al. (2003), were removed from the 
estimation because the former did not report estimates for CHD mortality combined but 
rather provided estimates separately for AMI mortality and for other ischemic heart 
disease (IHD) mortality, while in the latter study the control group was the one that 
received an intermediate level of fish intake, not the lowest level, as was done in the 
other studies.  
As for the five secondary prevention studies (four randomized controlled trials 
and one prospective cohort study), they are not included in the estimation because, as 
mentioned in subsection 4.4.1, omega-3 enriched eggs were principally targeted to 
improve the health of the general population, not patients who possibly follow a special 
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treatment. Also, those studies are based on supplements, and the higher amounts of 
EPA+DHA intake were difficult to categorize.  
The first is the well-known Diet and Reinfarction Trial (DART) (Burr et al. 
1989), which showed that a modest intake of fatty fish (two or three portions per week) 
decreased the risk of total mortality by 29%, which was entirely attributable to a 
reduction in the number of deaths from coronary heart disease, and reduced the risk of 
CHD events (CHD mortality and non-fatal MI) by 16% However, no estimation in the 
risk of CHD mortality was provided.   
The second randomized controlled trial (Nilsen et al., 2001) included 300 
patients, of which 150 received 3.5 g/d EPA+DHA, while the rest received corn oil. The 
results showed no association between EPA+DHA and a reduction in cardiac deaths. 
The third study, the Italian GISSI (Grupo Italiano per lo Studio della 
Sopravvivenza nell’Infarto miocardioco)-Prevenzione trial involving 11,324 patients of 
both sexes (primarily men), is the largest prospective clinical trial to assess the benefit of 
omega-3 polyunsaturated fatty acids for secondary prevention of CHD. After a three-
and-a-half year period, the experimental group, which received one fish oil capsule 
containing 850-882 mg of EPA+DHA as ethyl esters, experienced a significant 35% 
reduction in the risk of CHD death, 45% in the risk of sudden death, and 20% in the risk 
of all fatal events compared with the control group (GISSI, 1999). 
In another randomized controlled trial conducted by Singh et al. (1997), patients 
received two capsules of fish oil three times daily, which contained a total of 1.8 g 
EPA+DHA, and experienced a 48% reduction in total cardiac death than those who 
received a placebo treatment. 
The last secondary prevention study was a prospective cohort study conducted 
by Erkkilä et al. (2003). Compared with the zero fish intake, the researchers reported an 
inverse association between the highest fish intake (>57 g/d of fish) with low risks of 
all-cause mortality and the combined endpoint of CVD death, AMI (acute myocardial 
infarction), or stroke, but not with the CAD death.  
In total, seven primary prevention studies (prospective cohort studies) that 
reported a link between fish consumption or EPA+DHA intake and CHD mortality were 
used in the analysis. The results of these studies are conflicting as some studies found an 
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inverse relationship between fish consumption or EPA+DHA intake and heart disease, 
while others report no such benefit. However, all the studies are taken into 
consideration, and their main results are mentioned below. 
The Nurses’ Health Study conducted by Hu et al. (2002) included 84,688 healthy 
female nurses, aged 34-59 years, and used a semiquantitative food frequency 
questionnaire to assess dietary intake of long chain omega-3 fatty acids and fish 
consumption. The study reported an inverse association between fish intake and long 
chain fatty acids (LCFAs) and CHD death. More specifically, consumption of five or 
more servings of fish per week was associated with a 45% reduction in the risk of CHD 
mortality compared to consumption of less than one fish serving per month. A 37% 
reduction in the risk of fatal CHD also was reported when the highest quintile (0.24 as 
the percentage of total energy) of long chain polyunsaturated fatty acids (LCPUFAs) 
was compared with the lowest quintile (0.03 as the percentage of total energy). 
The Chicago Western Electric Study surveyed 1,822 healthy men, aged 40-55, 
years and reported a significant 38% lower risk of fatal CHD in men who consumed at 
least 35 g of fish daily compared with those who consumed none (Daviglus et al., 
1997a).   
The Zutphen Study, conducted by Kromhout et al. (1985), demonstrated a 
protective effect of fish consumption on CHD death among 852 middle-aged Dutch men 
during twenty years of follow-up. In particular, mortality from CHD was more than 50% 
lower among those who consumed at least 30 g of fish per day than those who did not 
eat fish. 
In the Cardiovascular Health Study, fish consumption was ascertained at baseline 
among 3,910 adults, aged ≥ 65 years and free of known cardiovascular disease. The 
result showed that consumption of at least three servings of tuna or other broiled or 
baked fish per week was significantly related to a 53% lower risk of IHD death 
(Mozaffarian et al., 2003). 
In a recent European study carried out by Oomen et al. (2000), the data suggest 
that fish consumption, especially fatty fish, is protective against CHD mortality. This 
association was examined in 1,088 Finnish, 1,097 Italian, and 553 Dutch men, aged 50-
69 years and free of CHD. In Finland and the Netherlands, no relation between total fish 
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consumption and CHD mortality was observed. In Italy, men who consumed ≥40 g/d of 
fish had a non-significant 31% reduction in fatal CHD compared with men who 
consumed no fish. However, in the case where the three population samples consumed 
fatty fish instead of lean fish, inverse associations were observed between fatty fish 
consumption and CHD death for all three countries. Specifically, the pooled results for 
fatty fish were connected with a 34% reduction in the risk of CHD mortality. It should 
be mentioned, however, that in this analysis only the participants from Italy were taken 
into consideration. Dutch participants were part of the Kromhout et al. (1985) study and 
double counting information was avoided, while the Finnish population has been 
ascertained to have increased risk of CHD mortality even though it consumes great 
quantities of fish. The Finnish results, however, are probably due to the high mercury 
content of fish, something also observed in two other studies (Salonen et al., 1995; 
Pietinen et al., 1997). 
Two of the primary prevention studies did not report a beneficial association 
between fish consumption or LCPUFA and CHD mortality. In the Physicians’ Health 
Study, involving 20,551 healthy US male physicians, aged 40-84 years, fish 
consumption assessed by semiquantitative food frequency questionnaire offered no 
protection against coronary heart disease mortality. However, total mortality and sudden 
cardiac death were indeed reduced in those who consumed fish. It should be noted, 
however, that the size of the reduction did not appear to differ substantially at levels of 
consumption greater than one fish serving per week, suggesting a threshold effect 
(Albert et al., 1998). 
Likewise, the Health Professionals Follow-up Study, a large-scale prospective 
cohort study that consisted of 44,895 male health professionals, aged 40-75 years and 
were initially free of cardiovascular disease, did not show an association between fish 
intake and EPA+DHA and a reduced risk of fatal CHD (Ascherio et al., 1995). 
There are a number of factors that might contribute to the apparently discordant 
outcomes among the studies regarding the relationship between fish consumption or 
EPA+DHA intake and coronary heart disease. This noticeable inconsistency may be due 
to: 
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(1) different methods of assessing diet and categorizing fish consumption 
(Daviglus et al., 1997b); 
(2) different distribution of reported fish (Daviglus et al., 1997b); 
(3) different types of fish consumed (fatty versus lean fish) (Daviglus et al., 
1997b); 
(4) differences in study sites and times, with associated dietary differences (e.g., 
levels of intake of cholesterol, saturated fats, antioxidants, and 
fiber);(Daviglus et al., 1997b); 
(5) different duration of follow-up (Daviglus et al., 1997b); 
(6) difference in study population (Wang et al., 2004); 
(7) various demographic features (e.g., sex, age) (Wang et al., 2004); 
(8) difference in subject characteristics (e.g., lipid levels, weight, blood pressure) 
(Wang et al., 2004); and 
(9) impact of environmental contaminants (Wang et al., 2004). 
4.5.2. Estimated Relationship of EPA+DHA and CHD Mortality 
The primary prevention studies analyzed in the previous section provided the 
necessary information for the purpose of quantitatively investigating and assessing the 
impact of EPA+DHA intake, mainly through fish consumption, on the risk of CHD 
morality. Table 4.2 summarizes the data from all the studies, which is necessary for the 
combined estimation, and depicts the procedure for estimating the change in risk of 
CHD mortality from a 0.1 g increase in EPA+DHA.  
Contrary to the estimation regarding the relationship of ALA and the risk of fatal 
CHD, the analysis of the effect of EPA+DHA intake on the risk of CHD mortality is 
more complicated. This is due to design variations in the studies. Most assessed the 
impact of fish consumption on the risk of fatal CHD by using different amounts (grams) 
of fish per day, while others used different servings of fish. Only a few studies provided 
information on EPA+DHA intake in grams per day and its effect on death from CHD. 
As a result, an assumption was essential in order to convert the servings and grams of 
fish into EPA+DHA grams per day, and thus make the data comparable. König et al. 
(2005) assumed that one fish serving per week is equivalent to 100 g of fish per week. 
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König mentioned that this assumption is consistent with U.S. EPA estimates (U.S. 
Environmental Protection Agency, 1997). Carrington and Bolger (2002) reported 
average omega-3 concentrations (EPA+DHA) on the order of 1% in a market basket of 
fish typically consumed in the United States. This means that one fish serving per week, 
which has been assumed to be 100 g of fish per week, contains 1 g EPA+DHA per week 
or 0.14 g EPA+DHA per day. Therefore, this assumption was applied to those studies 
that expressed fish consumption in terms of servings or grams. In cases where studies 
reported intervals, the average of the interval was used. For example, two to four fish 
servings per week were considered as three servings per week. Where the lowest fish 
intake level had an open lower bound of, for instance, less or equal to one fish serving 
per month, a half-serving per month was assigned as the lower bound. However, where 
no upper bound was specified—for example, more or equal to five fish servings per 
week—then the highest definite amount—five fish servings—was used as the upper 
limit. The same notion held in cases where grams of fish are reported.  
As was mentioned in the analysis of ALA intake, the base intake corresponds to 
the lowest EPA+DHA intake, which the control group received, while the trials 
correspond to higher levels of intake of EPA+DHA. The relative risks of CHD mortality 
for different intakes of EPA+DHA, reported in the studies were used for the estimation, 
and their values are depicted in the table. For example, Hu et al. (2002) found that an 
extra 0.513 g/d (called Δ(EPA+DHA) (trial 4-base) on the table) reduces the risk of 
CHD mortality by 38% (called ΔRR (base-trial 4) in the table). In order to be 
comparable, the change in EPA+DHA, as well as the change in relative risk when 
compared with the base, was calculated and used to measure the change in relative risk 
due to a 0.1 g increase in EPA+DHA intake in all studies. Then, the average change in 
relative risk was computed for all studies. This estimation was based on the assumption 
that the correlation between EPA+DHA and the risk of fatal CHD is linear.  
For a consistent estimation, both the number of participants and the period of 
follow-up were used as weights for the calculation of weighed average (as was also done 
in the ALA analysis). Both weights are considered important factors for the reliability 
and significance of the study’s outcome. Therefore, the total weighted average for every 
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0.1 g/d increase in EPA+DHA intake was found to be 0.10. In other words, for every 0.1 
g/d increase in EPA+DHA, the risk of fatal CHD is reduced by 10%.   
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Table 4.2. Estimation of CHD change due to 0.1 g per day EPA+DHA based on seven prospective cohort studies1. 
 
Hu et al., 
20022 
Daviglus et 
al., 1997a3 
Kromhout 
et al.,19854 
Mozaffarian 
et al., 20035 
Oomen et 
al., 20006 
Albert et 
al., 19987 
Ascherio 
et al., 1995 SUM 
EPA+DHA Base (g/d)8 0.073 0 0 0 0 0.016 0.07  
EPA+DHA trial 1 (g/d) 0.12 0.08 0.07 0.13 0.098 0.07 0.15  
EPA+DHA trial 2 (g/d) 0.195 0.24 0.22 0.267 0.288 0.14 0.24  
EPA+DHA trial 3 (g/d) 0.342 0.34 0.36 0.547 0.39  0.34  
EPA+DHA trial 4 (g/d) 0.586  0.44 0.919   0.58  
Δ(EPA+DHA) (base-base) (g/d) 9 0 0 0 0 0 0 0  
ΔEPA+DHA (trial 1-base) (g/d) 0.047 0.078 0.068 0.128 0.098 0.049 0.08  
ΔEPA+DHA (trial 2-base) (g/d) 0.122 0.24 0.215 0.267 0.288 0.124 0.17  
ΔEPA+DHA (trial 3-base) (g/d) 0.269 0.34 0.36 0.547 0.39  0.27  
ΔEPA+DHA (trial 4-base) (g/d) 0.513  0.44 0.919   0.51  
RR base (Pbase/Pbase)10 1 1 1 1 1 1 1  
RR trial 1 (Ptrial 1/Pbase) 0.93 0.88 0.64 0.78 0.94 1.18 1.14  
RR trial 2 (Ptrial 2/Pbase) 0.69 0.84 0.56 0.77 0.93 0.87 0.95  
RR trial 3 (Ptrial 3/Pbase) 0.54 0.62 0.36 0.53 0.67  1.03  
RR trial 4 (Ptrial 4/Pbase) 0.62  0.39 0.47   1.03  
ΔRR (base-base) (Δ(Pbase/Pbase)11 0 0 0 0 0 0 0  
ΔRR (base-trial 1) (Δ(Ptrial 1/Pbase)) 0.07 0.12 0.36 0.22 0.06 -0.18 -0.14  
ΔRR (base-trial 2) (Δ(Ptrial 2/Pbase)) 0.31 0.16 0.44 0.23 0.07 0.13 0.05  
ΔRR (base-trial 3) (Δ(Ptrial 3/Pbase)) 0.46 0.38 0.64 0.47 0.33  -0.03  
ΔRR (base-trial 4) (Δ(Ptrial 4/Pbase)) 0.38  0.61 0.53   -0.03  
ΔRR (base-base)/0.1Δ(EPA+DHA)12 ־ ־ ־ ־ ־ ־ ־  
ΔRR (base-trial 1)/0.1ΔEPA+DHA 0.15 0.15 0.53 0.17 0.06 -0.37 -0.18  
ΔRR (base-trial 2)/0.1ΔEPA+DHA 0.25 0.07 0.20 0.09 0.02 0.10 0.03  
ΔRR (base-trial 3)/0.1ΔEPA+DHA 0.17 0.11 0.18 0.09 0.08  -0.01  
ΔRR (base-trial 4)/0.1ΔEPA+DHA 0.07  0.14 0.06   -0.01  
Average ΔRR/Δ(EPA+DHA)13 0.16 0.11 0.26 0.10 0.06 -0.13 -0.04  
Number of follow-up years 16 30 20 9.3 20 11 6  
Number of Participants 84,688 1,822 852 3,910 1,097 20,551 44,895  
participant * years 1,355,008 54,660 17,040 36,363 21,940 226,061 269,370 1,980,442 
Weighted average14        0.10 
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1 The conversion of fish intake (either serving or g) in g/d of EPA+DHA is based on the assumption of one serving fish/w=100 g/w of fish=0.14 g/d EPA+DHA.  
2 The median intakes for the quintiles are 0.03%, 0.05%, 0.08%, 0.14% and 0.24% of total energy. The EPA+DHA intake in g/d was calculated by using 1 g=9 kcal conversion 
based on 2,200 kcal daily energy intake. 
3 The four levels of fish intake in g/d are 0, 1-17, 18-34, >=35. The mean intake was used as well as the assumption in note 1 in order to calculate the EPA+DHA intake in g/d. 
4 The five levels of fish intake in g/d are 0, 1-14, 15-29, 30-44, and >=45. The mean intake was used as well as the assumption in note 1 in order to calculate the EPA+DHA intake 
in g/d. 
5 The level of EPA+DHA (mg/d) of each of the five fish servings is reported in this study. 
6 The four levels of fish intake in g/d are 0, 1-19, 20-39, >=40. The mean intake was used as well as the assumption in note 1 in order to calculate the EPA+DHA intake in g/d. 
7 This study measures, initially, the RR for five categories of fish servings (lowest:<1s/mo, highest:>=5 s/w) and then calculates the RR for three categories of fish servings (<1 
s/mo,1-3 s/mo, and >=1 s/w) to make the results more significant. Although the results for fatal CHD are nonsignificant in both cases, the second one was used because it has 
lower P-value. For the conversion of fish serving to EPA+DHA g/d the assumption in note 1 was used. 
8 EPA+DHA base g/d is the lowest intake of EPA+DHA provided to subjects as a comparison with the higher intakes, which are named “trials.” 
9 The change in EPA+DHA intake (Δ(EPA+DHA)) is calculated by subtracting the lowest intake of EPA+DHA (EPA+DHA base) from the higher intakes (EPA+DHA trials). 
10 The relative risk (RR) of CHD mortality as it has been reported by the studies. The relative risk is the ratio of the probability of CHD mortality occurring in the trials versus the 
base. 
11 The change in RR (ΔRR) is calculated by subtracting the RR of the higher intakes (RR Trials) from the RR of the lowest intake (RR Base). 
12 The change in RR due to 0.1 g change in intake of EPA+DHA has been calculated by multiplying the change in RR (ΔRR) by 0.1 and dividing by the change in EPA+DHA 
intake (Δ(EPA+DHA)). 
13 The average ΔRR/0.1Δ(EPA+DHA) was calculated by taking the average of [ΔRR (base-trial 1)/0.1Δ(EPA+DHA), ΔRR (base-trial 2)/0.1Δ(EPA+DHA), ΔRR (base-trial 
3)/0.1Δ(EPA+DHA), ΔRR (base-trial 4)/0.1Δ(EPA+DHA)]. 
14 The total weighted average is the sum of the weighted averages found in each study. The weighted average for each study = (average 
ΔRR/0.1Δ(EPA+DHA)*(Years*Participants))/Sum of (Years*Participants). The weighted average for each study is:  
Hu et al., (2002): weighted average = 0.11 
Albert et al., (1998): weighed average = -0.01 
Daviglus et al, (1997a): weighted average = 0.003 
Ascherio et al., (1995): weighted average = -0.01 
Kromhout et al, (1985): weighted average = 0.002 
Mozaffarian, 2003: weighted average = 0.002 
Oomen et al., (2000): weighted average = 0.001. 
Source: Author’s estimates (see text for detail). 
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4.6. The Economics of Information of Omega-3 Enriched Eggs in Canada 
4.6.1. Estimation of the Potential Health Care Cost Savings 
The third step of the benefit analysis is an estimation of the potential health care 
cost savings due to an increase in the consumption of omega-3 fatty acids via omega-3 
enriched eggs. As research has shown, omega-3 fatty acids have a beneficial impact on 
cardiovascular diseases, whose treatment, as well as loss of income due to disability or 
death, are major costs in the Canadian health-care budget. In particular, it has been 
estimated that in 2006, cardiovascular disease accounted for $28,780 million.14 Direct 
costs comprise 48.3% ($13,903 million), while indirect costs account for 51.7% 
($14,877 million) of the total cardiovascular disease cost. It is worth mentioning that 
CHD events are the key contributor to CVD events. It has been reported that 54% of 
CVD deaths are due to CHD deaths (Heart and Stroke foundation of Canada, 2002). 
Thus, it is reasonable to expect that CHD costs represent a large part of CVD costs. 
CHD costs have been estimated to be $11,251 million ($2006) annually.  
The sensitivity analysis is based on three different scenarios (Base, High, and 
Low), which will provide a range of estimates regarding health care cost savings from 
CHD mortality. The estimation for the Base and Low Scenarios refers to the reduction in 
indirect costs from consuming omega-3 fatty acids and, in particular, in mortality costs. 
However, in the High Scenario, the total CHD costs (direct and indirect) are included, 
which implicitly assumes that total costs are reduced in the same proportion as mortality 
reduction. It has been estimated that mortality costs consist of 87.6% ($6,185.6 million) 
of CHD indirect costs, while the remaining 12.4% ($878 million) includes short- and 
long-term morbidity costs. The direct costs of CHD were estimated to be $4,187.6 
million.15 The main assumption for estimating the health care savings is a linear 1:1 
ratio between reduced risk of CHD incidence and mortality in the long run and health 
care cost savings. This means that if the risk in fatal CHD is reduced by 1% in the long 
run, CHD costs will be reduced by 1% (a similar assumption was made by Malla et al., 
2007). 
                                                 
14 The methodology used to estimate the cardiovascular disease (CVD) costs and coronary heart disease (CHD) costs 
for 2006 is shown in subsection 2.6.2. 
15 A detailed estimation of all the cost categories of direct and indirect costs of CHD is provided in Appendix A. 
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The process of estimating the change in CHD mortality by consuming omega-3 
enriched eggs is demonstrated in Tables 4.3 and 4.4 due to the difference in the impact 
of ALA and EPA+DHA intake on fatal CHD found in the literature. Table 4.3 reports 
the estimated change in CHD mortality due to an increase in intake of ALA, while Table 
4.4 depicts the estimated change in CHD mortality due to an EPA+DHA intake increase 
when consumers substitute a regular egg with an omega-3 enriched egg. After this 
separate estimation, results are combined in Table 4.5 to show the fundamental overall 
effect of omega-3 fatty acids contained in omega-3 enriched eggs on the risk of CHD 
death, and to provide the estimated potential total health care savings that can be 
achieved based on the current market share of omega-3 enriched eggs. A description and 
explanation of the results reported in the tables follows. 
As Table 4.3 depicts, the change in CHD mortality due to an increase in the 
consumption of ALA contained in an omega-3 enriched egg is estimated by using three 
different scenarios, with the Base providing the most reasonable estimate. The Base 
Scenario shows that if consumers consume daily an omega-3 enriched egg instead of a 
conventional one, then they could increase the intake of ALA by 0.313 g, which in turn 
could reduce CHD mortality on average by 6.26%. This calculation uses the relationship 
specified in sub-section 4.3.2, whereby CHD mortality is reduced by 2% for every 0.1 g 
increase in ALA intake. 
The High Scenario includes an optimistic estimate, which is based on the 
assumption that 0.1 g change in ALA intake can lead to a 3% reduction in fatal CHD. 
This means that the extra average ALA intake obtained from an omega-3 enriched egg, 
as compared with a regular egg, can reduce fatal CHD by 9.39% on average.  
The Low Scenario assumes that the reduction in CHD mortality is 1% for every 
0.1 g increase in ALA. This means that the extra ALA intake that a consumer receives 
by substituting regular eggs with omega-3 enriched eggs can reduce CHD mortality by 
3.13%. For this scenario, a positive effect of omega-3 fatty acids on CHD mortality is 
still assumed based on the fact that the FDA has approved a qualified health claim 
stating that “supportive but not conclusive research shows that consumption of EPA and 
DHA omega-3 fatty acids may reduce the risk of coronary heart disease” (FDA, 2004). 
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Health Canada has also approved the enrichment of various products with omega-3 fatty 
acids.  
 
Table 4.3. Estimated change in CHD mortality due to increase in ALA intake 
through the consumption of one omega-3 enriched egg per day. 
  Base   High  Low   
(a) Change in CHD mortality/0.1 g 
ALA (%)1 -2 -3 -1 
(b) Average ALA content in an omega-
3 enriched egg (g)2  0.34 0.34 0.34 
(c) Average ALA content in a regular 
egg (g)3  0.027 0.027 0.027 
(d) Extra average ALA intake from an 
omega-3 enriched egg (g) (b-c) 0.313 0.313 0.313 
(e) Total change in CHD mortality (%) 
(a*d)4 -6.26 -9.39 -3.13 
1 The percentage change in CHD mortality/0.1 g ALA is calculated in Table 4.1. For the Base Scenario, 
the total weighted average as calculated in Table 4.1 is used. For the High Scenario, an optimistic 
reduction in the risk of CHD equal to 50% higher than the Base Estimate is assumed, while for the Low 
Scenario the assumption is a modest reduction in the risk of CHD equal to 50% lower than the Base 
Estimate. 
2 Source: Flax Council of Canada, 2003b.  
3 Author's calculations based on Flax Council of Canada, 2003b. See Table 2.2.  
4 Total change in CHD mortality (%) is calculated by multiplying the %ΔCHD mortality with the extra 
average ALA intake. 
Source: Author’s estimates (see text for detail). 
 
Another estimation process was necessary because omega-3 enriched eggs also 
contain higher amounts of EPA+DHA fatty acids than regular eggs. The estimated 
change in CHD deaths is demonstrated in Table 4.4, and is also based on the three 
different scenarios. 
The Base Scenario assumes that 0.12 g EPA+DHA, which is the extra average 
amount found in an omega-3 enriched egg compared to a regular egg, can reduce the 
risk of CHD mortality by 12% on average. This uses the relationship specified in the 
sub-section 4.4.2, whereby CHD mortality is reduced by 10% for every 0.1 g increase in 
EPA+DHA intake. 
The High Scenario illustrates that 0.1 g EPA+DHA could reduce the risk of 
CHD mortality by 15%. For this scenario, it is assumed that the reduction in the risk of 
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fatal CHD is 50% higher than the reduction in the Base Estimate. This means that the 
0.12 g EPA+DHA contained in an omega-3 enriched egg could reduce CHD mortality 
by 18%. 
The Low Scenario is based on an assumption that the risk of fatal CHD can be 
reduced by half of what the Base Estimate shows for every 0.1 g intake of EPA+DHA. 
This means that CHD mortality can be decreased by 6% when consumers substitute each 
conventional egg with an omega-3 enriched egg.   
 
Table 4.4. Estimated change in CHD mortality due to increase in EPA+DHA 
intake through the consumption of one omega-3 enriched egg per day. 
  Base High Low 
(a) Change in CHD mortality/0.1 g 
EPA+DHA (%)1 -10 -15 -5 
(b) Average EPA+DHA content in an 
omega-3 enriched egg (g)2 0.13 0.13 0.13 
(c) Average EPA+DHA content in a 
regular egg (g)3 0.01 0.01 0.01 
(d) Extra average EPA+DHA intake from 
an omega-3 enriched egg (g) (b-c) 0.12 0.12 0.12 
(e) Total change in CHD mortality (%) 
(a*d)4 -12 -18 -6 
1 The percentage change in CHD mortality/0.1 g EPA+DHA is calculated in Table 4.2. For the Base 
Scenario, the total weighted average calculated in Table 4.2 is used. For the High Scenario, an optimistic 
reduction in the risk of CHD equal to 50% higher than the Base Estimate is assumed, while for the Low 
Scenario the assumption is a modest reduction in the risk of CHD equal to 50% lower than the Base 
Estimate. 
2 Source: Flax Council of Canada, 2003b. 
3 Author's calculations based on Flax Council of Canada, 2003b. See Table 2.2. 
4 Total change in CHD mortality (%) is calculated by multiplying the %ΔCHD mortality with the extra 
average EPA+DHA intake. 
Source: Author’s estimates (see text for detail). 
 
Combining the estimations regarding changes in CHD mortality shown in the 
above two tables, Table 4.5 summarizes the total change in fatal CHD due to an increase 
in omega-3 fatty acids found in an omega-3 enriched egg, and provides an estimation of 
the prospective annual CHD cost savings based on the three scenarios given the current 
consumption of an omega-3 enriched egg. As mentioned in Chapter Two (subsection 
2.5.3), omega-3 enriched eggs currently capture 15% of the egg market in Canada. 
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Given that the average total number of eggs consumed per capita per day is 0.52 (half 
egg per capita per day), the reduction of fatal CHD caused by current daily omega-3 
enriched egg consumption can be calculated. This is done by multiplying the market 
share of omega-3 enriched eggs by the average total number of eggs consumed per 
capita per day and then by the total change in CHD mortality for one omega-3 enriched 
egg consumed per day. The estimation of possible health savings is based on the 
assumption of a linear 1:1 ratio between the total change in CHD mortality due to the 
current omega-3 enriched egg consumption rate and the medical cost savings, which is 
then applied to all scenarios. A description of the three different estimates shown in the 
table, with an emphasis on the Base Estimate as being the most reasonable, follows.  
The Base Estimate illustrates that the intake of omega-3 fatty acids via the 
current consumption of omega-3 enriched eggs can reduce the risk of CHD mortality by 
1.42%. Based on the assumption of a linear 1:1 ratio between the CHD events and death 
and the related health costs savings, the estimation of the potential mortality cost savings 
could be $88.3 million per annum.  
The High Estimate depicts a more optimistic reduction in the risk of fatal CHD. 
It calculates that the omega-3 enriched eggs currently consumed in Canada can lower 
the risk of CHD mortality by 2.14%. For this scenario, however, both the direct and 
indirect CHD costs are taken into consideration, not just the mortality costs, and it is 
assumed that an increase in omega-3 fatty acids intake also makes possible a decrease in 
the risk of CHD events, fatal and non-fatal. With this set of assumptions, the High 
Estimate suggests a potential reduction of $241 million in health care costs annually. 
The Low Estimate shows that the existing market share of omega-3 enriched 
eggs can reduce CHD deaths by 0.71%. With an assumed 1:1 CHD risk to related health 
costs ratio, the potential estimated CHD mortality cost savings could be $44 million per 
year, demonstrating that major health savings can be achieved even with a less strong 
association between omega-3 fatty acids intake and the risk of fatal CHD. 
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Table 4.5. Annual Canadian health care savings due to ALA, EPA, and DHA 
from 15% omega-3 enriched egg consumption. 
 Base   High  Low   
(a) Total change in CHD mortality for one 
omega-3 enriched egg consumed/d (%)1 -18.26 -27.39 -9.13 
(b) Total disposition of eggs in 2006 
(million of dozens)2 517.8 517.8 517.8 
(c) Average total number of eggs 
consumed/capita/day3 0.52 0.52 0.52 
(d) Market share of omega-3 enriched eggs 
(%) 15 15 15 
(e) Total change in CHD mortality for the 
current consumption of omega-3 enriched 
eggs/capita/d (%) (a*c*d)4 
-1.42 -2.14 -0.71 
(f) CHD mortality to cost ratio 1 1 1 
(g) Total annual CHD cost (millions CAN$) ־ 11,251.65 ־ 
(h) Total annual CHD mortality cost 
(millions CAN$) 6,185.6 ־ 6,185.6 
(i) Total annual change in CHD cost  
(millions CAN$) (e*h) or (e*g)6 -88.3 -241 -44 
(j) CHD savings (millions CAN$) 88.3 241 44 
1 The total change in CHD mortality for one omega-3 enriched egg consumed/d is the sum of the total 
change in CHD mortality due to ALA intake increase (see Table 4.3) and the total change in CHD 
mortality due to EPA+DHA intake increase (see Table 4.4). 
2 Source: Statistics Canada, 2007c. The total disposition of eggs in Canada in 2006 was 588.4 million 
dozen eggs.  From these, 517.8 million dozens were sold for consumption, while 59.3 million dozens were 
sold for hatching and 11.3 million dozens were leakers and rejects. 
3 The average total number of eggs/capita/d was calculated by multiplying the total disposition of eggs in 
2006 (million dozens) by 12 to obtain the total number of eggs in millions, and then dividing by the 
population in 2006 (32,581,490 millions; Source: Cansim via E-Stat) and the number of annual days.  
4 The total percentage change in CHD mortality for the current consumption of an omega-3 enriched 
egg/capita/d is calculated by multiplying the total percentage change in CHD mortality for one omega-3 
enriched egg consumed/d by the average total number of eggs/capita/d and the market share of omega-3 
enriched eggs. 
5 In the High Scenario, the total CHD costs (direct and indirect) are included, which implicitly assumes 
that total costs are reduced in the same proportion as mortality reduction. 
6 The total annual change in CHD cost is calculated by multiplying the total annual CHD mortality cost 
with the percentage change in CHD mortality for the current consumption of omega-3 enriched 
eggs/capita/d. The High Scenario considers only the total annual indirect and direct CHD costs instead of 
the total annual CHD mortality costs. 
Source: Author’s estimates (see text for detail). 
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4.6.2. Estimation of the Costs  
In modeling the effects of an omega-3 PUFA labelling policy, both the health 
benefits and costs of omega-3 enriched eggs need be considered. Egg producers in 
Canada need to take into account some extra costs incurred when producing omega-3 
enriched eggs. These include flax feed cost, fixed costs, labelling costs, and marketing 
costs.   
The production of omega-3 enriched eggs requires the use of special feed, which 
is relatively more expensive for egg producers than that typically used. Flaxseed is the 
most common addition to hens’ feed ration to increase omega-3 PUFA content in the 
egg. Using flax as 10% of hens’ rations (on average), egg producers can obtain optimal 
results and market their eggs as omega-3 (Flax Council, 2007; Harman, 2007). Egg 
producers also bear fixed costs such as those associated with finding new suppliers and 
negotiating with distributors, as well as initial testing costs for labelling eligibility. A 
new package design and nutrient content claims are also part of the fixed costs. After 
producing omega-3 enriched eggs, additional costs arise. Labelling-related expenses are 
some of them. Specifically, product testing is required to ensure that eggs meet the 
omega-3 PUFA requirement, which enables egg producers to market them as omega-3 
enriched eggs, and various safety criteria. Furthermore, marketing opportunities 
represent additional costs for producers who want to promote their eggs as omega-3. 
The goal of producing and marketing omega-3 enriched eggs is to satisfy the 
needs of a niche market and thus increase revenues, which will more than compensate 
for the extra cost incurred. Omega-3 enriched eggs sell at a premium price compared to 
conventional eggs. Yet, many consumers in Canada are willing to pay a premium for 
eggs that are perceived as healthier. This observed premium (i.e., markup) is $1 per 
dozen on average, but this varies by brand and store. The author observed an 
approximate retail price in Saskatoon, Canada during a six-month period (January to 
July, 2007), but actual price differences are likely to differ by location and time. 
Before analyzing the additional estimated costs of producing omega-3 enriched 
eggs, there is a need to distinguish between markup and cost. These two concepts cannot 
be used interchangeably as markup may or may not be equal to cost. This is because 
markup may include economic rents, which are not additional economic costs as they 
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are transferred to other players (e.g., retailers) in the industry (in terms of surplus), and 
so no resources are being used. In other words, markup is not all cost to the society, but 
also includes benefits that should not be overlooked.   
Table 4.6 presents an estimation of the annual costs of producing, labelling, 
testing, and marketing the current number of omega-3 enriched eggs in Canada. In 
particular, estimates regarding the extra feed cost and the fixed, labelling, testing and 
marketing costs are provided, and appear on the last three rows of the table (including 
the total cost). The rest of the information in the table concerns calculations of these cost 
estimates.  
Statistics Canada estimated that in 2006, total disposition of eggs, excluding 
hatching and leakers and rejects, was 517.8 million dozens (Statistics Canada, 2007c). 
From these, 77.67 million dozens are omega-3 enriched eggs, according to the current 
15% market share. As was mentioned in the beginning of this subsection, the production 
of omega-3 enriched eggs includes the substitution of a portion of the typical feed with 
flax, which is responsible for the omega-3 PUFA enhancement in the eggs. The extra 
feed cost accounts for $72.74 per tonne according to Bert Harman, an egg producer in 
Saskatchewan, Canada, who indicated that the feed cost for regular egg production is 
$228.73 per tonne, while the feed cost for the omega-3 enriched egg production is 
$301.47 per tonne (Harman, 2007). Of course, this cost varies depending on the form of 
flax (whole or milled) and on additional nutrients (e.g., Vitamin E, lutein, selenium) that 
egg producers choose to add (Harman, 2007). Given that the feed conversion ratio per 
dozen eggs is on average 1.5 kg (or 0.0015 tonne),16 the extra feed cost per dozen can be 
calculated by multiplying the number of dozens of omega-3 enriched eggs with the feed 
ratio per dozen (Meyers Norris Penny LLP, 2006). The result shows that the additional 
feed cost per dozen omega-3 enriched eggs is $0.10911. Furthermore, it should be 
mentioned that this analysis is based on an average observed markup between omega-3 
enriched eggs and conventional eggs. Thus, the proportion of the markup attributed to 
the fixed, labelling, and marketing costs have been arbitrarily estimated due to a lack of 
data on actual costs.  
                                                 
16 It is assumed that the feed conversion ratio per dozen eggs has been remained the same for the period 2004-2006. It 
is also assumed that the feed conversion ratio is the same for flax-based diets and conventional diets. All that changes 
is the content of the feed. 
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As in the case of the health care cost savings analysis, three different scenarios 
are used to provide three different estimates—the Base Estimate, Low Estimate and 
High Estimate—which are shown in separate columns. The Base Estimate provides the 
most conservative result, and is based on the most plausible set of assumptions. The 
Low Estimate provides a low cost given a very modest set of assumptions, and is used to 
correspond the lower bound of the possible range. The High Estimate represents a high 
cost and provides an upper bound of the possible range.  
The Base Estimate shows that the total extra feed cost of the current production 
of omega-3 enriched eggs could reach $8.47 million. Other additional costs, such as 
fixed, labelling, and marketing costs, are estimated under the assumption that 50% of the 
markup, which is 50% of the difference between 1 and 0.01091, are pure rents that occur 
to the producer, retailer, and marketer. Thus, by multiplying 50% of the markup with the 
total number of dozens omega-3 enriched eggs, the fixed, labelling, and marketing costs 
are estimated to be $34.6 million. Adding these costs together generates the total costs 
of shifting production of regular eggs to omega-3 enriched eggs to be $43.1 million per 
annum. 
The Low Estimate assumes the same total extra feed cost as in the Base 
Estimate, which is $8.47 million, but uses different fixed, labelling, and marketing costs. 
It is assumed that 75% of the markup are rents that occur to the producer, retailer, and 
marketer, while the rest is the actual cost. This means that the fixed, labelling, and 
marketing costs would be $17.3 million. A total low cost is calculated to be $25.8 
million per year. 
The High Estimate provides an extreme situation where the total cost is very 
high. Once again, the total extra feed cost remains the same for all the three estimates, 
which is $8.47 million, while the rest additional costs differ. This estimation assumes 
that the entire additional markup is due to a cost increase and no additional rents are 
realized. As a result, the fixed, labelling, and marketing costs are measured to be $69.2 
million. Aggregating the costs, it is found that the total cost would be $77.7 million 
annually.   
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Table 4.6. Annual Canadian costs of producing, labelling, testing and marketing 
15% omega-3 enriched eggs. 
  Base   Low   High  
(a) Total disposition of eggs in 2006 
(million dozens)1 517.8 517.8 517.8 
(b) Market share of omega-3 enriched eggs (%) 15 15 15 
(c) Total disposition of omega-3 enriched eggs 
in 2006 (million dozens) (a*b)2 77.67 77.67 77.67 
(d) Feed price difference between conventional 
and omega-3 enriched eggs ($ per tonne)3 72.74 72.74 72.74 
(e) Feed conversion ratio per dozen (in tonne)4 0.0015 0.0015 0.0015 
(f) Extra feed cost ($ per dozen) (d*e)5 0.1091 0.1091 0.1091 
(g) Markup ($ per dozen) 1 1 1 
(h) Total extra feed cost (millions CAN$) (c*f)6 8.47 8.47 8.47 
(i) Fixed, labelling, testing and marketing costs 
(millions CAN$) 34.6
7 17.38 69.29 
(j) Total Cost (millions CAN$) (h+i)10 43.1 25.8 77.7 
1 Source: Statistics Canada, 2007c. The total disposition of eggs in Canada in 2006 was 588.4 million 
dozen eggs.  From these, 517.8 million dozens were sold for consumption, while 59.3 million dozens were 
sold for hatching and 11.3 million dozens were leakers and rejects. 
2 Currently, omega-3 enriched eggs make up 15% of the Canadian egg market. This means that 77.67 
million dozen eggs include omega-3 fatty acids, which was calculated by multiplying the total disposition 
of eggs in 2006 with the market share of omega-3 enriched eggs. 
3 Source: Harman, 2007. The feed price difference was calculated by subtracting the feed cost of regular 
eggs ($228.73/tonne) from that of omega-3 enriched eggs ($301.47/tonne). 
4 Source: Meyers Norris Penny LLP, 2006. The feed conversion ratio per dozen eggs, which is the amount 
of feed given to hens in Canada to produce a dozen eggs, is 1.5 kg or 0.0015 tonnes per dozen. 
5 The extra feed cost per dozen eggs was calculated by multiplying the feed price difference between 
conventional and omega-3 enriched eggs by the feed conversion ratio per dozen. 
6 The total extra feed cost was calculated by multiplying the total disposition of omega-3 enriched eggs 
with the extra feed cost. 
7 This assumes that 50% of the markup is pure rents that occur to the producer, retailer, and marketer.  
8 This assumes that 75% of the markup is pure rents that occur to the producer, retailer, and marketer.  
9 This assumes that the entire additional markup is due to cost increase and zero additional rents. 
10 The total cost is the sum of the total extra feed cost and the fixed, labelling, testing, and marketing costs.  
Source: Author’s estimates (see text for detail). 
 
Although the estimation of the extra feed cost is calculated based on the price 
difference in feed between regular eggs and omega-3 enriched eggs in this analysis, it 
could also be calculated by considering the average flaxseed price, which has been 
forecasted to be an average of $275 per tonne for 2006-2007 (AAFC, 2007). Knowing 
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also that egg producers use flax as 10% (on average) of hens’ rations the extra feed cost 
can be estimated by adding 90% of the regular feed price ($228.73) and 10% of the 
flaxseed price ($275). This gives an estimate of the feed price necessary to produce 
omega-3 enriched eggs, which is $233.357 per tonne. In this case, the difference 
between the feed price for regular eggs and the feed price for omega-3 enriched eggs is 
$4.627 per tonne, or $0.007 per dozen (based on 1.5 kg feed ratio per dozen). The total 
extra feed cost for production of the current amount of omega-3 enriched eggs would be 
$0.539 million annually. Although this estimate may be an actual average cost, it is 
considered very low according to the feed prices that the Saskatchewan egg producer 
provided. This is probably because feed companies may charge more than the margin 
because they have extra handing and processing costs. 
4.6.3. Overall Impact and Benefit/Cost Ratio 
After estimating the benefits and costs of omega-3 enriched eggs, the overall 
impact to society can be realized and measured, which in turn will determine the 
efficacy of the labelling policy in Canada. Table 4.7 provides the net benefit of 15% 
omega-3 enriched eggs and the benefit cost (B/C) ratio based on the estimated health 
benefits (see Table 4.5) and costs (see Table 4.6) for each scenario.  
For the Base Estimate, which is the most realistic, the net benefit is calculated to 
be $45 million per year. The B/C ratio of labelling omega-3 PUFA in omega-3 enriched 
eggs is 2.1:1. The High Estimate of the overall impact considers the High Estimate of 
CHD health benefits and the Low Estimate of costs in order to provide optimistic 
estimates. Thus, the net benefit is calculated to be $215 million annually, and the B/C 
ratio a very large 9.3:1. The Low Scenario provides very modest estimates. This means 
that the Low Estimate of CHD health benefits and the High Estimate of costs are taken 
into account. This results in a net cost of $33.7 million per annum and a B/C ratio of 
0.57:1. The negative social gain of this scenario may be explained by the High Estimate 
of costs and the Low Estimate of benefits. However, this result may not correspond to 
reality because omega-3 enriched eggs have already been introduced in the market and 
make up 15% of the Canadian egg industry. Additionally, the Base Scenario, which 
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provides reasonable estimates, showed considerable health savings that are double the 
cost. 
 Such results indicate that the implementation of labelling regarding the omega-3 
PUFA in the context of omega-3 enriched eggs is successful because the net benefit is 
positive, which means that the health care cost savings exceed the costs. As a result, the 
benefit cost analysis shows that the dissemination of nutrition information via labelling 
can be very advantageous for the Canadian economy as a whole. 
 
Table 4.7. Benefit/Cost ratio of 15% omega-3 enriched eggs. 
  Base   High  Low   
CHD savings (millions CAN$) 88.3 241 44 
Total Cost (millions CAN$) 43.1 25.8 77.7 
Net Benefit (millions CAN$) 45 215 -33.7 
Benefit/Cost 2.1 9.3 0.57 
Source: Author’s estimates (see text for detail). 
4.7. Summary 
This chapter provided an in depth benefit cost analysis of omega-3 enriched eggs 
in an attempt to investigate whether labelling the current number of dozens of omega-3 
enriched eggs is beneficial to society. In order to do so, both the health benefits and 
costs were measured and expressed in monetary terms. First, the health benefits in terms 
of health care cost savings were calculated. More specifically, it is estimated that the 
potential annual savings in CHD mortality costs could reach $88.3 million annually, 
according to a reasonable estimate. On the other hand, the total cost of omega-3 
enriched eggs, including production, labelling, and promotion costs, is estimated to be 
$43.1 million per year, based on the most realistic estimate. As a result, benefits 
outweigh costs, demonstrating that the provision of nutrition information to consumers 
through labelling has positive effects on Canadian society.  
If omega-3 fatty acids indeed have a beneficial impact on health, then not only 
mortality but also other indirect (e.g., morbidity costs) and direct CHD costs could be 
negatively affected. Other direct and indirect costs of some other diseases (e.g., cancer, 
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inflammatory disorders, and brain and eye problems) could possibly be reduced, as well. 
Considering all the potential health benefits, the net benefit could be even higher. 
Therefore, taken together, these numbers are likely to be conservative estimates of the 
health benefits of omega-3 enriched eggs. 
Considering that omega-3 enriched eggs are an example of functional foods that 
can be labeled, it can be concluded that labelling the healthy attributes of functional 
foods may considerably decrease the information asymmetry problem and improve 
Canadian economic welfare. 
 94
CHAPTER 5: POLICY IMPLICATIONS 
5.1. Introduction 
The results of the case study examined in this thesis suggest that the health of 
Canadians and the economic welfare of the country are affected by the provision of 
labelling information regarding the health-enhancing features of functional foods. In 
particular, the health benefits of the current omega-3 egg consumption outweigh the 
costs of producing and labelling omega-3 enriched eggs under the Base Scenario (most 
realistic). Labelling is generally presented as an instrument that can provide valuable 
health information and modify consumption decisions. To maximize the economic and 
health benefits that labelling information can provide, an appropriate regulatory system 
regarding labelling should be developed.   
This chapter begins with an extension of the analysis conducted in Chapter Four. 
It provides an estimation of the benefits and costs in the case where policymakers would 
regulate all the eggs to be enriched with omega-3 fatty acids. This policy would aim to 
improve the health of all egg consumers and move closer to the social optimum where 
information asymmetry and the moral hazard problem is reduced. The chapter closes 
with a discussion of policy implications.  
5.2. The Economics of a Mandated 100% Omega-3 Enriched Eggs in Canada 
As indicated in Chapter Four, the current consumption of omega-3 enriched eggs 
has substantial social benefits in terms of health care cost savings in Canada. The ability 
to label and make nutrient content claims in omega-3 enriched eggs has stimulated 
production of health-promoting eggs in order to meet the needs of the niche market and 
increase profits. However, while labelling can contribute significantly to an increase in 
the consumption of food products with healthy compounds like the omega-3 enriched 
eggs, the socially optimal amount cannot be achieved due to external factors such as 
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medical insurance. In such cases, one possible solution would be to regulate the use of 
omega-3 enriched eggs instead of the information. In other words, policymakers could 
require egg producers to produce all eggs with enhanced levels of omega-3 fatty acids so 
as to assist consumers to improve their health by increasing their intake of omega-3 fatty 
acids. Like any policy scheme, the social welfare impact should be determined before it 
is implemented. This section provides a benefit-cost analysis similar to that conducted in 
Chapter Four, which showed whether the mandatory development of omega-3 enriched 
eggs would provide a net social positive gain.   
5.2.1. Estimation of the Potential Health Care Costs Savings 
In order to calculate the possible health care costs savings, the same 
methodology explained in Chapter Four is followed here. The analysis includes three 
different scenarios that provide Low, Base, and High Estimates. The Base Estimate 
provides the most reasonable estimate, while the Low and High Estimates give a range 
of the potential health benefits. Considering the important impact that omega-3 fatty 
acids have on the risk of CHD mortality, the estimation refers to reduction in CHD 
mortality costs, apart from the High Scenario, which includes a reduction in all (direct 
and indirect) CHD costs. This High Estimate is based on the reasonable assumption that 
increasing omega-3 fatty acids levels in the diet could possibly improve heart health, 
thus reducing the risk of developing any CHD event, fatal or non-fatal. Additionally, a 
linear 1:1 ratio between the CHD and health-related costs savings is assumed, which 
means that a 1% reduction in CHD will reduce CHD costs by 1% (a similar assumption 
made by Malla et al., 2007). This assumption implies that CHD health costs are directly 
proportional to the incidence of CHD. 
The measurement of likely health savings first requires an estimation of the total 
change in CHD mortality as a result of the increase in omega-3 fatty acids found in 
omega-3 enriched eggs. Tables 4.3 and 4.4 show the impact of ALA and EPA+DHA on 
the population’s health. 
Table 4.3 shows that consumers who substitute regular eggs with omega-3 
enriched eggs can increase their level of ALA, thereby reducing the risk of CHD 
mortality. In particular, the Base Scenario illustrates that the extra ALA intake gained 
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from the consumption of an omega-3 enriched egg can reduce CHD mortality by 6.26% 
on average. The High Scenario provides an optimistic estimate, where the reduction in 
fatal CHD will be even higher, on average 9.39%. Lastly, the Low Scenario assumes 
that the reduction is half the reduction of the Base Estimate, or 3.13%. 
The consumption of omega-3 enriched eggs also enhances EPA+DHA levels of 
in the diet. Table 4.4 illustrates the possible change in CHD mortality due to increased 
EPA+DHA intake. The Base Scenario assumes that the extra average intake of 
EPA+DHA gained from an omega-3 enriched egg could decrease fatal CHD by 12% on 
average. The High Scenario shows that the reduction in CHD mortality could possibly 
be higher—18% on average—while the Low Estimate is the most modest estimate, 
showing a reduction of 6% in CHD deaths.  
Table 5.1 presents the total effect that omega-3 fatty acids have on the risk of 
CHD mortality if consumers start consuming omega-3 enriched eggs instead of 
conventional eggs. Given this effect, the health benefits can then be quantified by 
measuring the potential health care cost savings. Contrary to the analysis conducted in 
Chapter Four, where the health benefits are based on current consumption of omega-3 
enriched eggs, this estimation shows that the benefits could be higher if regulatory 
authorities intervene in the market by regulating that eggs be rich in omega-3 fatty acids.  
According to the Base Estimate, the total reduction in the risk of CHD mortality 
for 100% consumption of omega-3 enriched eggs per capita per day instead of regular 
eggs would be 9.49%. Given the assumption of a linear 1:1 ratio between CHD events 
and death and the related health care cost savings, the estimation of potential mortality 
cost savings could be $587 million annually. 
The High Scenario assumes that substituting omega-3 enriched eggs would lead 
to a greater reduction in the risk of CHD mortality, which, on average, is 14.24%. This 
scenario considers the total annual cost of CHD given that the increased intake of 
omega-3 fatty acids contained in omega-3 enriched eggs would improve health and thus 
reduce the risk of CHD incidence and mortality. Assuming a linear CHD cost ratio, the 
annual savings in the costs of illness are measured to be $1,602 million. 
The Low Scenario shows that the reduction in CHD mortality would be a modest 
4.74%. Still, substantial savings in societal health costs can be achieved. Based on an 
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assumed linear CHD cost ratio, the health care and related cost of illness savings is 
estimated to be $293 million per annum. 
 
Table 5.1. Annual Canadian health care savings due to ALA, EPA, and DHA 
from 100% omega-3 enriched egg consumption. 
  Base   High  Low   
(a) Total change in CHD mortality for 
one omega-3 enriched egg consumed/d 
(%)1 
-18.26 -27.39 -9.13 
(b) Total disposition of eggs in 2006  
(million of dozens)2 517.8 517.8 517.8 
(c) Average total number of eggs 
consumed/capita/day3 0.52 0.52 0.52 
(d) Total change in CHD mortality for 
the 100% consumption of omega-3 
enriched eggs/capita/d (%) (a*c)4 
-9.49 -14.24 -4.74 
(e) CHD mortality to cost ratio 1 1 1 
(f) Total annual CHD cost (millions 
CAN$) ־ 11,251.6
5 ־ 
(g) Total annual CHD mortality cost 
(millions CAN$) 6,185.6 ־ 6,185.6 
(h) Total annual change in CHD cost  
(millions CAN$) (d*g) or (d*f)6 -587 -1,602 -293 
(i) CHD savings  (millions CAN$) 587 1,602 293 
1 The total change in CHD mortality for one omega-3 enriched egg consumed/d is the sum of the total 
change in CHD mortality due to ALA intake increase (see Table 4.3) and the total change in CHD 
mortality due to EPA+DHA intake increase (see Table 4.4). 
2 Source: Statistics Canada, 2007c. The total disposition of eggs in Canada in 2006 was 588.4 million 
dozen eggs.  From these, 517.8 million dozens were sold for consumption, while 59.3 million dozens were 
sold for hatching and 11.3 million dozens were leakers and rejects. 
3 The average total number of eggs/capita/d was calculated by multiplying the total disposition of eggs in 
2006 (million dozens) by 12 to obtain the total number of eggs in millions, and then divided by the 
population in 2006 (32,581,490 millions, Source: Cansim via E-Stat) and the number of annual days.  
4 The total percentage change in CHD mortality for 100% consumption of omega-3 enriched eggs/capita/d 
is calculated by multiplying the total percentage change in CHD mortality for one omega-3 enriched egg 
consumed/d by the average total number of eggs/capita/d. 
5 In the High Scenario, the total CHD costs (direct and indirect) are included, which implicitly assumes 
that total costs are reduced in the same proportion as mortality reduction. 
6 The total annual change in CHD cost is calculated by multiplying the total annual CHD mortality cost 
with the percentage change in CHD mortality for the current consumption of omega-3 enriched 
eggs/capita/d. In the High Scenario, the total annual indirect and direct CHD costs are considered instead 
of the total annual CHD mortality costs. 
Source: Author’s estimates (see text for detail). 
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5.2.2. Estimation of the Costs 
Before implementation of the policy regarding the mandated use of omega-3 
enriched eggs, the estimated related costs should be taken into consideration. Currently, 
egg producers who choose to produce omega-3 enriched eggs experience extra 
production, fixed, labelling, and marketing costs. As indicated in Chapter Four 
(subsection 4.6.2), the production of omega-3 enriched eggs requires the substitution of 
a portion (10%) of regular feed with flaxseed, which is relatively more expensive. This 
means that in the case where all the produced eggs are regulated to contain increased 
levels of omega-3 fatty acids, production costs would increase as more flaxseed is 
required. However, the same would not hold for the fixed, labelling, and marketing 
costs. These costs would be almost eliminated if such a policy were applied. This is 
because the eggs would be required to be enriched with these beneficial fatty acids, 
meaning that egg producers would not bear labelling or marketing costs for their egg 
products and any premium would disappear. For the benefit cost calculation, it is 
assumed that this policy, which would modestly increase the price of the 85% of the 
(non-omega 3) eggs and decrease the price of 15% of the (omega-3) eggs by nearly $1 
per dozen, would have no net effect on the quantity demand. This is a reasonable 
assumption to make since eggs are a supply managed commodity in Canada. 
Furthermore, given a long-term elastic supply of flax, it is assumed that any increase in 
quantity demanded of flaxseed would not impact the price of flaxseed.  
 The annual production, labelling, and marketing costs incurred by a mandatory 
development of omega-3 enriched eggs are illustrated in Table 5.2. The table includes 
some additional information necessary for the estimation of the costs.17 Statistics 
Canada reported that the total disposition of eggs in 2006 was 517.8 million dozen 
(Statistics Canada, 2007c). This amount does not include hatching and leakers and 
rejects. Also, according to Bert Harman, an egg producer in Saskatchewan, Canada, the 
extra feed price difference between conventional eggs and omega-3 enriched eggs could 
be $72.74 per tonne (Harman, 2007). Given that the feed conversion ratio per dozen 
eggs is, on average, 1.5 kg (or 0.0015 tonne), the additional feed cost per dozen omega-3 
                                                 
17 An explicit explanation of this additional information can be found in Chapter Four (subsection 4.6.2).  
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enriched eggs is $0.10911 (Meyers Norris Penny LLP, 2006).18 Consequently, the total 
extra feed cost that egg producers bear is estimated to be $56.5 million annually, and is 
assumed to be the same for the Base and High Scenarios.  
The extra feed cost for the Low Scenario (i.e., most conservative) is calculated 
by using the price of flaxseed, which is estimated to be $275 per tonne, on average, for 
2006-2007 (AAFC, 2007). The price of feed for the production of conventional eggs 
was $228.73 (Harman, 2007). Knowing that 10% of flaxseed is used to satisfy the 
criteria for the omega-3 enriched eggs and the remainder is conventional feed, the 
estimate of the feed price necessary to produce omega-3 enriched eggs is $233.357 per 
tonne. Therefore, the difference between the feed price for regular eggs and the feed 
price for omega-3 enriched eggs is $4.627 per tonne, or $0.007 per dozen (based on 1.5 
kg feed ratio per dozen). Therefore, the total feed cost to produce 517.8 million dozen 
eggs is estimated to be $3.6 million per year, an amount much smaller than the $56.5 
million figure found for the other two scenarios.  
Furthermore, if policymakers require a mandatory omega-3 fatty acids 
enhancement of all eggs, the fixed, labelling, and marketing costs are virtually 
eradicated. Some minimal testing costs may continue to ensure that egg producers meet 
the nutrition standards, but are not considered in the estimation. The Canadian Egg 
Marketing Agency may also choose to advertise the additional health benefits from 
consuming omega-3 enriched eggs in order to inform and educate consumers. However, 
the additional benefits or costs associated with this action are not taken into account in 
the estimation. Therefore, the total cost that implementation of such a policy would 
demand of the industry is equal to the annual total extra feed cost—$56.5 million for the 
Base and High Scenarios, and $3.6 million for the Low Scenario.  
                                                 
18  It is assumed that the feed conversion ratio per dozen eggs has remained the same for the period 2004-2006. It is 
also assumed that the feed conversion ratio is the same for flax-based diets and conventional diets. The only change is 
the content of the feed. 
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Table 5.2. Annual Canadian costs of producing, labelling and marketing 100% 
omega-3 enriched eggs. 
  Base   Low   High  
(a) Total disposition of eggs in 2006 (million 
dozens)1 517.8 517.8 517.8 
(b) Feed price difference between conventional 
and omega-3 enriched eggs ($ per tonne)2 72.74 - 72.74 
(c) Feed price difference between conventional 
and omega-3 enriched eggs based on flaxseed 
price ($ per tonne)3 
- 4.627 - 
(d) Feed conversion ratio per dozen (in tonne)4 0.0015 0.0015 0.0015 
(e) Extra feed cost ($ per dozen) (b*d) or (c*d) 0.1095 0.0076 0.1095 
(f) Total extra feed cost (millions CAN$)7 56.5 3.6 56.5 
(g) Fixed, labelling and marketing costs8 0 0 0 
(h) Total Cost (millions CAN$)9 56.5 3.6 56.5 
1 Source: Statistics Canada, 2007c. The total disposition of eggs in Canada in 2006 was 588.4 million 
dozen eggs.  From these, 517.8 million dozens were sold for consumption, while 59.3 million dozens were 
sold for hatching and 11.3 million dozens were leakers and rejects.  
2 Source: Harman, 2007. The feed price difference between conventional and omega-3 enriched eggs was 
calculated by subtracting the feed cost of conventional eggs ($228.73/tonne) from the feed cost of omega-
3 enriched eggs ($301.47/tonne). 
3 Feed price difference between conventional and omega-3 enriched eggs based on flaxseed price = 
[((10%*$275+90%*$228.73)-$228.73)*0.0015 tonnes] = 4.627, where $275/tonne is the price of flax, 
$228.73/tonne is the average feed cost of conventional eggs, 10% is the portion of flax required for the 
omega-3 enriched eggs, and 0.0015 tonnes (1.5 kg) is the feed conversion ratio per dozen eggs. 
4 Source: Meyers Norris Penny LLP, 2006. The feed conversion ratio per dozen eggs, which is the amount 
of feed given to hens in Canada to produce a dozen eggs, is 1.5 kg or 0.0015 tonnes per dozen.  
5 The extra feed cost per dozen eggs for the Base and High Scenarios was calculated as follows: 
Extra feed cost per dozen eggs = (Feed price difference between conventional and omega-3 enriched 
eggs*feed conversion ratio per dozen). 
By holding the quantity constant, it is assumed that a 90-cent reduction per dozen in omega-3 egg prices 
for 15% of the consumers more than offsets the reduction in demand due to a 10-cent increase per dozen 
in omega-3 egg prices to 85% of the consumers. 
6 The extra feed cost per dozen eggs for the Low Scenario was calculated as follows: 
Extra feed cost per dozen eggs = (Feed price difference between conventional and omega-3 enriched eggs 
based on flaxseed price*feed conversion ratio per dozen). 
By holding the quantity constant, it is assumed that a 99.3-cent reduction per dozen in omega-3 egg prices 
for 15% of the consumers more than offsets the reduction in demand due to a 0.7-cent increase per dozen 
in omega-3 egg prices to 85% of the consumers. 
7 The total extra feed cost was calculated by multiplying the total disposition of omega-3 enriched eggs 
with the extra feed cost. 
8 Minimum testing costs to assure consumers that producers meet the nutrition standards are not included 
in this estimation. 
9 The total extra feed cost was calculated by multiplying the total disposition of eggs with the extra feed 
cost.  
Source: Author’s estimates (see text for detail). 
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5.2.3. Overall Impact and Benefit/Cost Ratio 
In order to decide whether the policy of mandatory use of omega-3 enriched eggs 
is socially preferable, it is necessary to compare the benefits and costs that will arise. 
Table 5.3 depicts the net benefit and benefit/cost ratio for each scenario, which will help 
determine if such policy is recommended.  
The Base Scenario (most realistic) shows that the net benefit is estimated to be 
$530 million per annum. Given that the social benefits in terms of health care cost 
savings are high if this policy is realized, the B/C ratio is equal to 10.4. The High 
Scenario provides optimistic estimates by considering the High Estimate of CHD cost 
savings and the Low Estimate of costs. The results show that the annual net benefit is 
$1,598 million, while the B/C ratio is very high, 445:1. Finally, for the Low Scenario, 
the Low Estimate of the CHD health benefits and the High Estimate of the costs are 
taken into account. Hence, the net benefit is $236 million per year, and the B/C ratio is 
5.2:1, illustrating the beneficial social welfare effects of such a policy, even under very 
modest assumptions.  
The results of the benefit cost analysis conducted in this section present the 
significance of implementing a policy that would require production of all eggs to have 
high omega-3 fatty acids content in Canada. This policy might be an effective means of 
correcting not only the market failure caused from asymmetrically distributed 
information, but also reducing the negative externality caused by medical insurance and 
improving society’s welfare by moving closer to the social optimum. According to 
Table 5.3, the most realistic estimate demonstrates a particularly high B/C ratio, 19.9:1. 
The High and Low Estimate forming the upper and lower bound of the range is also of 
particular importance. Therefore, in an attempt to improve Canadians’ health and thus 
decrease rising health care costs, such a regulatory policy change would be very 
beneficial for Canadians’ health and the nation’s economy. 
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Table 5.3. Benefit/Cost ratio of 100% omega-3 enriched eggs versus zero %. 
  Base   High  Low   
CHD savings (millions CAN$) 587 1,602 293 
Total Cost (millions CAN$) 56.5 3.6 56.5 
Net Benefit (millions CAN$) 530 1,598 236 
Benefit/Cost (millions CAN$) 10.4 445 5.2 
Source: Author’s estimates (see text for detail). 
 
Comparing the impacts of the mandated use to the current market reveals some 
interesting relationships (see Table 5.4). The health care cost savings can substantially 
increase, but the total cost would not increase as much as benefits. This is because the 
labelling and marketing costs would be almost eliminated.19 In particular, the Base 
Scenario shows that CHD savings will increase by $499 million annually. For the High 
and Low Scenario, the results indicate an annual increase of $1,361 million and $249 
million in health benefits, respectively. As regards to the total cost, the increase is 
incremental when compared to benefits. According to the Base Scenario, the total cost is 
estimated to increase by $13.4 million per year due to increased production costs. The 
High and Low Scenarios show a possible annual cost reduction of $22.2 million and 
$21.2 million, respectively.  
As illustrated in Table 5.4, 100% use of omega-3 enriched eggs would increase 
the benefits to a larger extent than the costs when compared to the current 15% rate. 
Therefore, the total net effect would be positive. The Base Scenario indicates that the 
annual net benefit would increase by $485 million. For the High Scenario, the net 
benefit would increase by $1,383 million annually, while for the Low Scenario the net 
benefit would increase by $270 million per annum. These results provide further insight 
into the beneficial effects that mandated use of omega-3 enriched eggs would provide 
compared to the current labelling policy. The health improvement is noteworthy and 
would result in major health care cost savings. Additionally, while the production cost of 
                                                 
19 Some minimal testing costs, which would continue to occur even after the mandatory development of the omega-3 
eggs to ensure that egg producers meet the nutritional standards, are not considered in the estimation. 
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omega-3 enriched eggs would increase, considerable labelling and marketing savings 
would incur under the 100% policy scenario, which explains why total cost increases are 
smaller than the benefits. 
According to the results of the estimation, the current labelling of omega-3 
enriched eggs has led to a notable B/C ratio of 2.1:1. The net benefit could be even 
higher if development of omega-3 enriched eggs were mandatory. Therefore, the 
hypothesis that the labelling of omega-3 enriched eggs has not led to benefits for 
Canadians is rejected, showing the potential importance of labelling and claims, and the 
magnitude of potential health benefits that would be forgone under a restrictive 
regulatory labelling regime. 
 
Table 5.4. Comparison of 15% versus 100% omega-3 enriched eggs. 
 Base High Low 
15% omega-3 enriched eggs1    
CHD savings (millions CAN$) 88.3 241 44 
Total Cost (millions CAN$) 43.1 25.8 77.7 
Net Benefit (millions CAN$) 45 215 -33.7 
Benefit/Cost 2.1 9.3 0.57 
100% omega-3 enriched eggs2    
CHD savings (millions CAN$) 587 1,602 293 
Total Cost (millions CAN$) 56.5 3.6 56.5 
Net Benefit (millions CAN$) 530 1,598 236 
Benefit/Cost  10.4 445 5.2 
Change from 15% to 100%    
CHD savings (millions CAN$) 499 1,361 249 
Total Cost (millions CAN$) 13.4 -22.2 -21.2 
Net Benefit (millions CAN$) 485 1,383 270 
1 The estimation of CHD savings, total cost, and net benefit and Benefit/Cost ratio for the current market 
share of omega-3 enriched eggs can be found on the Tables 4.5, 4.6, and 4.7, respectively. 
2 The estimation of CHD savings, total cost, and net benefit and Benefit/Cost ratio for the mandatory 
development of omega-3 enriched eggs can be found on the Tables 5.1, 5.2, and 5.3, respectively.   
Source: Author’s estimates (see text for detail). 
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5.3. Policy Implications 
The federal government, through labelling legislation, controls provision of 
information on food labels. This means that legislative rules regarding food labelling 
and claims can considerably influence the production and consumption of functional 
food products, correct the information asymmetry problem, and consequently affect the 
Canadian economy as a whole. The use of nutrient content claims and health claims can 
provide producers with an incentive to innovate and expand the functional food sector 
while simultaneously affecting consumers’ food choices. The case study presented in 
this research indicated how important labelling is to the health-enhancing properties of 
functional foods. If omega-3 fatty acids were not regulated as essential nutrients, and 
thus nutrient content claims could not be made, presumably no omega-3 enriched eggs 
would have existed in the market and significant health care cost savings would have 
been forgone.   
However, the current regulatory regime in Canada limits nutrient content and 
health claims, thus restricting the range of functional foods entering the market. In 
addition to this, uncertainty within government policy and a lack of co-operation among 
governmental agencies can be a concern to firms developing a new functional food. 
Therefore, a complicated and restrictive regulatory framework may discourage 
innovation in the functional food industry, inhibit economic efficiency, and lead to 
major welfare losses.  
A more extensive labelling scheme would be appropriate for boosting the 
functional food market. Flexible and well-organized legislation can encourage 
competition, improve research activities, increase investment in the development of new 
products, and promote international trade. This presupposes that Canada’s regulations 
will adapt quickly to new scientific advances and nutrition findings and allow more 
claims related to the beneficial compounds of functional foods. Additionally, closer 
relations and increased coordination are necessary between governments, industry, non-
governmental organizations, and citizens. All partners have to cooperate to address 
regulatory issues and improve the system. Thus, major innovative discoveries can occur 
and economic efficiency can be improved.  
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Furthermore, the information asymmetry problem apparent in the functional food 
market is related to the credibility of labelling (Zou and Hobbs, 2006). Consumers base 
their purchasing decisions on information attached to the labels. If labelling information 
is conflicting and untrustworthy, consumers will not be interested in consuming 
functional foods, and so the economic incentive to produce health-enhancing food 
products will not be present. So, clear, credible, and comprehensive information that 
accurately reflects the scientific evidence is necessary to motivate consumers to modify 
their eating patterns. Food labelling, in combination with consumer education, will help 
consumers make healthier and more informative food choices.  
 In designing labelling regulation, the research community plays a central role. 
Labelling and research are interlinked concepts. Without a flexible labelling system, no 
research can occur, and without consistent and effective research, labelling cannot take 
place. So, constant nutrition research is of utmost importance in order for more healthy 
food products to be labeled. Currently in Canada, a small amount of health care budget 
is being devoted to nutrition and health research, which undermines economic 
efficiency. However, this thesis has illustrated that when the health effects of specific 
nutrients are revealed through research, significant social benefits in terms of health care 
costs can be attained—assuming that labelling regulations will keep up with the 
evolution of science and research. Hence, it can be concluded that the research 
community in collaboration with the functional food industry can improve Canadians’ 
health and foster economic welfare. 
Lastly, a regulatory policy that requires mandatory development of omega-3 
enriched eggs may also have long-run implications on incentives for future innovation. 
Mandating all eggs to be rich in omega-3 fatty acids might regulate away the 
competitive advantage of the original omega-3 egg innovators, reducing incentives to 
research. This, of course, depends on the existing rules around the intellectual property 
rights and how first-movers (omega-3 egg innovators) would be compensated were such 
a policy implemented. 
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5.4. Conclusion 
This chapter discussed the need for policy change that would yield increased 
economic benefits. In addition to the health benefits that consumption of omega-3 
enriched eggs provides, a possible legislative policy was proposed in this chapter. This 
change would require mandatory omega-3 enrichment of all eggs in Canada. The results 
indicated that this policy would generate even greater health care cost savings while 
simultaneously lowering the total cost of omega-3 enriched eggs, resulting in a 
particularly high benefit cost ratio. The importance of information through food 
labelling for consumers’ health and the functional food market must be further 
understood. This entrusts government with the responsibility to make changes to the 
regulatory system so as to increase the benefits of labelling. 
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CHAPTER 6: SUMMARY AND CONCLUSIONS 
6.1. Summary 
Considering the growing consumer interest in the link between diet and health, 
innovations in the agri-food sector have led to the development of functional foods in 
Canada. These food products that confer health benefits can improve the population’s 
health, thereby resulting in large social benefits through reduced health care costs. 
However, the market for functional foods is characterized by information asymmetry for 
consumers with respect to the presence, level and efficacy of the functional attributes 
(Zou and Hobbs, 2006). The health components of specific foods and the future health 
outcomes attached to them are credence attributes, being that in the absence of 
information, consumers cannot generally observe such attributes. Given the information 
asymmetry inherent in functional foods, labelling can be used as a vehicle to transform 
credence attributes into experience and search attributes, differentiate products, and 
facilitate consumers’ purchasing decisions. This thesis has attempted to illustrate how 
the labelling of healthy nutrients could be one efficient and practical way to solve the 
market failure caused by asymmetric information, and thereby enhance economic 
efficiency. A case study provides further insight into the research problem.  
In order to obtain a general picture of the impact that information asymmetry 
causes on social welfare, a graphical illustration is provided in Chapter Three. Providing 
consumers with clear and comprehensive information can help them make healthy and 
informed food choices and decrease the health care costs that burden both the Canadian 
health care system and the economy as a whole. In general, informed consumers can 
increase the demand for healthier food products (or, likewise, decrease the demand for 
unhealthy foods). Therefore, a potential growth in the consumption of functional foods 
can increase both private and social welfare and decrease the dead weight loss that is 
created in the absence of nutrition information. The socially optimal amount cannot be 
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achieved even if consumers have perfect information because health and disability 
insurances cause a moral hazard problem that deter the consumption of healthier foods. 
Nevertheless, labelling information can substantially correct the market failure and 
improve social welfare.  
A graphical comparison of voluntary and mandatory labelling is also provided to 
demonstrate the beneficial effects of providing information on the healthy nutrients of 
functional foods, and suggests that mandatory labelling is a more effective policy to 
address the asymmetry of information. Currently, the regulatory labelling regime in 
Canada is mandatory and requires all pre-packaged products with certain kinds of 
ingredients to be labeled clearly in order to assist consumers in making comparisons 
between products and choosing foods according to their preferences. 
Although there is a range of functional foods available in Canada—such as 
probiotic yogurts, cholesterol-lowering spreads, vitamin E and C enhanced soft drinks, 
fiber enhanced cereals, and omega-3 enriched milk and eggs—the rate of development 
of functional foods remains slow due to stringent regulations. The allowance of certain 
nutrient content claims and the restricted to five health claims have been a major barrier 
to the introduction and commercialization of new functional foods. Firms may be 
hesitant to invest funds in the development of new value-added food products that could 
meet resistance at the regulatory approval phase. This means that complicated and 
ambiguous regulations can impede functional food innovations and deter investment in 
research and development. This, in turn, affects the economic efficiency in Canada due 
to diet-related health care costs.  
The primary conclusion of this research can be drawn from the examination of 
the case study, which has revealed the net economic benefit of producing a particular 
functional food and labelling its value-added attribute. Omega-3 enriched eggs were 
used as an example of functional foods and a benefit cost analysis was conducted to 
evaluate the efficacy of the current labelling policy. Based on a range of assumptions 
and using three different scenarios to cover a range of estimates, both health care cost 
savings and the costs incurred due to labelling and production are estimated for this 
functional food. 
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Specifically, in Chapter Four, the example of omega-3 enriched eggs is used to 
explore the potential magnitude of health care savings, as well as the costs related to 
labelling. The egg industry and scientific evidence showing the health effects of omega-
3 fatty acids have contributed in making the labelling of omega-3 enriched eggs of great 
value. Currently, omega-3 fatty acids are deemed essential nutrients by Health Canada 
and firms are allowed to make such nutrient content claims. This has led to an important 
functional food innovation in the egg product sector. Among their various health effects, 
adequate intake of omega-3 fatty acids in the diet can substantially reduce the risk of 
CHD, especially CHD mortality. Therefore, omega-3 enriched eggs are considered an 
easy way to increase the level of omega-3 fatty acids and simultaneously save billions of 
dollars in health care costs. Furthermore, labelling, testing, and marketing, as well as 
producing these eggs, creates extra costs for the industry, which have also been 
estimated based on the observed markup of the omega-3 enriched eggs. By comparing 
the estimated benefits and costs, it is indicated that the current consumption of omega-3 
enriched eggs provides a significant net economic gain.   
The benefit cost analysis of omega-3 enriched eggs was extended in Chapter 
Five, where the policy implications of the research were discussed. Realizing the current 
fundamental overall impact of omega-3 enriched eggs on society’s health and the 
national economy, it is interesting to test the effect of implementing a policy that would 
mandate the use of omega-3 enriched eggs. This policy can potentially be used to correct 
market failures related not only to asymmetric information but also to the negative 
externalities that medical insurances create. The results indicated that the health benefits 
would be greatly increased while costs would increase only slightly because almost all 
the labelling-related costs would be eliminated.20 Therefore, the net economic gain 
becomes even stronger if all eggs are regulated to be rich in these beneficial fatty acids. 
The case study shed light on the research problem and indicated the significant 
health improvements and overall positive economic effects that information on health 
compounds through labelling can provide. By examining this functional food, it also 
helps realize the potential gains that are foregone due to a lack of labelling of other 
                                                 
20  Some minimal testing costs, as well as additional benefits or costs associated with consumers’ education regarding 
the healthy characteristics of omega-3 enriched eggs, are not considered in the estimation. 
 110
beneficial nutrients in Canada (e.g., beta glucan, lutein, selenium). Consequently, the 
introduction of a regulatory process for approval and labelling of new functional foods 
could rectify the market failure of asymmetrically distributed information, stimulate 
innovation, and, therefore, result in increased economic welfare. 
6.2. Limitations and Recommendations for Further Research 
The primary objective of the thesis was to indicate whether labelling functional 
foods could decrease the information asymmetry problem and lead to a net benefit for 
society. This was examined through a case study of omega-3 enriched eggs. Examining 
more food products with health properties may provide additional insights into the 
effects of labelling information. There is a spectrum of functional foods available in the 
Canadian market. Research into more functional food product areas could enhance the 
value of the results, thereby motivating policymakers to allow additional claims for 
specific nutrients.  
Future research focusing on specific functional foods and their properties would 
also be very beneficial to the Canadian agri-food industry in terms of realizing the 
importance of supplying value-added functional foods and identifying possible strategies 
for the development of new healthy products. Examining the innovation process, 
existing private incentives, and current patterns of Canadian private and public 
investment in functional foods R&D would be interesting areas of study.  
One limitation of this study is the use of hypothetical values in the benefit cost 
analysis, specifically for the current fixed, labelling, testing, and marketing costs of 
omega-3 enriched eggs. The study was limited to hypothetical values due to difficulty in 
obtaining and revealing the magnitude of these cost categories. To remedy this, it is 
recommended that more in depth research be performed to calculate realistic values for 
the cost variables. 
Although this thesis briefly discussed the stiffness of the regulatory labelling 
system, additional research into industry perceptions could help identify potential and 
specific problems with the regulations. A survey of functional food firms could provide 
explicit information regarding costs of registration, the approval rate of functional foods, 
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product availability, and other regulatory barriers, which, in turn, would designate the 
degree at which the regulation is being restrictive.  
Further investigation is also recommended of the effects of the regulatory 
environment on incentives to innovate, including the use of intellectual property rights 
and the generation and sharing of knowledge regarding function, efficacy, and safety 
with respect to healthy foods. The identification of potential bottlenecks and hold-ups 
could also help explain the constraints to R&D and commercialization of functional 
food innovations in both domestic and international markets. A comparison of other 
regulatory systems (e.g., U.S., Europe, Japan) could help identify and understand the 
differences, and thus emphasize the limitations of the Canadian labelling legislation. 
Although the problem of moral hazard was briefly discussed in the thesis, and 
possible solutions were suggested, it was not explicitly modeled. The negative 
externality caused from private and public health insurances prevent the achievement of 
the social optimal, even when full information is provided. This study showed that by 
requiring all the eggs to contain omega-3 fatty acids, the moral hazard problem can be 
reduced. A more general solution was proposed by Malla et al. (2007), who 
recommended a pigovian tax on the production/consumption of unhealthy foods or 
subsidies to encourage consumption of healthier foods. It is clear that this problem area 
requires further study to determine the optimal legislative policy needed to correct the 
negative externality. 
Finally, with regards to the theoretical model examined in section 3.4, the 
magnitudes of the relative shifts in the demand curves were hypothetical and based on 
the labels and allowable claims. Therefore, it is recommended that more in-depth 
research be performed into consumer demand effects by using stated and/or revealed 
consumer preference methodologies. A study of consumer attitudes, choices, and 
motivations regarding food labelling could provide insight into consumers’ perceptions 
towards labelling regulations, and could give better indications of the relative size of 
consumer demand shifts. 
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6.3. Conclusions 
The purpose of this study was to examine why labelling information is 
particularly important in the functional food industry and how it can affect the economic 
welfare of Canada.  The information asymmetry problem is a key characteristic in the 
functional food industry and causes market failures. Labelling is necessary to correct 
this problem. Currently, functional foods have gained recognition as having valuable 
traits that can considerably influence citizens’ health if information is provided. 
However, this sector is developing slowly in Canada, unlike U.S., Europe, and Japan, 
due to the restrictive, rigorous, and complicated regulatory labelling system.  
This study has made a step towards understanding the potential for the functional 
food industry to contribute to the health of citizens if more flexible labelling regulations 
exist. It has helped determine the economic implications of labelling the health attributes 
of functional foods. Nevertheless, further research into the functional food industry is 
necessary.  
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Table A1 depicts a detailed estimation of health care costs of CVD for 2006. The 
total direct and indirect costs of CVD are calculated, as are all the cost categories of 
direct and indirect costs of CVD, by applying the change of CPI and the change of 
population to each cost category separately. It is important to note that hospitalization 
and mortality costs comprise a huge portion of the total costs of CVD as they account 
for 55% of total cost of CVD. 
In order to have a more explicit view of CHD costs, Table A2 reports estimates 
of the components of CHD’s direct and indirect costs in 2006. All the components of 
direct and indirect costs of CHD ($1998), as reported in Table A1, were used. 
Considering the change in CPI and change in population, each cost category of direct 
and indirect costs of CHD was estimated for 2006. As anticipated, hospital costs and 
mortality costs compose the largest amount of total costs, representing 69% of total 
CHD costs. 
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Table A1. Estimation of the categories of direct and indirect costs of CVD in 
Canada ($2006). 
  CVD 1998 CVD 2006 
DIRECT COSTS 
Hospital Costs (HC) (millions CAN$)1 4,161.8 5,312.5 
Drug Costs (DC) (millions CAN$)1 1,772.8 2,262.9 
Physicians Costs (PC) (millions CAN$)1 822.3 1,049.6 
Other Direct Costs (ODC) (millions CAN$)1,2 4,073.5 5,199.8 
Health Research Costs (HRC) (millions CAN$)1 61.2 78.2 
Total Direct Costs (millions CAN$)3 10,891.6 13,902.9 
Change in CPI (1998-2006)4 0.19 0.19 
Change in population (1998-2006)5 0.08 0.08 
   
INDIRECT COSTS 
Mortality Costs (MC) (millions CAN$)6 8,250 10,531.0 
Morbidity Costs due to Long-Term Disability (LTDMC) 
(millions CAN$)6 3,151.5 4,022.8 
Morbidity Costs due to Short-Term Disability (STDMC)  
(millions CAN$)6 253.3 323.3 
Total Indirect Costs ($1998) (millions CAN$)7 11,654.8 14,877.1 
Change in CPI (1998-2006) 0.19 0.19 
Change in population (1998-2006) 0.08 0.08 
   
TOTAL COST 
Total Cost (millions CAN$)8 22,546.4 28,780.1 
1 HC ($2006) = [HC ($1998)+ (HC ($1998)* change in CPI)+ (HC ($1998)* change in population)] = 
[4,161.8+(4,161.8*0.19)+(4,161.8*0.06)]. 
DC ($2006) = [DC ($1998)+ (DC ($1998)* change in CPI)+ (DC ($1998)* change in population)] = 
[1,772.8+(1,772.8*0.19)+( 1,772.8*0.06)]. 
PC ($2006) = [PC ($1998)+ (PC ($1998)* change in CPI)+ (PC ($1998)* change in population)] = 
[822.3+(822.3*0.19)+(822.3*0.06)]. 
ODC ($2006) = [ODC ($1998)+ (ODC ($1998)* change in CPI)+ (ODC ($1998)* change in population)] = 
[4,073.5+(4,073.5*0.19)+(4,073.5*0.06)]. 
HRC ($2006) = [HRC ($1998)+ (HRC ($1998)* change in CPI)+ (HRC ($1998)* change in population)] = 
[61.2+(61.2*0.19)+(61.2*0.06)]. 
2 Other direct costs (ODC) include expenditures for care in other institutions and additional direct health expenditures. 
However, they are net Health Research Costs. 
3 Total Direct Costs were calculated by summing HC, DC, PC, ODC, and HRC. 
4 Source: Statistics Canada, 2007b. The Consumer Price Index (CPI) for 1998 was 91.3; the 2006 CPI was 109.1. The 
change in CPI was calculated by subtracting 91.3 from 109.1 and dividing by 91.3. 
5 Source: Cansim via E-Stat, Table 051-0005. Quarterly population estimates. The average population estimate for 
1998 was 30,125,715, and 32,581,490 for 2006. The change in population was calculated by subtracting 30,125,715 
from 32,581,490, then dividing by 32,581, 
6 MC ($2006) = [MC ($1998)+ (MC ($1998)* change in CPI)+ (MC ($1998)* change in population)] = 
[8,250+(8,250*0.19)+(8,250*0.06)]. 
LTDMC ($2006) = [LTDMC ($1998)+ (LTDMC ($1998)* change in CPI)+ (LTDMC ($1998)* change in 
population)] = [3,151.5+(3,151.5*0.19)+(3,151.5*0.06)]. 
STDMC ($2006) = [STDMC ($1998)+ (STDMC ($1998)* change in CPI)+ (STDMC ($1998)* change in 
population)] = [253.3+(253.3*0.19)+(253.3*0.06)]. 
7 Total Indirect Costs were calculated by summing MC, LTDMC, and STDMC. 
8 Total Cost is the sum of Total Direct and Total Indirect Costs. 
Source: Author’s estimates (see text for detail). 
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Table A2. Estimation of the categories of direct and indirect costs of CHD in 
Canada ($2006). 
  CHD 1998 CHD 2006 
DIRECT COSTS 
Hospital Costs (HC) (millions CAN$)1 1,274.8 1,627.3 
Drug Costs (DC) (millions CAN$)1 512.7 654.5 
Physician Costs (PC) (millions CAN$)1 247.7 316.2 
Other Direct Costs (ODC) (millions CAN$)1,2 1,226.9 1,566.2 
Health Research Costs  (HRC) (millions CAN$)1 18.5 23.6 
Total Direct Costs (millions CAN$)3  3,280.5 4,187.6 
Change in CPI (1998-2006)4 0.19 0.19 
Change in population (1998-2006)5 0.08 0.08 
   
INDIRECT COSTS 
Mortality Costs (MC) (millions CAN$)6 4,845.8 6,185.6 
Morbidity Costs due to Long-Term Disability (LTDMC) 
(millions CAN$)6 567.9 724.9 
Morbidity Costs due to Short-Term Disability (STDMC) 
(millions CAN$)6 120.3 153.5 
Total Indirect Costs (millions CAN$)7 5,534 7,064 
Change in CPI (1998-2006) 0.19 0.19 
Change in population (1998-2006) 0.08 0.08 
   
TOTAL COST8  
Total Cost (millions CAN$) 8,814.5 11,251.6 
1 HC ($2006) = [HC ($1998)+ (HC ($1998)* change in CPI)+ (HC ($1998)* change in population)] = 
[1,274.8+(1,274.8*0.19)+(1,274.8*0.06)]. 
DC ($2006) = [DC ($1998)+ (DC ($1998)* change in CPI)+ (DC ($1998)* change in population)] = 
[512.7+(512.7*0.19)+(512.7*0.06)]. 
PC ($2006) = [PC ($1998)+ (PC ($1998)* change in CPI)+ (PC ($1998)* change in population)] = 
[247.7+(247.7*0.19)+(247.7*0.06)]. 
ODC ($2006) = [ODC ($1998)+ (ODC ($1998)* change in CPI)+ (ODC ($1998)* change in population)] = 
[1,226.9+(1,226.9*0.19)+(1,226.9*0.06)]. 
HRC ($2006) = [HRC ($1998)+ (HRC ($1998)* change in CPI)+ (HRC ($1998)* change in population)] = 
[18.5+(18.5*0.19)+(18.5*0.06)]. 
2 Other direct costs (ODC) include expenditures for care in other institutions and additional direct health expenditures. 
However, they are net Health Research Costs. 
3 Total Direct Costs were calculated by summing HC, DC, PC, ODC, and HRC. 
4 Source: Statistics Canada, 2007b. The Consumer Price Index (CPI) was 91.3; the 2006 CPI was 109.1. The change 
in CPI was calculated by subtracting 91.3 from 109.1 and dividing by 91.3. 
5 Source: Cansim via E-Stat, Table 051-0005. The average population estimate for 1998 was 30,125,715 and 
32,581,490 in 2006. The change in population was calculated by subtracting 30,125,715 from 32,581,490 and 
dividing by 32,581, 
6 MC ($2006) = [MC ($1998)+ (MC ($1998)* change in CPI)+ (MC ($1998)* change in population)] = 
[4,845.8+(4,845.8*0.19)+( 4,845.8*0.06)]. 
LTDMC ($2006) = [LTDMC ($1998)+ (LTDMC ($1998)* change in CPI)+ (LTDMC ($1998)* change in 
population)] = [567.9+(567.9*0.19)+(567.9*0.06)]. 
 STDMC ($2006) = [STDMC ($1998)+ (STDMC ($1998)* change in CPI)+ (STDMC ($1998)* change in 
population)] = [120.3+(120.33*0.19)+(120.3*0.06)]. 
7 Total Indirect Costs were calculated by summing MC, LTDMC, and STDMC. 
8 Total Cost is the sum of Total Direct Costs and Total Indirect Costs. 
Source: Author’s estimates (see text for detail). 
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A case-control study is a study design that examines one group of people who have 
experienced an event (usually an adverse event) and another who have not experienced 
the same event, and looks at how exposure to suspect (usually noxious) agents differed 
between the two groups. This type of study design is most useful for trying to ascertain 
the cause of rare events, such as rare cancers. Case control studies can only generate 
odds ratios (OR), but not relative risks (RR) (BMJ Clinical Evidence, 2007).  
 
A cross sectional study is a study of a group of people at one point in time to determine 
whether an exposure is associated with the occurrence of a disease. Because the disease 
outcome and exposure (e.g., nutrient intake) are measured at the same time, a cross-
sectional study provides a “snapshot” view of their relationship. Cross-sectional studies 
cannot provide information about causality (Oregon State University, 2007).  
 
An experimental study involves an investigator examining the effects of intentionally 
altering one or more factors under controlled conditions (BMJ Clinical Evidence, 2007).  
 
An experimental group is a group of subjects in an experimental study that receives a 
treatment. (IFIC, 2007).  
 
An observational study has no experimental intervention or treatment applied. 
Participants are simply observed over time (Oregon State University, 2007). 
Observational studies include prospective cohort studies, case-control studies, and cross-
sectional studies (Wang et al., 2004). 
 
In a placebo group, a group of subjects are given a “fake” treatment that seems 
identical in appearance and taste to the real treatment. Placebo treatments are used to 
eliminate bias that might arise from the expectation that a treatment should produce a 
particular effect (IFIC, 2007).  
 
A prospective cohort study is an observational study in which a group of people—
known as a cohort—are interviewed or tested for risk factors (e.g., nutrient intake), and 
then followed up at subsequent times to determine their status with respect to a disease 
or health outcome (Oregon State University, 2007).  
 
A randomized controlled trial is a clinical trial with at least one active treatment group 
and a control (placebo) group. In RCTs, participants are chosen for the experimental and 
control groups at random, and are not told whether they received the active or placebo 
treatment until the end of the study. This type of study design can provide evidence of 
causality (Oregon State University, 2007). 
 
